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Abstract
The VICKZ family of RNA-binding proteins controls many aspects of gene 
regulation including mRNA localization and mRNA stability. The regulatory capacity of 
these proteins is linked to their ability to bind mRNA targets at specific sequences and 
structural elements. Specifically, this thesis will investigate the role of one VICKZ protein 
family member, the coding region determinant binding protein (CRD-BP). CRD-BP has 
been reported to bind several mRNA targets, including c-myc mRNA. It has also been 
shown that CRD-BP binds to a region within the c-myc transcript known as the coding region 
determinant (CRD). Evidence suggests that the CRD imparts considerable instability to the 
c-myc transcript because this region is susceptible to endonucleolytic attack. A novel 
mammalian endoribonuclease that has recently been purified and characterized in our 
laboratory has the ability to cleave the c-myc CRD in vitro. The goal of this thesis was to 
determine if RNA-protein interactions between CRD-BP and c-myc CRD RNA are sufficient 
to shield the transcript from endonucleolytic attack in vitro.
It is proposed that c-myc mRNA stability is influenced via its interactions with CRD- 
BP and endoribonucleases. The shielding hypothesis proposes that RNA-protein interactions 
between CRD-BP and c-myc CRD RNA protect the transcript from endonucleolytic attack. 
This study demonstrates that recombinant CRD-BP binds with considerable specificity and 
affinity to c-myc CRD and MDR-1 RNA in vitro. In addition, it was demonstrated that the 
specific RNA-protein interactions between CRD-BP, c-myc CRD RNA and MDR-1 RNA 
shield these transcripts from endonucleolytic attack in vitro. Finally, RNA footprinting 
analysis of the CRD-BP, c-myc CRD interaction allowed for the identification of specific 
RNA sequence and structural elements required for CRD-BP binding. The data presented in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
this thesis provides the first direct in vitro evidence supporting the CRD-BP-c-myc CRD 
shielding hypothesis. The confirmation of the shielding hypothesis in vitro should provide 
the framework and motivation to further investigate possible interactions between CRD-BP, 
c-myc mRNA and endoribonucleases in vivo.
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Chapter 1
Introduction
Gene expression is controlled at the transcriptional, post-transcriptional and 
translational levels. Of great importance to these regulatory mechanisms is the requirement 
for controlled and specific recognition between RNA and protein. RNA-protein interactions 
represent a myriad of coordinated associations which ensure the timely execution of post 
transcriptional processes. A family of RNA-binding proteins known as the VICKZ protein 
family is reported to play a vital role in messenger RNA (mRNA) localization and mRNA 
stabilization. In contrast, another class of proteins, termed endoribonucleases, mediates the 
turnover (i.e. degradation) of mRNA. It is believed that some RNA-binding proteins 
stabilize mRNA by preventing their degradation from endoribonucleases. The primary focus 
of this thesis is to examine how RNA-protein interactions influence mRNA stability. 
Specifically, this investigation will determine if RNA-protein interactions between an RNA- 
binding protein and a mRNA target can prevent RNA degradation by a native mammalian 
endoribonuclease in vitro.
1.1 Post Transcriptional Regulation and the Vital Role of RNA-Protein 
Interactions
The mechanisms that regulate gene expression in eukaryotes are quite diverse 
(Haynes 1999). The production of mature mRNA requires numerous post transcriptional 
regulatory events (Alberts et al. 1994; Brewer 2003). Examples of post transcriptional 
events include pre-mRNA processing (Buratti et al. 2004), mRNA export (Neugerbauer et al.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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2002), mRNA stabilization (Prokipcak et al. 1994; Brewer 2003) and mRNA degradation 
(Parker et al. 2004). These regulatory events play a vital role in allowing different cells at 
different stages of development the opportunity to control their unique patterns of gene 
expression (Brewer 2003).
Post transcriptional regulatory mechanisms generally require coordinated interactions 
between RNA, RNA-binding proteins and numerous other factors (i.e. trans-acting factors) 
(Neugerbauer et al. 2002). RNA-protein activities are the result of specific interactions 
between RNA sequence/structural elements (i.e. m -acting elements) and specific motifs 
found within the globular structure of RNA-binding proteins (Chen et al. 2005). The 
following section will demonstrate the prevalence of RNA-protein interactions in several 
post transcriptional activities that influence mRNA expression in eukaryotic cells.
1.1.1 Post T ranscriptional Regulatory Activities Involving RNA-Protein Interactions
The interplay between RNA and protein begins the moment eukaryotic RNA is 
generated in the nucleus (Brewer 2003). For example, growing transcripts are condensed and 
packaged within protein structures called heterogeneous nuclear ribonucleoprotein particles 
(hnRNP) (Alberts et al. 2000). The hnRNP at its core is composed of numerous proteins, 
many of which are known RNA-binding proteins (Grishin 2001). In addition, eukaryotic 
primary transcripts associate with a variety of other proteins called small nuclear 
ribonucleoproteins (snRNPs) (Buratti et al. 2004). The snRNP (e.g. U l, U2, U4 U5, and U6) 
is a complex aggregate of RNA and protein (Alberts et al. 1994; Buratti et al. 2004). The 
binding of several snRNPs, in conjunction with other factors, results in the formation of the 
spliceosome (Alberts et al. 1994; Buratti et al. 2004). The primary function of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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snRNPs/splicesosome is to recognize and bind specific pre-mRNA cA-acting elements (i.e. 
splice sites) through RNA-RNA and RNA-protein interactions (Alberts et al. 1994; Buratti et 
al. 2004). The sum of these interactions, collectively known as pre-mRNA splicing, 
facilitates the removal of introns and the joining together of exons (Alberts et al. 1994; 
Buratti et al. 2004).
Eukaryotic RNA transcribed by RNA polymerase II has a 7-methyl guanosine cap 
structure at its 5" end (Derrigo et al. 2000). The 5" cap increases the stability of pre-mRNA 
and mature mRNA by protecting it from the activities of 5 ' to 3 ' exoribonucleases (Derrigo 
et al. 2000; Neugerbauer 2002). The 5 ' cap is also a binding site for two proteins, the 
nuclear cap-binding complex (CBC) in the nucleus and the eIF4E complex in the cytoplasm 
(Derrigo et al. 2000). When bound to the 5 ' cap the CBC contributes to the removal of the 
first intron, and in the cytoplasm, eIF4E aids in the initiation of translation (Derrigo et al. 
2000; Neugerbauer 2002).
In addition to the 5 ' cap, most mature mRNA has a tail of poly adenosine at their 3' 
end (Chao et al. 1999; Wang et al. 2000). The primary function of the poly(A) tail is three­
fold: (1) improves nuclear export, (2) regulates RNA stability and (3) increases translational 
efficiency (Chao et al. 1999; Wang et al. 2000). Polyadenylation involves the recruitment of 
two protein complexes that recognize and cleave between AAUAAA and G/U-rich structural 
elements in mRNA molecules (Chao et al. 1999; Wang et al. 2000). Following cleavage, 
polyadenylation is then performed by poly(A) polymerase (Chao et al. 1999; Wang et al.
2000). The 3' poly(A) tail is bound by the poly(A) binding protein (PABP) and together 
with the cap-binding complex, the transcript is protected by the activities of exoribonucleases 
(Chao et al. 1999; Wang et al. 2000; Neugerbauer 2002).
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The transport of mature mRNA from the nucleus to the cytoplasm requires numerous 
RNA-protein interactions (Haynes 1999). Proteins larger that 50kDa are unable to diffuse 
out of the nucleus and therefore require nuclear export and nuclear localization signals to 
transit the nucleus (Derrigo et al. 2000; Neugerbauer 2002). Nuclear export of mRNA occurs 
via structures called nuclear pore complexes (NPC), which are assemblies that form channels 
through the nuclear membrane (Derrigo et al. 2000; Neugerbauer 2002). The mRNA 
emerges from the nucleus enveloped in a protein complex known as ribonucleoprotein (RNP) 
(Derrigo et al. 2000; Neugerbauer 2002). RNP transport signals interact with nuclear 
transport receptors that mediate transit through the NPC (Derrigo et al. 2000; Neugerbauer 
2002). In eukaryotes, mRNA transport is mediated by the nuclear export factor I receptor 
(NXF1), a known RNA-binding protein containing multiple RNA-binding motifs (Derrigo et 
al. 2000; Neugerbauer 2002).
Upon arrival in the cytoplasm, mRNA molecules maintain some protein affiliations 
formed in the nucleus and engage in additional interactions with other proteins and form 
larger complexes known as RNP granules (Haynes 1999). The mRNA (i.e. RNP granule) is 
then transported to free polysomes or ribosomes of the rough endoplasmic reticulum in 
specific subcellular locations (Guhaniyogi et al. 2001). Typically, the translocation of 
mRNA is a mechanism to achieve appropriate protein distribution within the cell 
(Guhaniyogi et al. 2001). The cytoplasmic distribution of mRNA is mediated in part by 
structural elements in the 3 '-untranslated region (UTR) and 5'-UTR (Russell et al. 1996). 
For example cA-acting elements in the 3'-UTR of P-actin mRNA are recognized and bound 
by the RNA-binding protein; VglRBP (Git et al. 2002). VglRBP in combination with other
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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trans-acting factors transports fi-actin mRNA as a ribonucleoprotein granule through the cell 
via microtubules to the vegetal cortex in Xenopus laevis (Git et al. 2002).
Compared to other biomolecules like protein and DNA, mRNA is quite unstable 
(Haynes 1999). The stability profiles of mRNA are quite diverse and range from minutes to 
hours (Parker 2004). In many cases mRNA from highly expressed genes like p-globin are 
quite stable whereas mRNAs encoding proteins that regulate growth factors such as c-myc, 
are highly unstable (Ross et al. 1997; Bergstrom et al. 2006).
The stability of mRNA is closely linked to cA-acting elements within the body of 
their transcripts (Brewer 2003). Cis-acting elements that affect mRNA stability have been 
identified in the 3-U TR (Ostareck-Lederer et al. 1994; Brewer 2003), 5 '-UTR (Yeilding et 
al. 1996) and within the coding region (Bergstrom et al. 2006) of many functionally different 
mRNA. CA-acting elements associated with highly stable mRNA are categorized as stability 
determinants and cA-acting elements associated with highly unstable mRNA are categorized 
as instability determinants. The presence of cA-acting elements alone does not dictate the 
relative stability of mRNA (Doyle et al. 1998). Rather it is the complex interplay between 
trans-acting factors and higher order structures of RNA that modulate the stability of mRNA 
(Brewer 2003; Siomi et al. 1997; Doyle et al. 1998; Lee et al. 1998). The following section 
will briefly describe the influences affecting mRNA stability.
1.2 Messenger RNA Stability and the Vital Role of Ribonucleases
Messenger RNA stability is an important parameter that determines the levels of gene 
expression and allows for rapid and appropriate responses to cellular events (Guhaniyogi et 
al. 2001). Messenger RNA stability in eukaryotic cells is regulated in part by proteins that
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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degrade mRNA (Parker et al. 2004). Efficient and appropriate degradation of mRNA 
prevents excess accumulation of incorrectly processed, truncated or nonsense transcripts and 
ensures the correct distribution of mRNA in the cell. (Guhaniyogi et al. 2001; Brewer 2003; 
Parker et al. 2004). Messenger RNA stability and degradation is dependant upon the 
interactions between mRNA cA-acting elements and trans-acting factors such as 
ribonucleases (Beelman et al. 1995; Parker et al. 2004). The following sections will focus on 
the most relevant and prominent classes of ribonucleases, that facilitate mRNA decay in 
eukaryotes.
1.2.1 Exoribonucleases
Two types of exonucleolytic activities are found in eukaryotic cells, 5 ' to 3 ' decay 
and 3' to 5' decay (Parker et al. 2004; Brewer 2003; Beelman et al. 1995). 
Exoribonucleolytic activity that degrades mRNA at the 3' end of the molecule is termed the 
deadenylation-dependant pathway (Parker et al. 2004; Beelman et al. 1995; Guhaniyogi et al. 
2001). The first step in mRNA decay in eukaryotes is deadenylation and this event is 
catalyzed by enzyme complexes known as mRNA deadenylases (Parker et al. 2004). The 
major deadenylase enzyme in mammalian systems, poly(A) ribonuclease enzyme (PARN), 
catalyzes the removal of the poly (A) tail by shortening it to approximately 55-75 nucleotides 
(Parker et al. 2004). PARN activity is regulated by specific cis-acting elements in mRNA 
including the 5 Tap structure (Parker et al. 2004; Beelman et al. 1995; Guhaniyogi et al.
2001). Following deadenylation mRNA can be degraded in a 3' to 5' direction by the 
activity of a large complex known as the exosome (Parker et al. 2004; Beelman et al. 1995; 
Guhaniyogi et al. 2001). The exosome is a complex of RNA-binding proteins containing a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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variety of RNA-binding motifs and functions as either a hydrolase or phosphorylase 
depending on its substrate (Parker et al. 2004). Exosome-mediated decay is an ATP- 
dependant process that generates 5 ' monophosphate degradation products (Parker et al.
2004).
Figure 1: A schematic representation of exonucleolytic and endonucleolytic decay in 
eukaryotes (Parker et al. 2004)
Decapping is a process involving at least two enzymes (i.e. DcPl and DcP2) which 
catalyze the hydrolysis of the 5" cap structure from mRNA molecules (Parker et al. 2004). 
The decapping process yields mRNA with a 5" monophosphate. The 5 ' monophosphate is 
recognized by an exonuclease (i.e. X m l) and the mRNA is degraded via 5 ' to 3' decay 
(Parker et al. 2004). In addition, nonsense-mediated decay targets mRNAs that have 
acquired premature translation stop codons or frame shift mutations as a result of 
incomplete pre-mRNA processing (Parker et al. 2004; Guhaniyogi et al. 2001). These
MAAAAA^0
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nonsense-containing transcripts are degraded by either a deadenylation-independent 
pathway or through accelerated deadenylation followed by 5" to 3 ' exonucleolytic digestion 
(Parker et al. 2004; Guhaniyogi et al. 2001).
1.2.2 Endoribonucleases
In addition to exoribonucleases, some eukaryotic mRNA degradation is initiated by 
endonucleolytic cleavage independent of deadenylation (Parker et al. 2004). Several 
examples of mRNA targeted by endonucleolytic degradation include vitellogenin and serum 
albumin (Cunningham et al. 2000), a -globin (Kong et al. 2003), c-myc (Lee et al. 1998; 
Bergstrom et al. 2006), insulin-like growth factor II (van Dijk et al. 2000), the transferrin 
receptor (Cairo et al. 1994) and Xenopus $-globin (Bremer et al. 2003). In addition, a 
growing number of endoribonucleases have been purified and characterized and are believed 
to recognize and cleave mRNA at specific, cA-acting elements found within the 3'-UTR, 5'- 
UTR and the coding region (Brewer 2003). The endonucleolytic degradation profiles 
common to these aforementioned mRNA are quite varied (Parker et al. 2004). The spectrum 
of cleavage specificities suggests that a number of different endonucleases may be present 
and active in eukaryotic systems (Parker et al. 2004; Brewer 2003; Guhaniyogi et al. 2001).
Endoribonucleases are capable of degrading mRNA targets from within their 
sequence (Parker et al. 2004). Following endoribonucleolytic decay, the 5" cleavage 
fragments are degraded by 3' to 5 ' exoribonucleolytic decay and 3' fragments are degraded 
by either 5" to 3' decay or via exosome activity (Parker et al. 2004; Brewer 2003; 
Guhaniyogi et al. 2001). The effectiveness of endonucleolytic cleavage can be compromised 
when their mRNA target is bound by an RNA-binding protein or when it is present in a
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larger ribonucleoprotein complex (RNP) (Brewer 2003; Prokipcak et al. 1994). An increase 
in transcript stability may be observed if the endonuclease is unable to gain access to specific 
cleavage sites (Brewer 2003; Prokipcak et al. 1994).
PMR-1 was initially identified as a polysome-associated endoribonuclease that is 
activated following estrogen stimulation in Xenopus hepatocytes (Cunningham et al. 2000). 
In vitro studies have shown that in the presence of estrogen PMR-1 selectively degrades 
serum albumin mRNA within a single-stranded consensus pentamer, A-Pyr-U-G-A 
(Cunningham et al. 2000). In contrast, estrogen stimulation in Xenopus results in the 
stabilization of transcripts encoding the egg yolk precursor protein, vitellogenin 
(Cunningham et al. 2000). The vitellogenin transcript contains two copies of the A-Pyr-U-G- 
A consensus pentamer within its 3'-UTR and these sequences have been implicated in the 
control of vitellogenin mRNA stability (Cunningham et al. 2000). The 3TJTR of 
vitellogenin has also been shown to bind with the 115kDa RNA-binding protein, vigilin 
(Cunningham et al. 2000). Recent in vitro investigations have since shown that vigilin 
protects the vitellogenin transcript by blocking its cleavage from PMR-1 (Cunningham et al. 
2000).
It has also been demonstrated using in vitro methods that endonucleolytic degradation 
of a -globin mRNA is due to the activity of a sequence specific, erythroid-enriched 
endoribonuclease (ErEN) (Cairo et al. 1994). The identification of ErEN mRNA degradation 
intermediates in erythroid cell extracts suggests that ErEN activity in vitro plays a role in the 
natural turnover of a-globin transcripts (Cairo et al. 1994). The endonucleolytic cleavage 
sites in a -globin mRNA have been mapped to a region 47 nucleotides upstream of the poly-
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adenylation addition site in its 3'-UTR (Cairo et al. 1994). It has been reported that a 
cytosine-rich element (CRE) in the a -globin 3 '-UTR is targeted by ErEN (Cairo et al. 1994).
It has also been demonstrated (in vitro and in vivo) that a -globin mRNA interacts 
with a ribonucleoprotein complex known as the a-complex (Cairo et al. 1994). The de­
complex is comprised of multiple RNA-binding proteins that bind to the a -globin CRE 
(Cairo et al. 1994). It has been proposed that the a-complex in combination with PABP 
promotes the stabilization of a-globin mRNA (Cairo et al. 1994). ErEN-mediated decay of 
the a -globin 3 '-UTR requires deadenylation; therefore PABP may represent a potential 
safeguard from endonucleolytic cleavage (Cairo et al. 1994).
The decay mechanisms that regulate c-myc mRNA stability have been well- 
characterized (Lee et al. 1998; Yeilding et al. 1996; Bergstrom et al. 2006). In vitro and in 
vivo studies have revealed that c-myc mRNA can be degraded by two pathways. The first 
pathway is mediated by an undefined exoribonuclease that facilitates poly(A) removal 
followed by 3 ' to 5" decay (Brewer 2003). The second pathway is mediated by an 
endoribonuclease that was discovered using a polysome-based, cell-free mRNA decay assay 
(Bernstein et al. 1992). The endonuclease-mediated decay pathway degrades c-myc mRNA 
within its coding region (Bernstein et al. 1992; Prokipcak et al. 1994).
A native mammalian endoribonuclease that is capable of cleaving the c-myc coding 
region instability determinant has been purified from rat liver (Bergstrom et al. 2006). When 
a radiolabelled 88-nucleotide segment of the c-myc coding region was exposed to the native 
mammalian endoribonuclease, endonucleolytic degradation products were generated between 
the following dinucleotides: CA, UA and UG (Bergstrom et al. 2006). In addition, the native 
m ammalian endoribonuclease cleaved the 3' side of the phosphodiester bond leaving
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cleavage products with free 3 ' hydroxyl groups. The site-specific cleavage between these 
dinucleotides was also observed in other mRNAs tested including, MDR-1 and fi-globin. 
These observations suggest that the native mammalian endoribonuclease is a sequence and 
site-selective (Bergstrom et al. 2006).
1.3 The c-myc Proto-Oncogene
Advances in our understanding of the biology of cancer are attributed to the discovery 
of proto-oncogenes and oncogenes (Varmus 1984). Proto-oncogenes are cellular genes that 
code for proteins involved in a cell's normal growth-control pathway (Varmus 1984). A 
mutated (i.e. activated) form of a proto-oncogene is known as an oncogene (Varmus 1984). 
Oncogene activation is implicated in cellular transformations and malignancies associated 
with various cancers (Varmus 1984). The c-myc proto-oncogene is the normal cellular 
orthologue of the v-myc viral oncogene from the MC-29 avain myelocytomatosis virus 
(AMV) (Vennstrom et al. 1982). AMV has been shown to induce cellular transformations in 
cultured fibroblasts, carcinomas and myelocytomatosis in susceptible birds (Vennstrom et al. 
1982). It was later determined that translocations of the c-myc gene was an important 
transforming factor leading to the development of Burkitt’s lymphoma (Hermecking 2003). 
Since that time human and mouse c-myc genes have also been cloned and characterized 
(Facchini et al. 1998).
The family of myc genes includes B-myc, c-myc, L-myc, N-myc and s-myc, however, 
only c-, N- and L-myc have the capacity to regulate gene expression and induce neoplastic 
transformations (Hermecking 2003; Hann et al. 1984; Facchini et al. 1998). As a 
transcription factor the c-myc encoded product (c-Myc) activates target genes that play
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important roles in cell proliferation, differentiation and apoptosis (Levens 2003). The c-myc 
proto-oncogene is believed to influence the expression of 10% of all genes in humans 
(Levens 2003).
In general, c-myc expression and c-Myc protein production are normally associated 
with the proliferative potential of a cell (Levens 2003). In addition, c-myc plays an important 
role in cellular differentiation (Dang 1999; Fracchini et al. 1998). Historically, c-myc was 
regarded as a gene that caused cellular immortalization (Levens 2003). It has since been 
observed that under certain circumstances c-myc is able to induce apoptosis (Dang 1999). 
The role of the c-myc proto-oncogene in the regulation of cell cycle progression, cellular 
differentiation and apoptosis is vital for normal cellular development (Levens 2003). 
However, when the expression of this gene is altered its effects can lead to cellular 
transformations and tumorigenesis (Fracchini et al. 1998; Levens 2003).
Tightly regulated control of c-myc mRNA is essential for normal cell proliferation but 
in many human cancers it is expressed at elevated levels (Hermeking 2003). The c-myc 
proto-oncogene is activated through several mechanisms including, chromosomal 
translocations, gene amplification, aberrant mRNA stabilization and point mutations 
(Hermeking 2003). Alterations in c-myc expression have been demonstrated in many types 
of cancer including, Burkitt’s lymphoma, melanoma, breast, colon and prostate cancer 
(Hermeking 2003). In many cases, aberrant expression of c-myc mRNA results in the 
transactivation of numerous target genes known to promote growth (Hermeking 2003). 
Although it has been demonstrated that c-Myc transactivates several growth promoting genes 
implicated in many cancers the mechanisms by which c-myc causes transformations remains 
unclear (Levens 2003).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 1 - INTRODUCTION 13
1.3.1 Regulation of the c-myc Gene
The expression of the c-myc gene is regulated at multiple levels through, 
transcriptional initiation (Brewer 2003; Lee et al. 1996), translational elongation (Lemm et 
al. 2002) and post-transcriptional processes (Yeilding et al 1996). Many of these processes 
are mediated through the interaction between c/.s-acting sequence elements and trans-acting 
factors (Guhanyogi et al. 2001). Transcriptional initiation is mediated by m -acting elements 
upstream of the c-myc promoter region (Lee et al. 1996; DesJardins et al. 1993; Hann et al. 
1988). These elements, which include: GC-rich sequences, tandem CT- and TATA boxes, 
are recognized and bound by a variety of trans-acting factors that influence the repression 
and activation of the c-myc gene (Lee et al. 1996; Spotts et al. 1997).
Coding Region
3 '-UTR5'-UTR
CRDc-myc mRNA
c-myc CRD mRNA (nts 1705-1886)
Figure 2: A schematic view of c-myc mRNA including the 5 ' and 3 '-untranslated 
regions and the Coding Region D eterm inant (CRD). The 3' segment of the c-myc
CRD (nts 1705-1886) was utilized throughout this investigation.
Expression of the c-myc gene is also influenced by the stability (i.e. half-life) of its 
encoded mRNA (Yielding et al. 1996; Jones et al. 1987). Regulating gene expression 
through transient changes in mRNA stability is observed in a variety of proto-oncogenes 
including: erbB, N-myc, c-fos and c-myc (Lee et al. 1996; Meulia et al. 1993). The 
abundance of mRNA in cells is dependent upon post-transcriptional events including, mRNA 
processing, nucleus-to-cytoplasm transport, mRNA stability and mRNA degradation (Siaomi 
et al. 1997). The short half-life of c-myc mRNA (i.e. 15-120 minutes) allows for rapid
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changes in mRNA abundance in response to environmental stimuli (Prokipcak et al. 1994). 
Among the post-transcriptional events, mRNA turnover is emerging as an important process 
that controls the levels of c-Myc production (Derrigo et al. 2000). The mechanisms that 
facilitate c-myc mRNA turnover are believed to involve RNA-binding proteins and 
ribonucleases (Prokipcak et al. 1994).
The stability of individual mRNA species is attributed to determinants found within 
their 3"-UTR, 5'-UTR and coding region (Brewer 2003). One category of instability 
determinants found in the c-myc mRNA sequence is known as the AU-rich element (ARE) 
(Langa et al. 2001; Brewer 2003). ARE-containing mRNAs have been divided into two 
classes based on the number and distribution of the AUUUA pentamer (Langa et al. 2001; 
Brewer 2003). Proto-oncogene and other hyper-unstable mRNAs such as c-myc, 
generally contain one to three AUUUA elements spaced throughout the 3'-UTR (Jones et 
al. 1987; Langa et al. 2001; Brewer 2003). ARE’s are recognized and bound by proteins that 
trigger the removal of the poly(A) tail and the 5 "cap structure; thereby leaving the mRNA 
molecule susceptible to exonucleolytic decay (Park et al. 2000; Brewer 2003).
An additional instability determinant in c-myc mRNA is located within the 3" coding 
region of exon-3 (Brewer 2003; Prokipcak et al. 1994). The 3' coding region encodes the C- 
terminal portion of the c-Myc helix-loop-helix/leucine zipper (HLH/LZ) domain and is 
referred to as the coding region determinant (CRD) (Prokipcak et al. 1994; Dang 1999; 
Brewer 2003). The destabilizing properties of the CRD have been demonstrated to act 
independently of AREs. For example, wild-type c-myc mRNA is more unstable when 
compared to modified forms that lack their CRD (Bernstein et al. 1992). In addition, c-myc 
mRNA remains unstable in the absence of its 3 "-UTR (Bernstein et al. 1992). When the c-
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myc CRD is fused in frame with the notoriously stable glob in mRNA coding region, the 
resulting chimeric molecule is destabilized (Bernstein et al. 1992).
An additional control point in the regulation of the c-myc gene involves processes 
occurring at the translational level. In vitro and in vivo evidence suggests that the CRD plays 
a role in destabilizing c-myc mRNA during translation (Lemm et al. 2002). These studies 
proposed that the presence of rare codons in a region upstream of the CRD were responsible 
for translational pausing (Lemm et al. 2002). In addition, the CRD which comprises a stem- 
loop structure from nucleotides 1705-1790 has been shown to be susceptible to degradation 
by endoribonucleases (Lemm et al. 2002). The CRD is known to interact with an RNA- 
binding protein known as the coding region determinant binding protein (CRD-BP). 
Evidence suggests that when a ribosome pauses at a rare codon site CRD-BP may dissociate 
from the CRD leaving the stem-loop structure exposed to cytoplasmic endoribonucleases 
(Lemm et al. 2002).
The inherent instability and high turnover of c-myc mRNA ensures that proteins like 
c-Myc are maintained in limited amounts within the cell (Dang 1999; Ross et al. 2001). c- 
Myc protein levels are directly influenced by changes in c-myc mRNA stability (Ioannidis et 
al. 2003). Therefore, the presence of instability determinants like AREs and the CRD 
provide a mechanism to prevent aberrant expression of products whose function can interfere 
with cell replication, development and differentiation (Brewer 2003; Dang 1999; Yeilding et 
al. 1996).
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1.4 RNA-Binding Proteins and Their Impact on Messenger RNA 
Stability
The stability of mRNA molecules is in part dependent upon their susceptibility to 
ribonucleases, the presence of stability/instability determinants in their sequence and their 
interactions with RNA-binding proteins. RNA-binding proteins that interact with 
stability/instability determinants can function to either increase or decrease the half life of 
their mRNA targets. The following section will address the structural and functional 
interactions of RNA-binding proteins that regulate mRNA stability in cells.
1.4.1 General Properties of RNA-Binding Proteins
RNA-binding proteins have structural conformations that allow them to specifically 
recognize and bind with the complex secondary structure of many RNA molecules (Chen
2005). The structural conformations that mediate these specific interactions are known as 
RNA recognition or RNA binding domains. This section will review the major protein 
motifs involved in RNA recognition and common binding mechanisms associated with these 
domains. A diagrammatic summary of the structural features of several RNA binding motifs 
is shown in Figure 3.
1.4.2 RNA Recognition Motifs
The RNA recognition motif (RRM) is known to bind single stranded RNA (Maris et 
al. 2005; Siomi et al. 1997). Frequently, RRMs are associated with proteins involved in 
post-transcriptional regulation of RNA (Maris et al. 2005; Siomi et al. 1997). RRMs are 
often found in multiple copies or paired with other RNA-binding motifs in some proteins 
(Maris et al. 2005; Siomi et al. 1997). The multiplicity of RRMs and their combination with
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other types of domains in RNA-binding proteins allows for greater diversity in RNA-binding 
affinity, specificity and biological function (Maris et al. 2005; Siomi et al. 1997).
N ^
m RNP domain
p a p  p o p
KH domain
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dsRDB
COOH
Zinc knuckle
c
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Figure 3: Stick and ribbon representations of RNP, dsRBM, KH domain and Zinc 
Finger RNA-binding motifs
The RRM is composed of 90 amino acids and contains two conserved sequences that 
are essential for its RNA-binding properties (Maris et al. 2005; Siomi et al. 1997). The first 
conserved sequence, ribonucleoprotein domain-1 (RNP-1) is composed of eight, aromatic 
and positively charged residues (Maris et al. 2005; Siomi et al. 1997). The second, RNP-2, 
is composed of six mainly aromatic residues and is predominantly located in the N-terminal 
region of this motif (Maris et al. 2005; Siomi et al. 1997). X-Ray crystallography studies 
have revealed that the RNA-binding surface of this domain is composed of residues found in 
the RNP-1 and RNP-2 regions (Maris et al. 2005; Siomi et al. 1997).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 1 - INTRODUCTION 18
The core of the RRM (refer to Figure 3) is centered on a large antiparallel p-sheet, 
which is packed against two a-helices and its secondary structure follows the general pattern, 
P1-OC1-P2-P3-OC2-P4 (Maris et al. 2005; Siomi et al. 1997). The proposed interactions that the 
RRM encounters with nucleic acids were determined by examination of the RNP domain of 
the U1 A protein with its conjugate U1 RNA hairpin (Maris et al. 2005; Siomi et al. 1997). 
In this example, RNP-1 and RNP-2, which make up the P-sheet RNA-binding platform, 
binds RNA through non-specific stacking interactions (Maris et al. 2005; Siomi et al. 1997). 
The stacking interactions are mediated by intermolecular forces of attraction between RRM 
aromatic side chains and RNA bases (Maris et al. 2005; Siomi et al. 1997). The stacking 
interactions facilitate the alignment of the nucleic acid molecule such that the 5 ' end is 
located on the first half of the P sheet (P4-P1) and the 3 ' end located on the second half, (P3- 
P2) (Maris et al. 2005; Siomi et al. 1997). Hydrophobic interactions between aromatic 
residues and ribose molecules and salt bridges formed between positively charged residues 
and phosphate moieties solidify the RRM-nucleic acid association (Maris et al. 2005; Siomi 
et al. 1997).
The specificity of RRM interactions is reportedly due to the presence of the linker 
sequences that connect P2-P3 (Maris et al. 2005; Siomi et al. 1997). The linker portion which 
is rich in basic residues is believed to penetrate RNA loop regions and induce conformational 
changes in the RNA structure (Maris et al. 2005; Siomi et al. 1997). It should be noted that 
the interactions between the bases, sugars and phosphates need not all be present in order for 
RNA-binding to occur (Maris et al. 2005; Siomi et al. 1997). However, the stacking 
interactions involving the two aromatic side chains on the Pi and P3 surfaces are most 
commonly observed (Maris et al. 2005; Siomi et al. 1997).
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RRM binding is not necessarily sequence specific however, common dinucleotide 
recognition elements including: AG, CG, CA, GU, UC and UG have been identified (Maris 
et al. 2005; Siomi et al. 1997). The role of RNA secondary structure is also an important 
aspect in RRM-RNA associations (Maris et al. 2005; Siomi et al. 1997). The need for 
specific secondary structure elements in recognition was exemplified by the interaction 
between nucleolin and the nucleolin recognition element (sNRE) RNA stem (Maris et al. 
2005; Siomi et al. 1997). When mutations were incorporated into sNRE, the nucleolin 
dissociation constant increased 1 0 0  fold due to the loss of its necessary secondary structure 
(Maris et al. 2005; Siomi et al. 1997). RRMs can also form complexes with themselves so as 
to increase the length of their P-sheet binding surface which allows for the binding of larger 
nucleic acids (Maris et al. 2005; Siomi et al. 1997).
1.4.3 hnRNP K Homology Domain
The hnRNP K homology domain (KH domain) is one of the most commonly 
identified RNA-binding motifs and has been found in more than 300 proteins including all 
members of the VICKZ protein family (Grishin 2001). KH domains have been implicated in 
nuclear localization (Neilsen et al. 2004), nucleus to cytoplasm shuttling (Neilsen et al.
1999), and mRNA stability (Ioannidis et al. 2004).
The KH domain is composed of approximately 65-70 amino acids (Chen 2005; 
Grishin 2001). The tertiary structure of the KH domain (refer to Figure 3) consists of three 
antiparallel P-sheets, which are packed against three a-helices, forming a highly stable Pi-ai- 
ct2-p2-P3-a.3 arrangement (Musco et al 1996). This RNA-binding surface also contains a 
tetrapeptide sequence (Gly-Lys-X-Gly) which is present between the first and second alpha
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helicies (Chen 2005; Grishin 2001). The tetrapeptide segment contains a semi-conserved, 
positively charged residue denoted as “X”. In conjunction with an additional variable loop 
found between the second and third P-sheets, these structures are believed to play a key role 
in specific RNA recognition and binding (Chen 2005; Grishin 2001).
Table 1: KH domain containing proteins and their known RNA recognition sequences 
Mo
KH
Kll
KH
Kll 
KH 
Kll
KH
The progression of events that mediate specific recognition and binding begins when 
the hydrophobic RNA binding platform (i.e. Pi-ai-a2) interacts with single stranded 
tetranucleotide elements in RNA (Chen 2005; Grishin 2001). The specificity of the 
interaction is thought to be mediated by the tetrapeptide linker region found between a i -012 
and to a lesser extent by the loop region found between P2-P3 (Chen 2005; Grishin 2001). 
Again, it is believed that the linker regions penetrate RNA hairpin loops and induce
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conformational changes in the target thereby promoting further intermolecular interactions 
between RNA and protein (Chen 2005; Grishin 2001).
Several KH domains contain within their sequences a nuclear localization/export 
signal and a novel shuttling domain known as the hnRNP-K nuclear shuttling domain (Chen 
2005; Grishin 2001). These domains have been found in several KH domain containing 
RNA-binding proteins implicated in nucleus to cytoplasm shuttling (Neilsen et al. 2004). 
Another feature common to KH domain containing proteins is the arrangement of the motif 
itself. When greater than one KH domain is present in an RNA-binding protein one or more 
of these domains are localized to the N-terminus and one or more are localized to the C- 
terminus (Chen 2005; Grishin 2001).
The presence of multiple KH domains in certain RNA-binding protein suggests that 
multiple interactions may be required for stable, high affinity interactions (Cunningham et al. 
2000). In addition, multiple KH domains may also allow certain RNA-binding proteins to 
bind several RNA targets simultaneously (Ross et al. 1997). These implications are 
paramount when one considerers the multiplicity of function inherent to KH domain 
containing RNA-binding proteins. For example, the human zipcode binding protein (i.e. 
IMP1) has been shown to bind multiple RNA targets (Neilsen et al. 2004) via its 4-KH 
domains, bind several proteins such as FMRP (Rackham et al. 2004) and has also been 
implicated in shuttling mRNA targets from the nucleus to the cytoplasm in vitro and in vivo 
(Rackham et al. 2004). A function inherent to numerous KH domain containing proteins is 
their ability to regulate the stability of RNA targets (Chen 2005; Grishin 2001). Their 
stabilizing function therefore requires specific and highly stable interactions with RNA;
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especially in the context of RNA localization where exposure to ribonucleases is inevitable 
(Chen 2005; Grishin 2001).
1.4.4 RGG-Box
The discovery of a C-terminal polypeptide, plO from Nucleolin, revealed another 
RNA-binding domain known as the RGG box (Ghisolfi et al. 1992). The RGG-box is an 
eighty five-amino acid polypeptide containing a high composition of glycine, arginine and 
phenylalanine residues (Chen 2005; Siomi 1997). Structurally the RGG box adopts a helical 
conformation made up of repeated (3-tums (Ghisolfi et al. 1992; Chen 2005; Siomi 1997). 
The majority of the interactions involving RGG motifs are the result of hydrogen bonding 
between amino acid side chains and negatively charged phosphate and hydroxyl groups on 
RNA (Hermann 2000). The RNA-binding surface of this motif is generally rich in basic 
amino acids which contribute to hydrogen bonding (Chen 2005; Siomi 1997; Hermann 
2000). In addition, intermolecular stacking interactions between hydrophobic portions of 
RNA bases and non-polar side chains of amino acids stabilize the RGG-RNA complex (Chen 
2005; Siomi 1997; Hermann 2000).
1.4.5 Double-Stranded RNA Binding Motif
The primary function of the double-stranded RNA binding motif (dsRBM) is to bind 
structured RNA molecules (Chang et al 2005; Chen 2005; Siomi 1997). The dsRBM (refer 
to Figure 3) is approximately 70 amino acids long and forms a ai-Pi-P2-P3-oi2 arrangement 
(Chang et al 2005; Chen 2005; Siomi 1997). This diverse motif is found in eukaryotic and 
prokaryotic cells and is implicated in many processes including RNA processing and RNA
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localization (Chang et al 2005; Chen 2005; Siomi 1997). Proteins containing dsRBM 
generally contain multiple copies of this motif and are grouped into two categories depending 
on the presence or absence of a catalytic domain within the protein in which they are found 
(Chang et al 2005; Chen 2005; Siomi 1997). Examples of dsRBM proteins with and without 
a catalytic domain include RNA helicase A and the staufen RNP localization protein, XIrbpa 
(Chang et al 2005; Chen 2005; Siomi 1997).
It has been demonstrated that a dsRNA molecule is not crucial for recognition, 
however an RNA helix (i.e. A-Type helix) approximately 12-16 base pairs in length is the 
essential requirement for recognition (Chang et al 2005; Chen 2005; Siomi 1997). For 
example, the XIrbpa protein binds across 16 RNA bases and interacts with three successive 
minor, major and minor groves on the RNA helix (Chang et al 2005; Chen 2005; Siomi 
1997). The dsRBM-RNA interaction is predominantly the result of direct and water 
mediated hydrogen bonding (Chang et al 2005; Chen 2005; Siomi 1997). Specifically, the 
residues that make up the linker regions between P1-P2 and P3-012 interact with 2 'OH and 
phosphate groups of the major and minor grooves (Chang et al 2005; Chen 2005; Siomi 
1997).
1.4.6 Zinc Fingers
Zinc fingers are a common and diverse structural motif found in all eukaryotes and 
play a substantial role in post-transcriptional regulation (Chen 2005). Zinc fingers are mainly 
found in DNA-binding proteins such as transcription factors (e.g. TFIIIA) and are also 
known to bind RNA and protein (Chen 2005). A zinc finger typically contains 30 amino 
acids and structurally consists of two antiparallel P-strands and one a-helix (Chen 2005).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 1 - INTRODUCTION 24
The (X-P1-P2 secondary structure (refer to Figure 3) is stabilized by a zinc ion that is bound to 
a pair of cystine residues in the P-strands and to a pair of histidine residues in the a-helix 
(Chen 2005). There exists a variety of zinc finger classes (i.e. C2H2 , C2HC, C2C2 or CCHH) 
and they are differentiated from one another based on the manner in which they complex zinc 
ions (Chen 2005). Zinc fingers are capable of recognizing the complex structural elements 
inherent to RNA by recognizing exposed bases in looped out regions of RNA (Chen 2005). 
Examples of zinc finger interactions with RNA are diverse however only the CCCH class is 
directly involved in regulating mRNA stability (Chen 2005; Brewer 2003). For example, 
tristetraproline, a CCCH class zinc finger containing protein has been reported to destabilize 
ARE containing mRNA in vivo (Brewer 2003).
Of great importance to the study of RNA-protein interactions is the issue of structural 
recognition between RNA and protein. To date, in vitro studies have focused on analyzing 
interactions between isolated mRNA elements (i.e. 5'-UTRs, 3'-UTRs and coding regions) 
and various recombinant and native RNA-binding proteins (Chen 2005). These studies have 
revealed a wealth of information regarding the primary sequences and/or individual 
nucleotides recognized by these proteins. In addition, these studies have provided valuable 
insight into the potential function of these proteins. While there is some consensus regarding 
motif recognition of RNA it is unclear how individual RNA-binding proteins utilize the sum 
of their domains for specific recognition of RNA targets.
1.5 Properties and Functions of the VICKZ Family of RNA-Binding 
Proteins
A multifunctional family of RNA-binding proteins termed the VICKZ protein family 
is known to directly influence the expression of multiple genes (Yisraeli 2005). This family
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of proteins is responsible for the localization, stabilization and translation of target mRNA in 
developing cells (Yisraeli 2005). The VICKZ family is comprised of several orthologous 
proteins including: Xenopus-V g 1RBP/Vera, human-IMP-1, 2, 3, mouse-CRD-BP, the human 
KH domain-containing protein over expressed in cancer (KOC) and the chicken zipcode- 
binding protein (ZBP-1) (Yisraeli 2005).
There is a significant degree of sequence similarity between VICKZ proteins (i.e. 70- 
99%) (Yisraeli 2005). The highest degree of conservation between these proteins is found 
within their RNA-binding motifs, which includes 4 KH domains and 2 RRMs (Yisraeli 
2005). In addition, VICKZ proteins contain nuclear export and nuclear import signals (refer 
to Figure 2 for a generalized VICKZ protein map) and as a result they are localized in the 
cytoplasm and within the nucleoplasm (Nielsen et al. 2003). The manners in which VICKZ 
RNA-binding proteins elicit changes in gene expression are varied and will be the focus of 
the following sections.
1 2 0 1 2  2 2 2  0 0 0 0 0 0 0
Figure 4: Protein map of CRD-BP/IMP1. This schematic representation of CRD-BP/IMP 1 
includes the relative locations of the major RNA binding domains common to all VICKZ 
protein family members; RRM = RNA Recognition Motif, KH = KH domain. The pink 
rectangle between the KH domains represents the location of the nuclear export/import 
localization signals. The numbers 0, 1 and 2 represent the locations of N-myristoylation 
sites, Casein Kinase II and Protein kinase C phosphorylation sites.
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1.5.1 VICKZ Protein Function and Messenger RNA Targets
In vitro methods including UV crosslinking, electrophoretic mobility shift assays 
(EMSA) and microplate-based fluorescence anisotropy have elucidated numerous RNA 
targets recognized by VICKZ proteins (Mao et al. 2006). These techniques have also 
provided a wealth of information regarding the general components necessary to facilitate 
binding, binding kinetics and proposed functional roles for VICKZ proteins. A summary of 
the RNA targets and proposed functions of several VICKZ proteins are presented in Table 2.
Table 2: VICKZ Protein Targets and the Consequences of their Interactions
RNA-Binding RNA
Protein Target(s)
KOC I nhnown
VglRBP/Vera Vgl VLE
ZBP-1 /?-actin
IMP-1/CRD-BP H19, c-myc, 
yff-actin and 
IGF-II
IMP3 1119. IGI -II
Consequence(s) of RNA-Protein Interaction
Stabilization ol mRNA associated with tumor cel. 
proliferation in vivo (Mudicr-PiiUisch o al. m i)
Localization of Vgl mRNA to vegetal cortex during 
Xenopus oogenesis in vivo (Git e ta i .  2002)
Localization ol /I,ictin to the leading edge of libroblasls. 
oocytes and neurons in vivo k. ^ / .■/. I ■
(1)Affects localization in vivo, stability in vitro and 
translation of H I9, /?-actin in vivo (loannidis e ta i .  2005)
(2) c-myc mRNA stabilization hypothesized and based on 
indirect in vitro evidence (Prokipcak et al. 1994)
(3) repress translation of leader 3 7GF-II in vivo
i Ivuimiidis <-/ til. 20051
Translational activator of 1C i f - II leader 3 and leader 4 
mRNA in vivo d.iao <■/«/. 20041
One of the few interactions successfully mapped to date involves the interaction 
between ZBP-1 and /3-actin mRNA (Ross et al. 1997; Farina et al. 2002). In chicken embryo 
fibroblasts, fi-actin mRNA is localized to the leading edge of the cell in a region known as 
the lamella. The localization of P-actin to this region is required to ensure the appropriate 
distribution, translation and polymerization of actin which is necessary for directional
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movement (Ross et al. 1997; Farina et al. 2002). The VICKZ protein, ZBP-1, has been 
implicated in the translocation of /3-actin mRNA in vitro and in vivo (Ross et al. 1997; Farina 
et al. 2002). It was determined that this interaction was mediated exclusively via the ZBP-1 
KH domains and a highly conserved 54-nucleotide sequence (containing ACACCC rich 
elements) in the 3'-UTR of f3-actin\ a region known as the zipcode (Farina et al. 2002). 
When mutations were introduced into the P-actin zipcode binding, granule formation and 
peripheral localization was abolished (Ross et al. 1997; Farina et al. 2002). A similar loss in 
binding activity was observed in variant ZBP-1 proteins containing mutations in their KH 
domains (Ross et al. 1997).
In the early stages of Xenopus oogenesis Vgl mRNA is uniformly distributed 
throughout the cytoplasm (Git et al. 2005; Deshler et al. 1997). VglRBP/Vera is a protein 
involved in the localization of Vgl mRNA to the vegetal cortex during the late phases of 
oogenesis (Git et al. 2005; Deshler et al. 1997). Vgl mRNA encodes a transforming growth 
factor necessary for mesoderm induction (Deshler et al. 1997). Binding between VglRBP 
and Vgl mRNA is mediated by elements found in the 3 '-UTR of Vgl mRNA, a region 
known as the vegetal localization element (VLE) (Git et al. 2005; Deshler et al. 1997). 
Following binding to VglRBP and multiple other proteins the VglRBP/Vgi mRNA complex 
associates with microtubules and is translocated to the site of translation (Git et al. 2005). In 
vitro and in vivo studies have also revealed the specific sites within the VLE required for 
optimal VglRBP binding. Deletions and mutations in UUUCUA and UUCAC VLE 
sequences abolish binding in vitro and significantly decrease VLE localization in NIH-3T3 
cells (Git et al. 2005).
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IMP1/CRD-BP interacts with a range of mRNA targets which encode proteins that 
are essential for normal cellular development (Nielsen et al. 2003; Nielsen et al. 2004; 
Rackham et al. 2004). IMP1/CRD-BP has been shown to bind with 7GF-II, c-myc, H19 and 
neuron specific tau mRNAs (Nielsen et al. 2003; Nielsen et al. 2004; Rackham et al. 2004). 
EMP1/CRD-BP has been reported to inhibit the translation of 7GF-II leader 3 mRNA in vivo, 
proposed to increase the stability of c-myc mRNA in vitro (Bernstein et al. 1992), and 
localize 7779 and tau mRNA in vitro (Liao et al. 2005; Liao et al. 2004; Ioannidis et al.
2003).
IMP1/CRD-BP knockdown experiments in K562 and MCF-7 cell lines have reported 
an increase in IGF-II expression and a significant increase in cell proliferation rates (Liao et 
al. 2005; Liao et al. 2004; Ioannidis et al. 2003). These studies also demonstrated that c-myc 
mRNA and c-Myc protein levels were not significantly altered by the knockdown of CRD- 
BP (Liao et al. 2005; Liao et al. 2004; Ioannidis et al. 2003). To date, abundant in vitro and 
in vivo evidence supports the proposed function of IMP1/CRD-BP as an mRNA localizing 
factor. However, the proposed mRNA c-myc mRNA stabilizing function of IMP1/CRD-BP 
has yet to be supported by direct in vitro evidence.
The interactions between IMP1 and IGF-U mRNA have been evaluated in COS-7 cell 
lines using bimolecular fluorescence complementation (Rackham et al. 2004). IMP1 is 
believed to bind 7GF-II leader 3 in the nucleus, mediate nucleus to cytoplasm translocation 
and localization to specific subcellular regions via cytoskeletal tracts (Nielsen et al. 2003; 
Nielsen et al. 2004; Rackham et al. 2004; Liao et al. 2005). It was also shown that 
IMP 1/CRD-BP binds to 7GF-II leader 3 mRNA at C-rich elements in the 5'-UTR (Rackham 
et al. 2004).
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The binding of IMP1 to IGF-ll has been shown to follow a sequential, cooperative 
mechanism (Nielsen et al. 2004). Sequential binding involves the formation of an unstable 
intermediate binding complex (i.e. high on and off rates) between one mRNA molecule and 
IMP1 (Weiss 1997). The second IMP1 molecule then enters the initial complex through 
interactions with another binding site on the RNA (Weiss 1997). The resulting complex is 
thought to be stabilized by protein-protein interactions between the two IMP1 molecules 
(Nielsen et al. 2004). Binding in this way is reflective of a cooperative mechanism and is 
observed in several VICKZ-RNA interactions (Nielsen et al. 2004).
IMP3 is another example of a VICKZ protein family member and shares 
approximately 70% amino acid sequence homology with IMP1 (Liao et al. 2005). IMP3 is 
known to associate with IGF-ll leader 3 and leader 4 mRNA and H19 mRNA in vivo and has 
not been shown to associate with c-myc (Liao et al. 2005). IMP3 knockdown via siRNA has 
been reported to cause significant reductions in IGF-II protein levels and also significantly 
inhibits cell proliferation in K562 cell lines (Liao et al. 2005). Based on the results of these 
observations IMP3 is believed to be a translational activator of 7GF-II and plays a critical 
role in regulating cell proliferation via an 7GF-II dependant pathway (Liao et al. 2005).
1.5.2 The Influence of RNA Secondary Structure on Messenger RNA Recognition
Limited experimental evidence pertains to the significance of RNA secondary and 
their influence on VICKZ-RNA interactions. Examining these interactions is complicated by 
the fact that the free-energies associated with individual RNA molecules are varied and this 
contributes to a diversity of secondary structures within a given mRNA species (Buratti et al.
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2004). It is therefore difficult to accurately determine which mRNA configuration is 
representative as the optimal binding target.
It is believed that VICKZ proteins initiate their interactions with targets in the nucleus 
during different phases of transcription and pre-mRNA post-transcriptional processes 
(Vikessa et al. 2006). During transcription hnRNPs maintain the linear conformation of pre- 
mRNA however; specific regions may still fold into localized RNA structures (Buratti et al.
2004). The potential for RNA-binding proteins and/or protein complexes to bind to these 
localized RNA structure is enhanced because the RNA has not folded into complex tertiary 
structures. It seems likely that some RNA-binding proteins (i.e. the VICKZ family) bind 
sequence specific regions of RNA in the nucleus before the RNA folds into its tertiary 
structure and before it is becomes enveloped in protein.
A common theme in RRM and KH domain interactions with RNA is the need for 
secondary structures such as hairpin, bulge and branch loops and single stranded pyrimidine 
tracts (Yisraeli 2005; van Dijk et al. 2000). An additional theme emerging from in vitro and 
in vivo investigations is the observations that individual VICKZ proteins recognize several 
RNA targets (Yisraeli 2005). As a consequence, VICKZ proteins may exert a wider range of 
post-transcriptional effects than originally thought. The combined effects of multiple RNA- 
binding proteins interacting with multiple RNA targets may provide a redundant RNA 
regulatory check point which ensures proper distribution, stabilization and expression of 
mRNA.
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1.5.3 VICKZ Multiple Protein Interactions
VICKZ proteins are also known to associate with a multitude of proteins via RNA- 
dependant and RNA-independent interactions (Yisraeli 2005). The formation of large RNA- 
protein complexes (i.e. RNP granules) has been observed in many systems directly by 
fluorescence microscopy (Rackham et al. 2004; Farina et al. 2002) or indirectly by 
immunoprecipitation (Ross et al. 1997). For example, ZBP-1 was found to co-purify and co- 
immunoprecipitate with three other proteins, only one of which was capable of binding to the 
P-actin zipcode using EMSA (Ross et al. 1997). The investigators proposed a hypothesis 
that ZBP-1 binds to the zipcode stem-loop sequence (ACACCC) and this association was 
stabilized by the three other co-purified proteins (Ross et al. 1997). The additional proteins 
which include hnRNPs, motors and translation factors form a transport complex known as 
the locasome (Farina et al. 2002). It is thought that locasome plays a role in attachment to 
the cytoskeleton, transport and anchoring to the fibroblast cell periphery (Farina et al. 2002).
Another example involving a VICKZ protein complex involves the association of 
Vgl mRNA with VglRBP in the nucleus (Git et al. 2002). Several proteins believed to play 
a role in the localization process of Vgl mRNA include VglRBP, hnRNPl/PTB and a 
purine-rich RNA-binding protein (PrrP) (Git et al. 2002). Vgl RBP/Vera and hnRNPI are 
reported to bind with repetitive pyrimidine rich motifs (UUUCUA, UGCACAGAG, 
CUGUUA and UUCAC) within the Vgl VLE (Git et al. 2002). In contrast, PrrP is reported 
to bind purine rich elements and interact with ligands involved in actin polymerization and 
may also mediate anchoring of Vgi-RNP to the cytoskeleton (Git et al. 2002).
In another example IMP1 was shown to associate with the RNA-binding protein, 
FMRP, through an RNA independent mechanism (Rackham et al. 2004). It has been
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proposed that the formation of transport granules and the efficient localization of p-actin 
mRNA were mediated via protein-protein interactions between FMRP and IMP1 (Rackham 
et al. 2004). IMP1 which is predominantly a cytoplasmic protein has been shown to 
associate with FMRP and P-actin mRNA in the nucleus (Rackham et al. 2004). The 
proposed interaction is initiated by IMP1 binding with the P-actin zipcode followed by 
FMRP binding to IMP1 through protein-protein interactions (Rackham et al. 2004). It has 
also been reported that IMP1 and FMRP carry out similar association with FMR1 3'-UTR 
RNA (Rackham et al. 2004).
These observations lend further support to the belief that RNA binding proteins bind 
a wide range of RNA targets and their functional role may be augmented by their association 
with various proteins. Cooperative protein complexes therefore represent an efficient use of 
resources. In this way, proteins with diverse functional roles work in concert to ensure the 
execution of timely post transcriptional processes including the facilitation of nuclear export, 
distribution of mRNA and the regulation of gene expression through transcript stabilization.
1.5.4 VICKZ Proteins and Developmental Regulation
The majority of developmental studies have determined that VICKZ proteins are 
highly expressed during developmental stages in a variety of different organisms (Yisraeli 
2005). In Xenopus Vgl RBP/Vera is expressed in the late gastrula and early neural stages in 
the epidermal ectoderm and later in the neural crest and central nervous system (Git et al. 
2002). In embryonic mice, strong expression has been detected in the brain, thymus, 
pancreas and lungs (Ross et al. 1997; Yisraeli 2005). After birth, VICKZ expression is
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significantly down regulated and is detectable at very low levels in the placenta, testes and 
intestine (Mueller-Pillasch et al. 1997; Yisraeli 2005).
The expression patterns of VICKZ proteins suggest that their activities play an 
essential role in the developing organism (Yisraeli 2005). The expression of VICKZ proteins 
in adult organisms has been examined in order to gauge what their role in development may 
be. The abnormalities resulting from overexpression of VICKZ proteins are varied. For 
example, overexpression of KOC in mice caused subtle changes in the microarchitecture of 
the pancreas and parathyroid gland (Mueller-Pillasch et al. 1997). In contrast, pregnant mice 
over expressing CRD-BP exhibited a significantly higher incidence of mammary tumors 
when compared to the negative control group (Tessier et al. 2004).
Experiments using antisense morpholino oligonucleotide (AMO)-mediated down 
regulation of VglRBP/Vera illustrate the developmental necessity of VICKZ proteins (Git et 
al. 2002). In these knock down experiments Xenopus phenotypes were characterized by a 
loss of lateral pigment, reduced or absent dorsal fin, abnormal head morphology, impaired 
lens formation and a dorsally open neural tube (Git et al. 2002). The impaired migration of 
neural crest and neural roof plate cells was the result of a significant reduction (i.e. 80%) in 
VglRBP protein levels (Git et al. 2002). In addition, neural crest cells isolated from AMO- 
treated embryos demonstrated reduced mobility and an absence of VglRBP expression (Git 
et al. 2002). The evidence suggests that VglRBP ensures the asymmetric migration of cells 
during embryogenesis (Git et al. 2002).
The localization of mRNA to distinct regions within the cell is another way to 
regulate developmental gene expression (Ross et al. 1997). In neuronal development, 
dendritic filopodia require local polymerization of actin and $-actin mRNA localization to
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these regions is an essential part of the process (Yisraeli 2005). However, AMO-directed 
knock down of ZBP-1 in neuronal cells blocks the localization of P-actin and contributes to a 
loss of dendritic filopodia and reduced synapse development (Yisraeli 2005). In contrast, 
when P-actin is over expressed in the presence of normal levels of ZBP-1, dendritic filopodia 
and synapse density significantly increase (Yisraeli 2005). This evidence suggests that ZBP-
I plays a role in P-actin mRNA localization and normal neuron development (Yisraeli 2005). 
CRD-BP/IMP1 is also known to co-associate with HuD and tau mRNA. HuD is an RNA- 
binding protein known to localize tau mRNA from the cell body to distal parts of an exon 
during neuron development (Park-Lee et al. 2003). The association between CRD-BP/IMP1 
and HuD, further supports the observation that CRD-BP/IMP1 is involved in protein 
complexes associated with mRNA trafficking (Park-Lee et al. 2003; Deschenes-Furry et al.
2005).
CRD-BP and its human ortholouge, IMP1, are also closely associated with normal 
cellular development as they are believed to regulate mRNA stability (Nielsen et al. 2003). 
For example, CRD-BP/IMP 1 deficient mice exhibit dwarfism, impaired gut development and 
increased mortality (Ioannidis et al. 2005). CRD-BP/IMP1 was initially identified as a 
regulatory protein that interacts with c-myc mRNA in vitro and is believed to play a role in c- 
myc stabilization (Bernstein et al. 1992). However, IMP1/CRD-BP knockdown experiments 
in HeLa cells failed to show any decrease in the levels of c-myc mRNA or c-Myc protein 
levels (Vikessa et al. 2006).
In addition, CRD-B P/IMP 1 regulates a fetal growth factor, insulin-like growth factor
II (IGF-II), essential for the normal growth of cells during embryonic development (Ioannidis 
et al. 2005). Interestingly, CRD-B P/IMP 1 knock down via siRNA caused a modest (22%)
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reduction in c-myc mRNA levels, a significant (15-fold) increase in the levels of IGF-ll 
mRNA and a reduction in cell proliferation in MCF-7 cells (Ioannidis et al. 2005). 
IMP1/CRD-BP has recently been shown to play a role in the regulation of genes encoding 
cell-cell adhesion proteins and invadopodia in vivo (Vikessa et al. 2006). IMP1/CRD-BP 
knockout mice showed a down regulation in transcripts encoding the cell adhesion proteins, 
ALCAM, CD24, CD44, MCAM and SynCAM (Vikessa et al. 2006). In normal cells these 
transcripts are associated with IMP1 granules, which is further support the mRNA 
localization function of IMP 1 /CRD-BP.
1.6 The Coding Region Determinant Binding Protein
The c-myc coding region determinant binding protein (CRD-BP) was initially 
discovered in polysome extracts from K562 human erythroleukemia cell extracts (Bernstein 
et al. 1992). CRD-BP has subsequently been purified and its cDNA has been cloned and 
sequenced (Doyle et al. 2000). The CRD-BP gene contains 15 exons and 14 introns and is 
located on chromosome 11 in mice and chromosome 17 in humans (Doyle et al. 2000; Leeds 
et al. 1997). CRD-BP is made up of 577 amino acids (approximately 6 8 kDa, p i 9.20) and 
shares the full complement of RNA-binding motifs shared by VICKZ family members 
(Doyle et al. 1998; Leeds et al. 1997). CRD-BP has been shown to bind with four RNA 
targets including HI 9, leader 3 IGF-II, tau (in vivo) and c-myc mRNA (in vitro) (Ioannidis et 
al. 2005; Liao et al. 2004; Doyle et al. 2000 ). The human equivalent, IMP1, is reported to 
suppress IGF-ll leader 3 RNA expression, and bind H I9 mRNA (Ioannidis et al. 2003; Liao 
et al. 2004).
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CRD-BP is primarily found in the cytoplasm, co-sediments with polysomes and is 
also distributed along microtubules (Ioannidis et al. 2003). Immunohistochemistry 
investigations have reported that CRD-BP also localizes within the nucleus (Doyle et al. 
1998; 2000). These observations suggest that CRD-BP may play dual functional roles, as an 
mRNA localization factor and potentially as an mRNA stabilizing factor.
Typically CRD-BP is expressed in embryonic tissues and its mRNA and protein 
levels steadily decrease until birth (Leeds et al. 1997). CRD-BP is virtually undetectable in 
adult tissues (Leeds et al. 1997). However, expression has been detected in human 
spermatogenic cells using immunohistochemistry (Ioannidis et al. 2005). Using RT-PCR, 
CRD-BP mRNA has been detected in the intestines and placental tissue of adult mice 
(Ioannidis et al. 2005). The presence of CRD-BP in proliferative adult tissues prompted 
Ross et al. 2001 to propose that its potential role in the stabilization of c-myc mRNA 
contributes to the normal development and proliferation of these tissues. A more detailed 
analysis regarding the proposed functional role of CRD-BP will be discussed in the following 
section.
1.6.1 CRD-BP and c-myc mRNA Stability
A number of experiments have utilized in vitro mRNA decay assays to indirectly 
investigate how the CRD affects c-myc mRNA stability (Bernstein et al. 1992; Prokipcak et 
al. 1994). These cell-free assays utilized polysomes from cultured cells, which contain a 
variety of other proteins and co-factors that normally influence mRNA stability. These 
studies found that deprotenized c-myc mRNA is degraded in a 3' to 5" direction by the 
activities of exoribonucleases (Brewer 2003). In a separate study where a 180nt RNA sense
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strand competitor corresponding to the c-myc CRD was added to the reaction, an alternative 
degradative pathway was observed (Bernstein et al. 1992). The competitor RNA strand 
induced endonucleolytic cleavage within the c-myc CRD and destabilized the mRNA 8 -fold 
(Bernstein et al. 1992).
A regulatory protein with affinity for the c-myc CRD termed, CRD-BP, was 
subsequently identified and isolated (Prokipcak et al. 1994). CRD-BP was identified using 
EMSA and was shown to bind with considerable specificity to the c-myc CRD in vitro 
(Prokipcak et al. 1994). The increased destabilization of c-myc mRNA upon addition of 
competitor RNA was believed to be the result of CRD-BP being titered off the endogenous 
mRNA and binding to the sense strand competitor (Prokipcak et al. 1994). The absence of 
CRD-BP from these transcripts may have contributed to an increased susceptibility to 
endonucleolytic attack (Prokipcak et al. 1994). The use of different competitor RNAs 
corresponding to other c-myc RNA sequences had no destabilizing effect on the transcript 
and c-myc CRD competitor RNA did not destabilize other mRNAs tested. These 
observations led to the hypothesis which suggests that specific binding between CRD-BP and 
the CRD stabilizes the c-myc transcript by shielding it from endoribonucleolytic attack 
(Prokipcak et al. 1994).
Animal models had been used to determine if CRD-BP abundance is associated with 
increased c-myc mRNA levels (Doyle et al. 2000; Ross et al. 2001; Tessier et al. 2004). 
These studies found that: (i) CRD-BP and c-myc mRNA were not detected in various adult 
tissues such as liver, (ii) CRD-BP and c-myc mRNA were detected in early neo-natal 
hepatocytes and their levels diminished 14 days after birth and (iii) only c-myc mRNA 
increases in abundance following a partial hepatoectomy whereas CRD-BP remains
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undetectable (Ross et al. 2001). Similar experiments found detectable levels of both CRD- 
BP and c-myc in transformed cell lines (Ioannidis et al. 2004; Leeds et al. 1997).
These observations suggest that CRD-BP is an oncofetal protein that may contribute 
to cellular transformations and cancer phenotypes via deregulation of growth promoting 
genes when expressed in adult cells (Ioannidis et al. 2004). The absence of CRD-BP 
expression in regenerating adult hepatocytes suggests that mRNA stabilization of growth 
promoting genes such as c-myc may be not be regulated by CRD-BP (Leeds et al. 1997). 
The abundance of CRD-BP mRNA and CRD-BP protein during periods of rapid cell growth 
in embryogenesis and in neonatal life is consistent with the hypothesis that cell proliferation 
requires elevated levels of gene products that stimulate growth (Prokipcak et al. 1994; Leeds 
et al. 1997). Therefore the shielding model of c-myc mRNA stabilization in embryonic and 
neonatal cells could account for the increase in cell proliferation observed in developing 
tissues. Evidence in support of c-myc stabilization by CRD-BP (i.e. shielding hypothesis) 
has not been directly tested or confirmed in vitro. In addition, in vivo studies have yet to 
show a correlation between increased CRD-BP mRNA/protein levels and increased c-myc 
mRNA stability or c-Myc abundance. However, one study has shown a relationship between 
CRD-BP and c-myc mRNA levels (Ioannidis et al 2005). When CRD-BP expression was 
knocked down in MCF-7 cells a subsequent decrease in c-myc mRNA levels were observed 
(Ioannidis et al 2005).
1.6.2 RNA-Binding Proteins Affecting mRNA Stability
Several RNA-binding proteins including: HuD, HuR, aCP, IRE-BP and vigilin are 
capable of increasing the stability of target mRNA through interactions with instability
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determinants. Human neuron-specific RNA-binding proteins, HuD and HuR belongs to the 
Hu family of RRM-containing proteins, all of which bind to AU-rich elements (ARE) in the 
3 "-UTR of unstable mRNA (Park-Lee et al. 2003). These proteins, are reported to increase 
target mRNA stability by preventing ARE-mediated mRNA turnover (Park-Lee et al. 2003). 
The stabilizing function of Hu proteins was supported by antisense HuR knockdown and 
HuR overexpression experiments. These in vivo investigations revealed that a decrease in 
HuR protein levels correlated with an increase in ARE mediated mRNA decay. In addition, 
overexpression of HuR correlated with an increase in ARE mRNA stability (Kong et al. 
2003; Deschenes-Furry et al 2005).
The human a2-globin mRNA belongs to a subset of mammalian mRNA that are 
considered highly stable (Parker et al. 2004). The RNA-binding protein a-globin poly(C) 
binding protein is a 39kDa protein that has been shown to associate with a C-rich motif found 
in the 3'-UTR of a2-globin mRNA in vivo (Kong et al. 2003). When bound to its mRNA 
target one or more isoforms of a-globin poly(C) binding proteins, collectively known as the 
a-complex (aCP), is reported to interfere with poly(A)binding protein (PABP) associations 
with the 5 "cap thereby lowering the rate of poly(A) removal (Kong et al. 2003). In addition, 
in vitro studies have revealed that aCP prevents endoribonucleolytic cleavage of globin 
mRNA within its 3"-UTR by ErEN (Kong et al. 2003). Together these in vivo and in vitro 
observations suggest a role for the a-complex in regulating the steady-state levels of a 2 - 
globin mRNA.
The iron responsive element (IRE) is a 30 nucleotide stable hairpin structure found in 
the 5'-UTR of ferritin mRNA and the 3"-UTR of the transferrin receptor (TfR) mRNA 
(Cairo et al. 1994). The IRE in both cases is implicated in regulating the stability of these
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two transcripts in vivo (Cairo et al. 1994). The post-transcriptional regulation of TfR and 
ferritin mRNA is also influenced by the presence of the iron-responsive element binding 
protein (IRE-BP) (Cairo et al. 1994). In regenerating rat hepatocytes, an increase in TfR 
mRNA was observed in the absence of significant changes in TfR gene transcription (Cairo et 
al. 1994). The increased TfR mRNA abundance is the result of IRE-BP binding to one of 
five iron-response elements in the 3'-UTR of TfR mRNA (Cairo et al. 1994). Cellular iron 
homeostasis is maintained by controlling iron uptake by regulating TfR mRNA stability and 
by modulating iron sequestration by controlling the translation of ferritin (Cairo et al. 1994). 
When intracellular iron concentrations are low IRE-BP protects the TfR transcript from 
degradation and suppresses ferritin translation (Cairo et al. 1994). When intracellular 
concentrations of iron are high IRE-BP does not interact with TfR thereby destabilizing the 
transcript (Cairo et al. 1994).
One final example of an mRNA stabilization factor is the RNA-binding protein 
vigilin (Cunningham et al. 2000). In Xenopus, estrogen stabilizes the mRNA encoding the 
egg yolk precursor protein vitellogenin and destabilizes albumin mRNA (Cunningham et al.
2000). In addition, an endoribonuclease, termed PMR-1, has been shown to selectively 
degrade albumin and vitellogenin mRNA in vitro (Cunningham et al. 2000). A 155kDa 
RNA-binding protein containing 15 KH-domains has been shown to bind to the 3'-UTR of 
vitellogenin and prevents its cleavage by PMR-1 (Cunningham et al. 2000). The vigilin 
binding site on the vitellogenin transcript was determined using in vitro selection and is 
believed to be located in unstructured G-rich regions in the 3'-UTR (Cunningham et al. 
2000).
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1.6.3 CRD-BP and Cancer
The importance of RNA-protein interactions in normal cell function is highlighted by 
the severity of the defects that results when these systems are altered (Ioannidis et al. 2003). 
There is a growing list of RNA-binding proteins whose aberrant expression has been detected 
in a variety of cancers (e.g. IMP1, KOC and CRD-BP) (Yisraeli 2005). Many of these RNA- 
binding proteins are responsible for the post-transcriptional regulation of mRNA encoding 
proto-oncogenes, cytokines and growth factors (Yisraeli 2005). Altered expression of these 
mRNA targets may directly or indirectly contribute to carcinogenesis. Recent in vivo studies 
have attempted to define the role of CRD-BP in the development and progression of cancer. 
The results from these studies have revealed a strong correlation between CRD-BP 
expression and malignant tumor phenotypes. A summary of these studies is presented in 
Table 3.
Animal studies have shown that overexpression of CRD-BP strongly correlates with 
mammary adenocarcinomas in 60% of female mice (Tessier et al. 2004). A concurrent 
increase in IGF-ll mRNA and H19 mRNA were also observed whereas c-myc and P-actin 
levels were unchanged (Tessier et al. 2004). The observation that c-myc mRNA expression 
remained unchanged was unexpected because it is believed that CRD-BP plays a role in 
stabilizing c-myc transcripts (Prokipcak et al. 1994; Ross et al. 2001). However, in vivo 
evidence has yet to correlate increased CRD-BP expression with concurrent increases in c- 
myc expression in tumor cells.
An additional study found high levels of CRD-BP gene amplification in tumor cells 
isolated from human breast cancer tissue (Doyle et al. 2000). CRD-BP gene amplification 
was observed in 35% of the samples with no apparent increase in c-myc mRNA or c-Myc
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protein levels (Doyle et al. 2000). In addition, a high level of CRD-BP mRNA expression 
and detectable levels of CRD-BP protein were observed in tumor cells isolated from human 
colorectal cancer tissue with no concurrent increase in c-myc expression (Ross et al. 2001). 
Tumors positive for CRD-BP expression have also been reported in colon carcinomas, 
sarcomas, breast cancer, non-small cell carcinomas and brain tumors (Ioannidis et al. 2003). 
Interestingly CRD-BP is not expressed in other cancers including, prostate cancer and 
chronic myelogenous leukemia (Ioannidis et al. 2003). The most convincing evidence 
linking CRD-BP expression to cancer phenotypes is its absence of expression in normal cells 
(Ioannidis et al. 2003).
The role CRD-BP plays in the development and progression of cancer is unknown 
however several theories do exist. In mammary adenocarcinomas expressing CRD-BP, IGF- 
II is up-regulated 100 fold and H I9 mRNA is upregulated 8 -fold. IGF-ll is a growth 
promoting gene implicated in Beckwith-Wiedmann syndrome; a disorder resulting in 
disproportionate growth of the fetus (Nielsen et al. 1999). H19 encodes an oncofetal protein 
whose function remains enigmatic but has been implicated in cell proliferation (Yisraeli
2005). It is believed that IGF-ll and H19 gene products do not initiate cancerous 
transformation however they may contribute to the increased proliferative potential of cancer 
cells (Ioannidis et al. 2003). In addition, CRD-BP overexpression has also been implicated 
in the increased expression and production of proteins that are involved in cell-cell adhesion 
and cellular invasiveness (Vikessa et al. 2006). The overexpression of these proteins results 
in loss of cell-cell contact and has been shown to increase the invasiveness of some 
cancerous cells (Vikessa et al. 2006). It should also be noted that a characteristic phenotype
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in CRD-BP expressing tumors is increased invasiveness and metastatic potential (Ioannidis et 
al. 2003; Vikessa et al. 2006).
The ability of CRD-BP to regulate genes involved in growth and development and its 
ability to bind c-myc mRNA in vitro suggests that CRD-BP/c-myc interactions may take 
place in vivo. In addition, alterations in c-myc expression at the post-transcriptional level 
have been reported. For example, in multiple myeloma a mutation in the 5'-UTR result in 
increased c-myc mRNA translation and in lung cancer the stabilization of c-myc is observed 
(Ioannidis et al. 2003). Therefore in tumors in which both CRD-BP and c-myc are 
abundantly expressed the probability of specific interactions between CRD-BP and c-myc 
increases and their combined proliferative effects are enhanced. Currently, limited in vivo 
evidence supports the claim that cancer phenotypes are the result of CRD-BP induced 
stabilization of c-myc mRNA. One study has reported that IMP1/CRD-BP knockdown in 
MCF-7 cells significantly down regulates c-myc mRNA and protein levels (Neilsen et al. 
1999). However, MCF-7 cell proliferation was believed to occur via increased translation of 
IGF-II mRNA (Nielsen et al. 2002).
The presence of CRD-BP in various tumors and the absence of CRD-BP from normal 
cells do not explain how or when CRD-BP over-expression emerges and affects the diseased 
state. Furthermore, these studies were unable to show any significant increase in c-myc 
mRNA stability or c-Myc protein levels as a result of expression of CRD-BP. To date, it is 
unclear whether increased CRD-BP expression leads to tumorogenesis or if it contributes to 
undifferentiated, proliferative phenotype characteristic of tumor cells (Ioannidis et al. 2004). 
The role of CRD-BP in cancer is unknown. However, its oncofetal pattern of expression
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 1 - INTRODUCTION 44
coupled with it ability to regulate genes involved in growth control link it to abnormal cell 
growth (Ioannidis et al. 2004).
Table 3: Changes in CRD-BP and c-myc mRNA levels in various systems
l> pt* of 
study
Human or 
animal models 
(in vivo)
Cell line
Cell free 
systems 
(in vitro)
Type of tumor/source
Human pancreatic 
carcinoma tumor 
Human colorectal 
carcinoma tumor 
Human Liver carcinoma 
tumor
Human Brain tumor
Human Non-small lung 
carcinoma tumor 
Mouse mammary 
adenocarcinoma tumor 
Human Chronic 
myelogenous leukemia 
Human prostate 
earcimoma 
K562
HeLa
K562
Polysome extracts from 
K562 cells
Status of CRD-BP 
expression
Over-expressed
Changes in 
c-myc mRNA 
levels or half- 
life
No change in 
mRNA levels
None
None/siRNA 
knockdown
None/si KY-\ 
knockdown 
None/siRNA 
knockdown 
Anliscnsc 
oligonucleotide 
directed kmvkdow 
ol CRD-BP 
Normal
expression/addition of 
c-myc sense strand 
competitor
as
No change in 
mRNA levels
Decrease in 
mRNA levels 
No change in 
mRNA levels 
Decrease in 
RNA levels
Reference
Mueller-Pillasch 
e ta l. 1997
Koss el nl. 2001
Yisraeli 2005
Ioannidis et td.
■ ■ ■ ■ ■ I
Ioannidis et al. 
2004
Ioannidis et al. 
2004
Doyle et al. 2000
Ioannidis et al. 
2004
Liao et a l 2004
Ioannidis el al.
2005
Vikessa et al.
2006
Oiulis et al.
2000
Decrease in 
mRNA-half-life
Bernstein et al. 
1992
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1.7 Research Objectives
In embryonic cells CRD-BP is reported to function as an oncofetal protein that is vital 
to normal cellular development. CRD-BP and its human ortholouge, IMP1, are implicated in 
the post transcriptional regulation of several mRNA targets implicated in growth and 
development. The majority of mRNA targets for CRD-BP have been identified through in 
depth in vivo investigations, however one exception remains. The reported in vitro 
interactions between CRD-BP and c-myc mRNA are believed to shield the c-myc CRD from 
endonucleolytic attack. The shielding hypothesis is thought to contribute to carcinogenesis 
via enhanced expression of c-myc mRNA and its encoded products (Ross et al. 2001). To 
date, the shielding hypothesis has not been tested in vitro.
The biological function of CRD-BP remains to be fully understood. The roles of 
CRD-BP in nucleic acid binding, mRNA shuttling between the nucleus and cytosol and the 
subcellular localization of mRNA are well established. In contrast, its role in the 
stabilization of mRNA is less clear. In order to explore this function of CRD-BP in cells it is 
important to establish if CRD-BP is capable of binding and shielding RNA from 
endonucleolytic degradation. The following investigation attempts to address the functional 
interactions and biological significance of RNA-protein interactions between CRD-BP and c- 
myc mRNA in vitro. Specifically, this investigation will directly test the hypothesis that 
RNA-protein interactions between the c-myc CRD and CRD-BP shield the CRD from 
cleavage by a recently discovered novel mammalian endoribonuclease (Bergstrom et al.
2006).
The first aim of this investigation was to generate and purify recombinant 6 xHis- 
tagged proteins including, CRD-BP, Rpp20, Rpp21, Rpp25 and Rpp40. The second aim of
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this investigation was to detect the presence and determine the specificity of RNA-protein 
interactions between CRD-BP and c-myc CRD, MDR-1 and P-globin RNAs using EMSA. In 
addition, Rpp20, Rpp21, Rpp25 and Rpp40 were also tested to determine if they were 
capable of forming RNA-protein interactions with c-myc CRD RNA. The third aim of this 
investigation directly tested the CRD-BP shielding hypothesis by challenging RNA-protein 
interactions with a purified novel mammalian endoribonuclease. The final aim of this 
investigation employed RNA footprinting techniques to map the location of CRD-BP binding 
sites within c-myc CRD RNA.
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Chapter 2
Generation and Purification o f the Coding Region Determinant 
Binding Protein and Recombinant Proteins Rpp20, R pp2land Rpp40.
The following chapter describes the experimental approach leading to the successful 
generation and purification of recombinant 6 xHis-tagged proteins. In addition, this section is 
dedicated to the presentation and analysis of experimental results and observations.
The recombinant proteins used in this investigation were chosen on the basis of their 
ability or inability to bind to nucleic acids. The criteria used to determine if the recombinant 
proteins possessed this binding potential was based on the presence of putative nucleic acid- 
binding domains in their sequence and known RNA-protein interactions. As stated in the 
introduction, CRD-BP possesses KH domains and RRMs and has been shown to bind a 
variety of RNA targets including the c-myc CRD.
Upon the analysis of Rpp25 and Rpp20 sequences using the Simple Modular 
Architecture Research Tool (SMART) as described by Schultz 2000, it was determined that 
both proteins contain a nucleic acid binding domain known as an Alba motif. The novel 
chromatin associated protein, termed Alba, was first discovered and characterized in 
Sulfolobus solfataricus (Aravind 2003). Alba shares common features with other nucleic 
acid binding proteins including a common fold with DNase-1 and the C-terminal domain of 
the transcription initiation factor IF3 (Aravind 2003).
Sequence comparisons of the Alba protein using PSI-BLAST revealed similar 
sequences found in the two subunits of RNase P, Rpp20 and Rpp25 (Aravind 2003). The 
residues in Rpp25 (34-104) and Rpp20 (33-109) that exhibit sequence homology with Alba 
are indicated in Table 5. SMART analysis of Rpp 40 and Rpp21 failed to reveal any known
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nucleic binding domains within their sequences. Additional experimental characterization of 
Rpp40 and Rpp21, reports that only Rpp21 is capable of binding to precursor tRNA (Jarrous 
2001). It is thought that a unique cystine arrangement in Rpp21 spanning residues 62-95 
(CX2CX9CX6CX9CX2) may account for its nucleic acid binding capabilities (Jarrous 2001).
The absence of putative nucleic acid binding domains in Rpp40 and Rpp 21 allowed 
for the prediction that these proteins would not bind to the c-myc CRD. Therefore these 
proteins could predictably serve as a negative control to demonstrate that nucleic binding 
motifs are required for associations with RNA. The presence of Alba motifs within the 
Rpp25 and Rpp20 sequence allowed for the prediction that one or both of these proteins 
could bind to the c-myc CRD. If either protein (Rpp25 or Rpp20) was found to bind this 
would further support the notion that RNA-protein interactions are facilitated by nucleic acid 
binding domains. In addition, it would lend support to the belief that nucleic acid binding 
proteins are capable of binding to a greater variety of RNA targets than previously thought. 
If either protein failed to bind to the target RNA the result would suggest that specific 
domains (e.g. KH or RRM) are necessary for interactions with the c-myc CRD.
2.1 M ethodology
2.1.1 Preparation of Competent Escherichia coli BL21 (DE3) Cells
The initial preparation of competent cells involved the incubation of 0.5mL 
Escherichia coli BL21 (DE3) cells in 50mL LB broth (Invitrogen Life Technologies, Toronto 
Ontario) with agitation at 37°C for 2 V2 hours until an optical density of 600nm, OD600 = 0.4- 
0.5 was reached. After centrifugation at 2500rpm for 5 minutes the supernatant was removed 
and the pellet was resuspended in 2.5mL cold 50mM calcium chloride/CaCL, (Sigma, St. 
Louis MO) and then brought up to a volume of 25mL with additional 50mM CaCL.
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Figure 5: E.coli expression vectors used in the generation of recombinant 6xHis-tagged 
proteins. (A) Mouse CRD-BP cDNA with a C-terminal 6 xHis-tag was subcloned into 
pET28a/b(+) (Novagen) cut with Ncol and Xhol (pET28a/b(+)-CRD-BP was a generous gift 
from Dr. J. Ross). Rpp20 and Rpp21 cDNA were subcloned into pHTT7k cut with Sacl, 
downstream from a T7 promoter and in frame with a 6 xHis-tag. Rpp40 cDNA was subcloned 
into pHTT7k cut with Ndel downstream from a T7 promoter and in frame with a 6 xHis-tag. 
For Rpp20, 21 and 40 the 6 xHis-tag was found on the N-terminus of the resulting protein. 
pHTT7k constructs containing Rpp20, Rpp21 and Rpp40 cDNA were generous gifts from 
Dr. S. Altman.
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2.1.2 Transformation of E. coli BL21 (DE3) Cells
Approximately 200ng of purified plasmid was added to 200pL of competent E. coli 
BL21 cells and then placed on ice for 30 minutes. Expression vectors used in the 
transformation process are illustrated and described in Figure 5.
The transformation mixture was subjected to heat shock for 2 minutes at 42°C and 
was then placed on ice. Approximately lm L of warm LB-broth was added to the 
transformation reaction and incubated with vigorous shaking for 30 minutes at 37°C. 
Dilutions prepared from the transformation mixture (i.e. 1:1, 1:10 and 1:100) were plated on 
LB-agar (Invitrogen) containing 25pg/mL kanamycin sulfate (Invitrogen) and were 
incubated overnight at 37°C. As a negative control non-transformed E.coli BL21 cells were 
also plated using the identical dilutions, growth media and incubation conditions. A single 
positive clone was then removed from the plate and inoculated into 3mL of LB-broth 
containing 25pg/mL kanamycin overnight at 37°C.
2.1.3 Small Scale Induction of Transformed E. coli BL21 Cells
Approximately 240pL of the overnight, transformed E. coli BL21 cells was added to 
24mL LB-broth containing 25pg/mL kanamycin and was incubated at 37°C with vigorous 
shaking until an OD6oo= 0.4-0.5 was reached (approximately 4 hours). The 24mL pre­
induction culture was then divided into two 12mL cultures and to one culture lmM  (final 
concentration) of isopropyl-P-D-thiogalactopyranoside (IPTG) (Invitrogen) was added. The 
second 12mL culture served as the uninduced sample. Both cultures were incubated at 37°C 
with vigorous shaking and lm L aliquots were removed from both the induced and uninduced 
cultures at specific time intervals: t = 0, 1, 2, 4 and 6  hours. Cells were harvested from
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individual fractions by centrifugation at 1 0 ,0 0 0 rpm for 15-minutes and following removal of 
the supernatant the pellet was stored at -20°C.
2.1.4 Protein Purification Using Denaturing Conditions
Recombinant 6 xHis-tagged proteins were purified using the QIAexpress nickel- 
nitrioltriacetic acid (Ni-NTA) metal affinity spin kit (QIAGEN Montreal, QC) under 
denaturing conditions.
Table 4: Reagents used in the purification, analysis and dialysis of recombinant 6 xHis- 
tagged proteins
icli-nl if \
Buffer B
Buffer C 
Buffer D 
Buffer h
Iti-ugi-nl com position
XM urea (Sigma). 0 .1M sodium pliospliale/NalKPO.i I Sigma). 0.01 \1 Tris-C'l; pi I X (Sigma) 
Same as above; pH 5.4
lxSDS loading 25mM Tris-Cl, 20% glycerol (Sigma), 0.2% (w/v) bromophenol blue (Sigma), 4% (v/v) SDS
dye (OmniPur/EM Science, Gibbstown NJ), 0.1% (v/v) p-mercaptoethanol (Sigma)
Cooma.ssie blue 50% methanol. 10% acetic acid and 1% C'oomassie Brilliant Blue (w/v) (Sigma)
Coomassie blue 50% methanol, 10% acetic acid
de-staining
solution
I’lxiem Ji.tK.--i-. 
solution
.'iHtniM p.-ia-dum clilmide ■ Kl lnSigm ai. ImMI 1)1 \  ■ pi I X11 Sigma i. 10'.. i \ '• H u i’iol :
■ Sigma >. IniM I clui.Kliioiie Kciluccd. O.ImM o\idi/cd glutalhixne'Si-.'m.ii. 0.01'. n . \ '
I lit.<n X IfHi (Signin'. 2(>m.M mvlhunolummc iSigm .f and 10 Mini.I I>’l A lice puMcasc 
iiiiubiioi tablet' i K"i he1 I acli diuKms butler u.i- - alibiated to a spi\ die pi I and contaiiit. 
in ca at \ .n m i- M'lkoiiirutioii-. pllS'f.M tu e a .  plI^.S. l \ |  uiea. pll n ‘2M uiea. pi I (>._ ,l M 
urea and pll 7.4/OM urea
Induced and uninduced cell pellets were thawed for 15 minutes at room temperature, 
resuspended in lm L buffer B (buffer contents listed in Table 6 ) and incubated with gentle
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agitation for 60 minutes at room temperature. Following the incubation period the cell lysate 
was centrifuged at 13,200rpm for 30 minutes at room temperature to pellet the cellular debris 
and the supernatant (i.e. cleared lysate) was retained. The cleared lysate was then quantified 
using a Bio-Rad protein quantification assay (Bio-Rad Hercules CA) and a bovine serum 
albumin (BSA, New England Biolabs, Beverly MA) standard curve.
A Ni-NTA spin column was then equilibrated with the addition of 600pL buffer B 
followed by centrifugation at 2400rpm for 2 minutes at room temperature (all subsequent 
steps with the Ni-NTA spin columns were conducted at room temperature and centrifugation 
at 2400rpm for 2 minutes). Approximately 600pL of the cleared lysate containing the 6 xHis- 
tagged protein was loaded onto the equilibrated Ni-NTA spin column and the flow-through 
fraction was collected. The Ni-NTA spin column was then washed two times with 600pL 
buffer C and all fractions were retained. The 6 xHis-tagged protein was then eluted from the 
column once with the addition of 100-200pL buffer D. Throughout this investigation only 
D-eluate fractions were utilized because they represent monomeric proteins whereas E-eluate 
fractions commonly purify as protein aggregates (QIAGEN 2003).
Protein quantification was performed on all flow-through, wash and elution fractions 
prior to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE). Aliquots 
from the Ni-NTA protein fractions (approximately 20pL) were combined with an equal 
volume of lxSDS loading dye, boiled for 3 minutes and loaded onto a 12% SDS PAGE gel; 
19:1 acrylamide and resolved at 120V until the bromophenol blue reached the bottom of the 
gel. Gels were stained overnight with gentle shaking in Coomassie blue staining solution. 
Gels were then placed in Coomassie blue de-staining solution for 3 hours and were visualized 
by transillumination using a Chemlmager (Alpha Innotech Corporation, San Leandro CA).
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Table 5: Protein sequences 
identified
Prolei ii/NCR I Sequence 
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ghpsqfsgrk 
qiqehqpkva 
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of the recombinant proteins used in this investigation with their putative nucleic acid binding sites
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2.1.5 Large Scale Expression and Purification of CRD-BP
Large scale protein purification was performed using an ISCO Model 160 Gradient 
Former and a Foxy® Jr. Fraction Collector (ISCO, Lincoln NB, USA). Large scale 
expression and purification was only used in the preparation of recombinant CRD-BP. CRD- 
BP expression cultures (2L) were induced with ImM IPTG for 6  hours followed by 
centrifugation at 5000rpm for 30 minutes at 4°C. The pellet was then split into two equal 
portions, resuspended in 50mL buffer B and incubated with agitation for 1.5 hours at room 
temperature. Following the incubation period the cell lysate was centrifuged at 13,200rpm 
for 30 minutes at room temperature to pellet the cellular debris and the cleared lysate was 
retained. The cleared lysate was then quantified using a Bio-Rad protein quantification 
assay.
A 500mL KX 50 column (GE Healthcare) containing 50mL of Ni2+-charged 
chromatography resin (Ni-NTA, QIAGEN) was equilibrated with the addition of 150mL 
buffer B. Approximately 25mL of the cleared lysate (8 mg/mL) was loaded onto the pre­
equilibrated Ni2+-charged chromatography resin. The column was then washed with 150mL 
buffer B and individual lOmL fractions were collected at a flow rate of 1 .OmL/minute. The 
column was then washed with 120mL buffer C and again individual lOmL fractions were 
collected. The recombinant 6 xHis-tagged protein was eluted by the addition of 60mL buffer 
D followed by 60mL buffer E and lm L fractions from each elution stage were collected. 
Protein fractions from various stages of the purification were quantified using a Bio-Rad 
protein quantification assay and visualized by 12% SDS PAGE.
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2.1.6 Protein Dialysis
All purified proteins were dialyzed using a stepped gradient to remove urea, change 
the pH and alter the buffer conditions. Purified proteins in buffer D were transferred into 
Slide-A-Lyzer mini dialysis units (Pierce, Rockland IL, USA) to a maximum volume of 
lOOpL (containing approximately 50pg total protein). The dialysis units were placed in a 
beaker containing 250mL protein dialysis solution and gently mixed with a magnetic stir bar 
at 4°C. The stepped dialysis (3 hours/buffer) continued through a series of protein dialysis 
solution exchanges from: pH5/6M urea, pH5.5/4M urea, pH 6/2M urea, pH 6.7/1M urea and 
pH 7.4/OM urea. At the completion of the dialysis procedure the protein fractions were 
transferred to 1.5mL microfuge tubes and centrifuged at 13,200rpm for 30 minutes to remove 
precipitated proteins. Following centrifugation, protein fractions were quantified using a 
Bio-Rad protein quantification assay and analyzed by 12% SDS PAGE gels to confirm their 
presence in the post dialysate.
2.2 Results and Discussion
The transformation of E.coli with the four different plasmid constructs produced 
bacterial colonies on the kanamycin selective media in all cases. In contrast, the non­
transformed E.coli cells did not produce colonies on the kanamycin selective media. The 
presence of colonies implies that E.coli cells were successfully transformed with the plasmid 
containing the kanamycin resistance gene. Single bacterial colonies isolated from the 
selective media were induced with IPTG and were permitted to grow for 6  hours.
The induction of recombinant CRD-BP (Figure 6 A) yielded a band at approximately 
6 6 kDa that increased to a maximum intensity after 6  hours (refer to lanes 2-7). The 
induction of Rpp21 and Rpp20 (Figure 6 B-C) yielded bands of increasing intensity at
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 2 -  GENERATION AND PURIFICATION 56
approximately 24kDa (Figure 6 B, lanes 4-9) and 22kDa (Figure 6 C, lanes 4-9) respectively. 
The induction of Rpp40 (Figure 6 D) yielded a discrete band at approximately 44kDa and 
showed a modest increase in intensity during the 6  hour induction (refer to lanes 3-8). It 
should be noted that a similar band at approximately 44kDa was observed after 6  hours in the 
uninduced cleared lysate (Figure 6 D lane 1).
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Figure 6: SDS PAGE analysis of 6xHis-tagged recombinant proteins following a time 
course induction in E. coli. Recovered cleared lysates from the time periods indicated were 
quantified using a Bio-Rad protein quantification assay and approximately equal 
concentrations (indicated below) were loaded onto a 12% SDS polyacrylamide gel and 
visualized with Coomassie blue stain; (A) RppCRD-BP [4pg total], (B) Rpp21 [6 pg total], 
(C) Rpp20 [6 pg total] and (D) Rpp40 [3pg total].
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The band at approximately 6 6 kDa is consistent with the predicted and previously 
reported molecular weight of recombinant CRD-BP (i.e. 6 8 kDa) (Doyle et al. 1998). The 
observed molecular weights of Rpp20, Rpp 21 and Rpp40 were also consistent with the 
previously reported molecular weights from studies using the identical proteins (Jarrous 
2001; Li 2001). The low level induction of Rpp40 observed in Figure 6 D and the presence of 
a similar size band in Figure 6 A-C suggests that the induction of Rpp40 was unsuccessful.
1 2 3 4 5 6 7
Figure 7: Small scale purification of Rpp20 and Rpp21 using Ni-NTA spin columns.
Lane 2 & 5 represent the induced cell lysates, lane 3 and 6  represent the wash fractions and 
lane 4 and 7 are the recombinant proteins eluted with buffer D (pH 5.4). Equal 
concentrations of protein (approximately 8 jig as determined by a Bio-Rad quantification 
assay) were loaded onto the 12% SDS polyacrylamide gel and stained with Coomassie blue.
The purification of Rpp20, Rpp21 and Rpp40 was performed using Ni-NTA spin 
columns under denaturing conditions because they have been found to aggregate within 
inclusion bodies (Jarrous 2001). Individual proteins were purified in three distinct stages 
which involved 6 xHis-tagged protein binding, one to two wash steps and one to two elution 
steps. A typical small scale purification strategy involving Rpp 20 and Rpp21 is depicted in 
Figure 7.
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The results suggest that the 6 xHis-tagged proteins avidly bound to the matrix as 
indicated by the minimal loss of protein in the flow through and wash fractions (Figure 7 
compare lanes 2-3 and 5-6). In general, a single wash step was sufficient to remove 
contaminating proteins (Figure 7 lanes 3-6). The recombinant proteins were typically eluted 
upon the addition of lOOpL buffer D and lOOpL buffer E. The protein yields ranged from 
0.05-0.4mg/mL (Figure 7 lanes 4-7) for a 12mL induced culture. In spite of the low level 
induction of Rpp40 a 44kDa protein was observed in the D-eluate fractions. Rpp40 protein 
yields ranged from 0.05-0.15mg/mL (Figure 9 lane 2). Furthermore, a 44kDa band was not 
observed in the uninduced D-eluate fractions (data not shown). However, a protein with a 
molecular weight of 44kDa was also observed in the Rpp20 and Rpp21 D-eluate fractions 
(Figure 7 lanes 4 and 7). In spite of the induction and purification of a 44kDa protein, its 
definitive identification as Rpp40 was not confirmed.
Figure 8: Following expression in E.coli, 6xHis-tagged recombinant CRD-BP was 
purified using immobilized Ni-NTA chromatography under denaturing conditions (8M 
urea; elution at pH 5.4 and 4.5). (A) Depicts the flow-through and wash fractions (pH 6.3) 
and (B) depicts the purified D-eluate. All gels were stained with Coomassie blue. Numbers 
in brackets indicate the fraction number from which the protein sample was acquired.
A
1 2 3  4 5 6 7  8 9  10 1 2 3 4 5  6 7 8 9
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A typical large scale Ni-NTA purification strategy involving CRD-BP is depicted in 
Figure 8 A-B. Upon examination of the flow-through fractions (Figure 8 A, lanes 2-5) it was 
apparent that a high percentage of the recombinant CRD-BP bound to the column with 
considerable affinity. This observation is supported by the absence of CRD-BP in the flow 
through fractions (Figure 8 A, lanes 2-5). The majority of the contaminating proteins were 
removed with approximately 40mL of buffer C (Figure 8 A, lane 6 ). However in subsequent 
wash fractions recombinant CRD-BP was eluted from the column (Figure 8 A lane 6 ). The 
D-eluate (Figure 8 B) and E-eluate (not shown) possessed similar elution profiles. In both 
cases the majority of CRD-BP was eluted from the column with approximately 30mL of 
buffer D or buffer E. The presence of contaminating proteins at approximately 55kDa and 
60kDa was evident in both the D- and E-eluate fractions (Figure 8 B, lanes 5-7). The 
contaminating proteins represented only a fraction (approximately 7%) of the total protein 
present in the eluate. In general, the large scale Ni-NTA column produced highly purified 
recombinant CRD-BP with yields ranging from 0.01-0.5mg/ml.
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Figure 9: SDS PAGE analysis of purified recombinant 6xHis-tagged proteins. 12% SDS
PAGE depicting the purified recombinant 6 xHis-tagged proteins from the post-dialyzed, D- 
eluate fractions. Both gels were stained with Coomassie blue
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Purified proteins subjected to dialysis in general were unaffected (i.e. not subject to 
significant aggregation) by the change in buffer environment. In most cases when proteins 
were dialyzed the total volume of the dialysate would be greater than its initial volume of 
lOOpL. Typically, the increase in volume would range from 50-100pL and this would also 
correspond with a decrease in protein concentration. Final concentrations of protein differed 
between the pre-and post dialysis fractions however, the total amount of protein (i.e. pg total) 
was not significantly different. It should be noted that the protein concentrations recorded 
throughout this investigation may not accurately reflect the concentration of protein that 
exists in its native and functional form. Based on the results and evidence from previous 
investigations the generation, purification and dialysis of Rpp20, Rpp21 and CRD-BP was 
successful.
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Chapter 3
Assessing the Ability o f CRD-BP and Other Recombinant Proteins to 
Bind to c-myc CRD, p-Globin and M D R -1 RNA Using the 
Electrophoretic M obility Shift Assay
The following chapter describes the experimental approach used in the detection of in 
vitro interactions between the purified recombinant 6 xHis-tagged proteins and a panel of in 
vitro transcribed RNA constructs. In addition, this section is dedicated to the presentation 
and analysis of experimental results and observations.
The rationale behind the use of the RNA panel chosen for this investigation was 
based on three criteria: known RNA-binding protein interactions, the presence of cis-acting 
stability/instability elements in their sequence and their predicted secondary structures. Both 
c-myc CRD-1705-1886 and 1705-1792 RNAs were chosen because these regions influence 
the overall stability of human c-myc mRNA in vitro and in vivo (Yeilding et al. 1996). The 
instability of c-myc is partly due to the presence of instability elements located in the 3 end 
of the exon-3 coding region. In addition, the c-myc CRD RNA constructs used in this 
investigation are capable of in vitro associations with CRD-BP (Prokipcak et al. 1994).
P-globin RNA was chosen primarily because of its documented stability in vitro and 
in vivo (Russell et al. 1996; Bremer et al. 2003). Specifically, the stability of human P- 
globin mRNA has been associated with cis-acting structural elements in its 3 -UTR (Russell 
et al. 1996). In contrast, the 5 -UTR has not been implicated in imparting stability and e x ­
acting elements, apart from the 5 "cap structure, have not yet been identified in p-globin 
mRNA (Russell et al. 1996). The portion of the human P-globin cDNA used in the 
generation of this RNA was limited to the first 145 nucleotides of its 5" region. It is 
predicted that the absence of known cis-acting elements in the 5" region would impair CRD-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 3 -  ASSESSING BINDING USING EMSA 62
BP from recognizing and binding to the fi-globin RNA fragment. Therefore, fi-globin would 
serve as a negative control for the EMSA component of this investigation.
MDR-1 RNA was chosen because of its ability to cause cellular transformations when 
over-expressed (Lee et al. 1998). Like c-myc mRNA, the stability of MDR-1 mRNA 
products (i.e. P-glycoprotein 1-3) is carefully controlled at the post-transcriptional level. The 
stability profile and expression of MDR-1 mRNA products are influenced by the 
developmental state of the cell (Goto et al. 2003). For example, in the human intestinal cell 
lines, Caco-2, the stability of P-glycoprotein (Pgp) mRNA is increased during cell 
proliferation and decreased as cells achieve confluence (Goto et al. 2003). The fluctuating 
stability profile observed in Caco-2 cells may be due to the influence of trans-acting factors 
such as, but not limited to, RNA-binding proteins and ribonucleases. The rationale behind 
the use of MDR-1 RNA was to challenge CRD-BP with an additional RNA that is known to 
induce/contribute to cancerous phenotypes when aberrantly expressed. If CRD-BP was 
found to bind with MDR-1 this result would support the current evidence that RNA-binding 
proteins recognize and bind a diverse range of RNA targets in vitro. If CRD-BP was found 
not to bind to MDR-1 RNA then this would serve as an additional negative control.
3.1 M ethodology
3.1.1 Plasmid Digestion
The plasmid constructs used in this investigation include pSPkpC (human P-globin), 
pUC 19-CRD-myc-1705-1792, pUCl9-m yc-l705-1886 and pGEMZ7-MDRl-V2 (MDR-1). 
Plasmid digestion was performed using a single restriction enzyme and appropriate buffer at 
37°C for 60 minutes (all enzymes and buffers were from New England Biolabs and are 
indicated in Table 6 ). All restriction digests were performed in lOpL reaction volumes
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containing at least lpg of undigested plasmid. Immediately following plasmid digestion, the 
preparation was treated with 0.5% SDS, 50pg/ml Proteinase K (New England Biolabs) and 
incubated at 50°C for 30 minutes.
Table 6: Vectors and cDNA templates used for in vitro transcription of RNA.
r i i iM i i i t i  ( '( in s t ru c t /  c l ) N . \  T rm p h i tc  S c i i i i c i i c c  R cstr ic lio ii
I 'r u in n tc r  l - j i / \  m c/h u ll 'c r
pSPk(3C-P-globin-nts 1 - 5 ’acatttgcltctgacacaactgtgttcactagcaacctcaaacagaca fo/:I/React-2
145 ccalggtgcacclgactcctgaggagaagtctgcggttactgccctgt
(SP6 promoter) gggcaagttgaagttggatgaagttggtggtgaggccctgggcag
3’
pl)(’l9-C'Rl)-mv<- 5'aecagalCLVggagltggaaaaeaalgaaaaggeeL'ccaaggta EcoV.U\()\ React3
1705-1792 gttalcetlaaaaaageeacagcatacalecig(ccgtceaage3'
pUC 19-myc-1705- 5’accagatcccggagttggaaaacaatgaaaaggcccccaaggta EcoVA/\ Ox React-3
1886 gttatccttaaaaaagccacagcatacatctgtccgtccaagcagagg
(SP6 promoter) agcaaaagctcatttctgaagaggacttgttgcggaaacgacgagaa
cagttgaaacacaaacttgaacagctacggaactcttgtgcgtaagg 
3’
pGHM7/.-.VlDR I - V2- 5'ggaggaagacatgaceagglalgeeialtattacagtggallggtg /\/wLI/NliH-4
nts735-922 eiggggtgellgtlgelgctlacatlcaggltlealtttggtgeciggeag
(T7 promoter) ciggaagacaaatacacaaaallagaaaacagUlltlcatgetalaatg
egaeaggagalaggctggtttgatgtgca3’
■
Following treatment with Proteinase K, the preparation was quenched with 90 pL of 
Milli-Q-ddHaO and treated with phenol/chloroform extraction and ammonium 
acetate/isopropanol precipitation. To the lOOpL reaction, one half volume of phenol (Sigma) 
and one half volume of chloroform: isoamyl alcohol (CHCI3 : IAA) (49:1) (Fluka) was added 
and thoroughly mixed. Following centrifugation at 13,200rpm for 5 minutes, the aqueous 
layer was extracted. Approximately 100pL of chloroform was then added to the aqueous 
phase and the contents were thoroughly mixed. Following centrifugation at 13,200rpm for 5 
minutes the aqueous layer was extracted. The DNA was then precipitated by the addition of 
1/10 volume of 5M ammonium acetate (NH4CH3COO /NH4OAC) (Ambion) and 1 volume of
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isopropanol (Sigma). Following centrifugation at 13,200rpm for 30 minutes at 4°C, the 
supernatant was removed by aspiration and the pellet was washed once in 200pL of 70% 
ethanol. The supernatant was aspirated and the pellet was air dried for 5 minutes prior to 
resuspension in 20pL Milli-Q-ddHoO.
Following re-suspension the DNA was quantified by UV-spectrophotometry using an 
ND-1000 Spectrophotometer (NanoDrop Wilmington, Delaware). DNA concentrations were 
determined at 260nm using the following relationship: DNA concentration (pg/ml) = (OD 
26o) x (dilution factor) x (50 pg DNA/ml)/(l OD260 unit). Digestion products were then 
resolved in a 50mL, 2% agarose (Invitrogen) gel containing lpL  of lOmg/mL ethidium 
bromide. Agarose gels were resolved at 30mA in lxTBE buffer for 45-minutes and 
visualized by UV-transillumination.
Table 7: Reagents used in the generation of RNA and EMSA protocols
Reagent identity 
lxTBE  
lx.VlOPS 
RNA loading dye
roriiisimidi' 
loading d \e  
Probe elution 
buffer
CMS \  binding 
Inillcr
EMSA loading 
dye
Reagent composition
0.9M Tris-Cl/Boric acid (Sigma), 0 .01M EDTA (pH 8.3)
0.2M MOPS (Sigma), 5()mM sodium acelalc (Sigma) and K)mM KOTA
50% formamide, 2% formaldehyde and lxMOPS, 0.05mg/mL bromophenol blue (Sigma),
0.05mg/mL xylene cyanol (Sigma) and 0 .0 1M EDTA (Sigma) pH 8
SO'yf formamide, 0.05mg/ml. bromophenol blue (Sigma). ().()5mg/ml. xylene cyanol
(Sigma) anil 0.01M EDTA (Sigma) pH 8
7.5M NH4OAc, 0.5M EDTA pH 8, 20% SDS, l/ 2 volume of phenol and Vi volume of 
chloroform
Sm \l 111'  Cl .p ll " .1 .. 2 5 niM I I VIA ipll S). huW  HI I A  . gKccm l.u Imginl . Its \ i .  
n.5ir-_' ml w.isi [K \ \  lAmbion . and 51 of KN;mm
250mM Tris-Cl (pH 7.4), 0.2% bromphenol blue. 0.2% xylene cyanol and 40% sucrose
3.1.2 Generation of Unlabelled RNA
Unlabelled RNA was generated by T7 or SP6 RNA polymerase-directed in vitro 
transcription (MEGAscript, Ambion) from templates inserted downstream from T7 and/or 
SP6 RNA polymerase promoters. Briefly, each 20pL in vitro transcription reaction utilized:
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ljag of linearized plasmid, 5mM (final concentration) of ATP, CTP, GTP and UTP, 20mM 
DTT (Promega Madison WI), lx  reaction buffer (Ambion), 40U RNasin (Promega) and 
either 30U of T7 or 40U of SP6  RNA polymerase (Ambion). In vitro transcription reactions 
were incubated at 37°C for 1 hour. Following the incubation period, 2U of TURBO DNasel 
(Ambion) was added and the contents were incubated for an additional 15-minutes at 37°C. 
The RNA was isolated using standard phenol/chloroform extraction followed by ammonium 
acetate/isopropanol precipitation and resuspension in 20pL diethylpyrocarbonate (DEPC) 
(Sigma) treated Milli-Q-ddH20 . RNA concentration was determined using the relationship; 
RNA concentration (pg/ml) = (OD 26o )  x (dilution factor) x (40 pg RNA/ml)/(l OD26o unit). 
In addition, RNA purity was assessed by examination of the A26o:A280 ratio using the ND- 
1000. RNA integrity was assessed using a 50mL, 2% agarose gel containing 37% 
formaldehyde (v/v) (Sigma) and lpL  of lOmg/mL ethidium bromide. Approximately 200- 
500ng of RNA was combined with RNA loading dye and resolved at 20mA for 2 hours and 
visualized using UV-transillumination. All formaldehyde containing agarose gels were run 
in lxMOPS running buffer.
3.1.3 Generation of 5 '-Radiolabelled RNA
A typical de-phosphorylation reaction contained 5pg of RNA, 10U of calf intestine 
alkaline phosphatase (GE Healthcare), lx  dephoshphorylation buffer (GE Healthcare), 
lOmM DTT and 40U RNasin (Promega). The reaction volume was brought up to 50pL with 
DEPC-treated Milli-Q-ddH20  and incubated at 37°C for 30 minutes. The dephosphorylated 
RNA was then recovered by standard phenol/choloroform extraction and ammonium 
acetate/isopropanol precipitation. RNA pellets were resuspended in 20pL of DEPC-treated 
Milli-Q-ddH20 . The RNA was quantified using the ND-1000 and its integrity was assessed 
on a 2 % agarose gel.
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Approximately 6 pg of de-phosphorylated RNA was phosphorylated using 25U of T4 
polynucleotide kinase (New England Biolabs) and 60pCi y32-P ATP (Amersham 
Biosciences), lx  T4 polynucleotide kinase buffer (New England Biolabs), 12mM DTT and 
40U RNasin. Following a 60-minute incubation at 37°C the RNA was recovered using 
standard phenol/chloroform extraction followed by ammonium acetate/isopropanol 
precipitation.
The RNA pellet was then resuspended in 20pL of formamide loading dye and loaded 
onto a 5% denaturing polyacrylamide (29:1, acrylamide:N,N’-methylenebisacrylamide) gel 
containing 7M urea (Invitrogen). The RNA bands were resolved at 30mA until the 
bromophenol blue migrated to the bottom of the gel. The RNA bands were imaged using a 
Cyclone Storage Phosphor Screen System (Packard, Meriden CT). An audioradiograph was 
then printed and under audioradiographic guidance the appropriate bands were excised from 
the gel. Gel slices were placed into 1.5mL microfuge tubes containing probe elution buffer 
and were incubated at 45°C for 5 hours.
Following elution from the gel slices the RNA was recovered using standard 
phenol/chloroform extraction and ammonium acetate/isopropanol precipitation. The RNA 
pellet was resuspended in 20pL DEPC-treated Milli-Q-ddH2 0  and its activity (i.e. counts per 
minute/cpm) was quantified using a Packard 1600 TR liquid scintillation analyzer. In 
addition, determination of RNA concentration was performed using a Biochrom Ultraspec 
1000 UV-spectrophotometer at 260nm. All 5 "-radiolabelled RNA preparations were 
maintained at 100,000cpm and stored at -20°C.
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3.1.4 Electrophoretic Mobility Shift Assays (EMSA)
EMSA binding buffers were prepared fresh on ice prior to each experiment. In order
for 5 minutes and once cooled to room temperature it was added to the EMSA binding 
buffer. EMSA binding buffer containing radiolabelled RNA was then incubated with 
purified recombinant protein in a 20pL reaction volume at 30°C for 10 minutes and 
transferred to ice for 5 minutes. The reaction was again incubated at 30°C for 10 minutes 
and transferred to ice for an additional 5 minutes. Heparin (Sigma) was then added to a final 
concentration of 5mg/mL and the reaction was incubated on ice for a final 5 minute period. 
A total of 2pL EMSA loading dye was added to each reaction and IOjiL of the EMSA 
reaction was loaded onto an 8 % native polyacrylamide gel and resolved at 25 mA for 90 
minutes. Following elecrophoresis the gel was transferred onto a piece of Whatman filter 
paper, dried using a gel dryer (LABCONO, Kansas City MO) for 1 hour and exposed to a 
phosphorimager screen overnight. The dried gel was imaged and audioradiographs were 
generated using a Cyclone Storage Phosphor Screen System and Optiquant Software. Unless 
otherwise stated, all native and denaturing polyacrylamide gels used throughout this 
investigation were dried and imaged as previously described.
3.1.5 Saturation Binding Experiments
All saturation binding experiments were carried out using the EMSA protocol and the 
dissociation constant (Kd) for CRD-BP against MDR-1 and c-myc CRD RNA was determined
to facilitate RNA denaturation and renaturation, the [32P] RNA sample was heated to 50°C
by fits to the Hill equation: bound
Total
where Kd is the dissociation constant and
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[L] is the concentration of CRD-BP and n is the Hill coefficient. All saturation binding data 
was analyzed by densitometry of the audioradiograph using the Cyclone Storage Phosphor- 
System and Optiquant software. For each reaction the total activity in each lane was 
determined; this involved summing the total activity in bound complexes with the total 
activity present in the unbound fraction. It should be noted that in lanes in which both 
Complex I and Complex II were present their total activity was added together and therefore 
represented the total bound fraction. This analysis allowed for the calculation of the 
percentage of RNA bound to the protein. The percentage of bound RNA and the protein 
concentration (nM) were inserted into the Hill equation and the results were expressed 
graphically.
3.1.6 EMSA Competition Assays
5'-[32P] radiolabelled c-myc CRD-1705-1886 RNA and unlabeled in vitro transcribed 
competitor RNA were prepared as previously described. EMSA binding buffers and EMSA 
reaction mixtures were prepared and 350nM of CRD-BP was added to the reactions 
containing one of the following unlabeled competitors: c-myc-CRD-1705-1885, c-myc-CRD 
1705-1792, MDR-1 or ft-glob in RNA. EMSA competition assays involved the pre­
incubation between competitor RNA and CRD-BP for 10-minutes at 30°C. Following the 
pre-incubation, 40nM [32P] c-myc CRD-1705-1886 RNA was added to the reaction and then 
incubated according to the standard EMSA conditions. The concentrations of unlabeled 
competitor RNA employed were 1, 2, 5, 10 and 50-times greater than the 40nM [32P] c-myc- 
CRD-1705-1886 RNA used.
An additional EMSA competition assay involved the incubation of 1500nM CRD-BP 
with 30nM [32P] c-myc CRD-1705-1886 RNA under the standard EMSA conditions.
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Following this incubation, 5x and lOx molar excess of unlabelled competitor c-myc-CRD- 
1705-1886 RNA was added to the reaction for either 2, 4, 6, 8, or 10 minutes prior to being 
loaded onto an 8% non-denaturing polyacrylamide gel.
3.2 Results and Discussion
3.2.1 Generation of Unlabeled and Radiolabelled RNA
The linearization of pUC 19-myc-1705-1886 and pUC 19-CRD-myc-1705-1792 with 
EcoRl generated discrete single bands (i.e. linearized plasmid) at approximately 3000bp and 
4000bp respectively (Figure 10A-B). As expected, the digested plasmids exhibited different
migration rates when compared to their undigested, supercoiled forms.
Figure 10: Agarose gel analysis demonstrating the digestion of plasmids used for in vitro 
transcription. All gels were visualized using UV-transillumination by staining the DNA 
with ethidium bromide. (A) 2% agarose gel showing the 30-minute (lane 3) and 60-minute 
(lane 4) digestions of pUC19-myc-1705-1886 with 10U of EcoRI. (B) 1% agarose gel 
showing the 60-minute digestion of pUC19-CRD-myc-1705-1792 with 10U of EcoRI. (C) 
2% agarose gel showing the 60 minute digestion of pGEM7Z-MDRl-V2 with 20U of ApaLI 
and (D) 2% agarose gel showing the 60-minute digestion (lanes 3 & 5) of pSPkpC-(3-globin 
with 8U of Fokl.
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The digestion of pGEM7Z-MDRl-V2 (Figure 10C) with ApaLI generated three 
bands (refer to lane 3) ranging in size from approximately 4000, 1300 and 850bp. The 
digestion of pSPkpC-(3-g/t>hm with FokI (Figure 10D) also generated multiple bands ranging 
in size from, 1100, 800 and 650 bp (refer to lanes 3 & 5). The additional bands generated as 
a result of pGEM7Z-MDRl-V2 digestion are accounted for by the fact that this plasmid 
contains three ApaLI sites in its sequence. The additional bands generated as a result of 
pSPkpC-(3-g/ohm digestion are accounted for by the fact that the vector contains several FokI 
restriction sites.
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Figure 11: The generation of unlabelled and 5' radiolabelled RNA. (A) 1.5% 
agarose/formaldehyde/formamide gel illustrating the dephosphorylated, in-vitro transcription 
products generated from the linearized plasmid constructs. Approximate concentrations of 
RNA loaded into lanes 2 through 5; MDR-1 500ng, p-globin 200ng, c-myc CRD-1705-1792 
200ng and c-myc CRD 1705-1886 500ng. (B) Audioradiograph of a denaturing, 5% 
polyacrylamide gel illustrating the products of 5 "-end labeled phosphorylation reactions 
using y23P-ATP and T4 polynucleotide kinase and (C) Audioradiograph (identical to B) 
showing the radio-labeled fragments excised from the gel.
In vitro transcribed RNA concentrations ranged from 400-2000ng/pL and RNA with 
A260A 280 ratios of 1.9-2.1 were deemed acceptable for use in subsequent experiments. In 
addition, in vitro transcription products were examined using denaturing agarose gel 
electrophoresis. The RNA generated from linearized pGEM4Z-myc-1705-1886 (Figure 11 A, 
lane 5) migrated to a distance between 0.280kb and 0.155kb which is consistent with its
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intended transcript length of 0.186kb. The RNA generated from linearized pUC19-CRD- 
myc-1705-1792 (Figure 11 A, lane 4) migrated to a distance below the lowest size marker of 
0.155kb which is consistent with its intended length of 0.088kb. The RNA generated from 
linearized pGEM7Z-MDRl-V2 (Figure 11 A, lane 2) migrated to a distance approximately 
equal to that of c-myc CRD-1705-1886, which is consistent with its intended length of 
0.176kb. In addition to the band found between 0.280kb and 0.155kb (Figure 11 A, lane 2) a 
second band with decreased mobility was observed between 0.530kb and 0.280kb. The 
larger than expected transcription product may be due to T7 polymerase transcription of a 
larger, partially digested template present in the MDR-1 in vitro transcription reaction. The 
RNA generated from linearized pSPk(3C-P-g/ofon (Figure 11 A, lane 3) migrated to a distance 
approximately equal to that of its intended length of 0.145kb. The in vitro transcribed p- 
globin RNA appeared diffuse in the agarose gel. However, when phosphorylated and 
resolved on a denaturing polyacrylamide gel the P-globin migrated as a discrete band to its 
anticipated nucleotide position (refer to Figure 1 IB).
Following phosphorylation, the RNA was electrophoresed on a 5% polyacrylamide 
gel and exposed to a phosphorimager screen in order to generate an audioradiograph (Figure 
11C-D). The audioradiograph from the phosphorylation reaction revealed a vertical banding 
profile that typically possessed a high activity zone at specific regions in the gel (Figure 
11 A). Xylene cyanol and bromophenol blue were used as visual indicators in order to 
determine the relative position of the RNA. In a 5% denaturing polyacrylamide gel xylene 
cyanol migrates at approximately 150nt and bromophenol blue migrates at approximately 
30nt (Promega 2005). Based on the migration of xylene cyanol all three of the [32P] RNAs 
migrated to their approximate nucleotide position within the gel as shown in Figure 1 IB.
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3.2.2 Electrophoretic Mobility Shift Assays
EMSA protocols were adopted from the methods previously described by Prokipcak 
et al. 1994. Initial experiments involving EMSA were conducted in order to optimize the 
binding conditions between CRD-BP and [32P] c-myc CRD-1705-1886 RNA. Optimum 
incubation conditions for EMSA were determined experimentally and the results are 
presented in Figure 12A.
nM CRD-BP ^ &  ' S  S  ' S  S
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
+ H eparin - H eparin
B  nM  C RD-BP ^  ^  ^
Complex II □ 
Complex I G------
1 2 3 4 5  6 7  8 9  10 11
Figure 12: EMSA optimization experiments (A) Audioradiograph illustrating the 
optimization of the EMSA incubation conditions in the presence and absence of 1U RNase 
T l. The binding reaction optimization scheme involved a 10 minute incubation on ice or at 
30°C, a second incubation for 10 minutes on ice or at 30°C, a 5 minute incubation on ice, a 5 
minute incubation with heparin and a final 5 minute incubation with 1U RNase T l (if 
indicated by +T1). (B) Illustrates the effect of adding 5mg/mL heparin after two, 10 minute 
incubations at 30°C and one 5 minute incubation on ice. Both A and B utilized 
approximately 40nM [32P] c-myc CRD 1705-1886 RNA (50,000cpm) and CRD-BP at the nM 
concentrations indicated.
It was determined that optimum incubation conditions involved one 10 minute 
incubation at 30°C followed by a 5 minute incubation on ice. An additional 10 minute
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incubation at 30°C followed by a 5 minute incubation on ice was repeated. Heparin was then 
added to the binding reaction and the reaction was incubated on ice for a final 5 minutes. 
Optimum binding conditions were measured by the presence and intensity of binding 
complexes. While all test conditions generated detectable binding complexes the conditions 
in Figure 12A, lanes 5-8 were considered optimal.
It was also determined that the use of 1U RNase T l (Ambion) at the end of the 
heparin incubation had no noticeable effect on binding and was therefore omitted from 
subsequent experiments (Figure 12A). It has been previously suggested that the addition of 
heparin positively influences binding interactions as it is thought to reduce non-specific 
RNA-protein interactions (Prokipcak et al. 1994). In the absence of heparin there remains 
visible evidence of binding, however the band exhibiting enhanced mobility, Complex I, is 
absent (Figure 12B; compare lanes 7-9 with 2-4). Based on the evidence in Figure 12B, 
(compare lanes 2-4 with lanes 7-10) the addition of heparin may have positively influenced 
the formation of binding complexes.
Figure 13 represents the typical, highly reproducible binding profile involving a 
freshly dialyzed CRD-BP D-eluate fraction and [32P] c-myc CRD-1705-1886. At low 
concentrations of CRD-BP (i.e. 0-75nM) (refer to Figure 13, lane 2) Complex I is most 
prominent, whereas at concentrations in excess of 75nM a second slower migrating band, 
Complex II, emerges (Figure 13, lanes 3-5). As the concentration of CRD-BP increased 
beyond 219nM, Complex I was significantly reduced and the intensity of Complex II became 
significantly enhanced (Figure 13, compare lanes 3, 4 and 5).
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Complex II 
Complex I
^  Free probe
Figure 13: Audioradiograph depicting the formation of binding Complexes I & II.
EMSA in which CRD-BP (at the nM concentrations indicated) was incubated with 
approximately 40nM [32P] c-myc CRD 1705-1886 (50,000cpm) under the standard EMSA 
conditions described in section 3.1.4.
The results depicted in Figure 13 suggest that Complex I may form when one CRD- 
BP molecule binds to a structural element or target sequence within the c-myc CRD. In 
addition, the formation of Complex II may result from the interaction of two CRD-BP 
molecules with one RNA target; assuming there are two putative binding sites within the c- 
myc CRD. Alternatively, Complex II may form when one CRD-BP binds to the c-myc CRD 
and a second molecule of CRD-BP binds to the protein interacting with the RNA (i.e. via 
self-association).
As demonstrated in Figure 13, lane 2, the preferential formation of Complex I at low 
concentrations of CRD-BP may represent the formation of an obligate intermediate binding 
complex. Therefore, the intermediate binding complex may represent an essential, 
concentration dependant step leading to the formation of Complex II. The preferential 
formation of Complex I at low concentrations of CRD-BP may be the result of excess RNA 
binding with relatively few molecules of CRD-BP. As the CRD-BP concentration increases 
the ratio of free RNA possessing the required secondary/tertiary structure to RNA in
CRD-BP D-eluate
nM *  $
1 2 3 4 5
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Complex I configuration decreases. At that point the excess CRD-BP either associates with 
another RNA binding site in Complex I configuration or it self-associates with a protein 
already bound to the RNA (i.e. formation of Complex II).
Rpp20 Rpp21 Rpp25 Rpp40
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Figure 14: CRD-BP and Rpp25 are capable of in vitro interactions with the c-myc CRD.
EMSA in which Rpp 20, 21, 25 and 40 (at the nM concentrations indicated) were incubated 
with 40nM [32P] c-myc CRD 1705-1886 (50,000cpm). Lane 2 represents a positive control 
involving 750nM CRD-BP incubated with the indicated RNA substrate.
Figure 14 illustrates the absence and/or presence of binding profiles exhibited by the 
other purified 6 xHis-tagged recombinant proteins. An absence of binding was detected in the 
Rpp 20, 21 and 40 fractions whereas binding was observed in the Rpp25 fraction. The ability 
of Rpp25 to bind to the c-myc CRD was not surprising given the fact that it possesses an 
Alba domain and is known to bind to several RNA targets including a 71nt segment of HI 
RNA, M l RNA and E.coli tRNAtyr (Guerrier-Takada 2002).
The binding profile of Rpp25 is hallmarked by three binding complexes that show an 
increase in intensity with increasing protein concentration (Figure 14B, lanes 9-11). It 
should be noted that the intensity of the Rpp25 binding complexes is significantly less than 
CRD-BP binding complex at the same concentration (Figure 14 compare lanes 2 and 11). 
The evidence does not definitively prove that c-myc CRD is a bona fide CRD-BP target.
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However, these findings do support previous observations that Alba domains play a role in 
forming relatively non-specific associations with a variety of RNA targets. The role Alba 
domains play in mediating nucleic acid binding is unclear. Other factors such as Rpp25 self­
associations via Alba domains to existing RNA-Alba protein interactions should be 
considered as possible recognition and binding mechanisms.
In contrast, Rpp20 was unable to associate with c-myc CRD RNA despite possessing 
an Alba domain. The inability of Rpp20 to bind RNA suggests that the Alba motif alone is 
not the essential element required to engage in nucleic acid binding with the c-myc CRD. 
The inability of Rpp21 to bind c-myc CRD RNA suggests that its unique cystine arrangement 
is also incapable of in vitro associations with the RNA substrate. The inability of Rpp20 and 
Rpp21 to bind CRD suggests that these proteins, which have been previously shown to bind 
RNA, do not (on their own) possess elements that mediate recognition and binding. Finally, 
the inability of Rpp40 to bind with the c-myc CRD was supported by the previous claims that 
this protein in isolation does not play a role in nucleic acid binding (Jiang et al. 2001).
3.2.3 Saturation Binding Experiments
Saturation binding experiments were carried out using the standard EMSA conditions 
and employed a wide range of CRD-BP concentrations. The saturation binding experiments 
were conducted three times, using three different purified CRD-BP preparations. The results 
are presented in Figure 15A, B and C. It was determined experimentally that the minimum 
concentration of CRD-BP required to generate Complex I was 15nM (Figure 15C, lane 2). 
At concentrations above lOOnM, Complex II was frequently observed (Figure 15C, lanes 8 - 
16). In many instances, at higher concentrations of CRD-BP (e.g. 500-750nM), Complex I
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was absent and it would appear that the bound RNA shifted exclusively to Complex II 
(Figure 15A, compare lanes 5 and 20).
nM CRD-BP ©
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nM CRD-BP 227 380 760 1520 2270
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nM CRD-BP *  ^  ^ nM CRD-BP
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Figure 15: (A, B and C) Saturation binding experiments between CRD-BP and [32P] c- 
myc CRD 1705-1886 (50,000cpm/40nM), (D) [32P] p-globin RNA (25,000cpm/30nM) (E) 
[32P] MDR-1 RNA (30,000cpm/30nM).
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Figure 16: Saturation binding curves as generated by the Hill Equation. (A) Was
generated from the data collected from the experiments in Figure 15A-C and involved the 
incubation of recombinant CRD-BP with [32P] c-myc CRD-1705-1886 (50,000cpm/40nM).
(B) Was generated from the data collected from in the experiment depicted in Figure 15E in 
which recombinant CRD-BP was incubated with [32P] MDR-1 RNA (30,000cpm/30nM) 
under the standard EMSA conditions.
When the saturation binding data (from Figures 15A, B and C) was fit to the Hill 
equation and expressed graphically a sigmoidal curve was generated (Figure 16A). The 
curve allowed for the non-linear regression of the CRD-BP vs c-myc CRD-1705-1886 
dissociation constant which was approximately 500nM.
Saturation binding experiments were also used to determine if CRD-BP could bind 
with other radiolabelled RNA substrates. When challenged with [32P] fi-globin RNA, CRD- 
BP was unable to form an observable RNA-protein complex (Figure 15D). However when 
CRD-BP was challenged with [32P] MDR-1 RNA, two RNA-protein complexes that 
exhibited a similar profile to that of the c-myc CRD-CRD-BP interaction were observed; Kd
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= 500nM (Figure 15E). The analysis of the binding data revealed a level of cooperativity 
was present between the formation of the first and second binding complexes.
The cooperativity observed is also reflected in the Hill coefficient, which for CRD- 
BP vs c-myc CRD (Figure 16A) was 2.06 and 2.6 when challenged with MDR-1 RNA 
(Figure 16B). The Hill coefficients in both cases suggest that two molecules of CRD-BP 
bind with one molecule of c-myc CRD RNA and one molecule of MDR-1 RNA at identical 
or non-identical sites. Evidence to support a two RNA binding site model is provided by the 
kinetic analysis of IMP1 and 7GF-II RNA (Nielsen et al. 2004). In this study IMP1 was 
shown to bind through a cooperative, sequential mechanism via two binding sites within the 
JGF-11 transcript (Nielsen et al. 2004).
3.2.4 EMSA Competition Experiments
In order to determine if the c-myc CRD-1705-188-CRD-BP association was specific, 
the interaction was challenged with unlabeled competitor RNA. The competition assays 
revealed that unlabelled p-globin competitor RNA at 50X molar excess was unable to dilute 
the binding between CRD-BP and [32P] c-myc CRD (Figure 17B; compare lanes 2 and 8 ). 
The inability of unlabelled P-globin competitor to dilute the CRD-BP-c-myc CRD interaction 
in conjunction with the saturation binding experiment in Figure 17D support the observation 
that the 145nt P-globin is not a bonafide CRD-BP target in vitro. The P-globin results from 
this investigation are also supported by the findings of (Prokipcak et al. 1994; Doyle et al. 
1998).
MDR-1 RNA at IX molar excess was capable of diluting the CRD-BP-[ P] c-myc 
CRD interaction and at 5X and 10X molar excess it diluted the interaction completely 
(Figure 17A; compare lane 2 and lanes 11-14). Unlabelled competitor c-myc CRD-1705-
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1886 RNA at IX molar excess was also capable of diluting the CRD-BP-[32P] c-myc CRD 
interaction and at 10X molar excess the interaction was completely diluted (Figure 17A; 
compare lane 2 and lanes 3-6). Unlabelled competitor c-myc CRD 1705-1792 was observed 
to dilute the interaction when a minimum of 2X molar excess was added and even at 50X 
molar excess the CRD-BP-[32P] c-myc CRD interaction was still visible (Figure 17A; 
compare lane 2 and lanes 7-10 and Figure 17B; compare lane 2 and lanes 5-6).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 1 2 3 4 5 6 7 8 9 10
Figure 17: (A and B) EMSA competition assays with competitor c-myc CRD, p-globin or 
M DR-1 RNA. Approximately 350nM of recombinant, 6 xHis-tagged CRD-BP was incubated 
with 40nM [32P] c-myc CRD-1705-1886 (50,000cpm) with or without the indicated molar 
excess of unlabeled competitor RNA.
The competition assay results suggest that while the c-myc CRD-1705-1792 is a bona 
fide protein target, CRD-BP possess increased affinity for the c-myc CRD-1705-1886 RNA 
substrate; a result reflected in previous studies (Prokipcak et al. 1994 & Doyle et al. 1998). 
It is possible that the secondary structure of the c-myc CRD-1705-1886 contains the full 
complement of recognition and binding elements that facilitate high affinity binding 
interactions with CRD-BP. The observation that CRD-BP bound equally well with c-myc 
CRD and MDR-1 suggests that they possess similar secondary structure and/or sequence 
elements.
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Figure 18: Modified EMSA competition assay involving the incubation of 1500nM CRD- 
BP and 30nM [32P] c-myc CRD 1705-1886 (35,OOOCPM) under the standard EMSA reaction 
conditions. Unlabelled c-myc CRD 1705-1886 competitor RNA was added at the end of the 
incubation period for the time periods indicated and were loaded onto an 8 % non-denaturing 
polyacrylamide gel and resolved at 25mA for 90 minutes.
In order to determine if Complex II represents a stable, higher order binding 
interaction a modified competition assay was conducted. In this experiment, approximately 
1500nM CRD-BP was incubated in the presence of 30nM of [32P] c-myc CRD-1705-1886 
under the standard EMSA conditions. Unlabelled competitor c-myc CRD-1705-1886 (5x or 
lOx molar excess) was then added for either 2, 4, 6 , 8  or 10 minutes prior to being loaded 
onto a non-denaturing polyacrylamide gel. The CRD-BP concentration employed in this 
reaction ensured that Complex II would be the predominant binding interaction present in the 
reaction.
It was anticipated that if Complex II represents a stable RNA-protein complex (i.e. 
containing 2 molecules of CRD-BP) its presence would be only slightly diluted by the 
presence of competitor RNA. The results depicted in Figure 18 illustrate that Complex II is 
moderately diluted (20%) upon the addition of lOx molar excess competitor RNA (compare 
lane 2 with lanes 3-7). In addition, no significant difference in Complex II dilution is
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apparent at the time intervals and concentrations tested. The limited dilution of Complex II 
upon the addition of competitor c-myc CRD-1705-1886 RNA, regardless of exposure time 
suggests that Complex II represents a stable RNA-protein interaction.
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Chapter 4
Testing the CRD-BP Shielding Hypothesis and M apping the CRD-BP  
Binding Site on c-myc CRD RNA
4.1 M ethodology
4.1.1 Endonuclease Shielding Experiments
In order to test the CRD-BP shielding hypothesis a two-step experimental process 
was utilized. The first step involved the binding between one of the radiolabelled RNA 
constructs: c-myc CRD-1705-1886, MDR-1 or fi-globin and one of the purified recombinant 
proteins: CRD-BP, Rpp20, Rpp21, Rpp25 or Rpp40. The binding reactions were conducted 
under the identical conditions described in the standard EMSA protocol in section 2.2.4. 
However, immediately following the final step in the EMSA procedure 1.85pL 
(approximately 1-3U) of heparin-sepharose purified native mammalian endoribonuclease was 
added to the binding reaction, mixed and incubated at 37°C for 3 minutes. As a positive 
control dialyzed native mammalian endoribonuclease was added to EMSA buffer in the 
absence of recombinant protein and incubated at 37°C for 3 minutes.
The modified EMSA endoribonuclease-shielding reaction was terminated by heating 
the tubes at 100°C for 3 minutes followed by the addition of lpL  phenol and 3pL formamide 
loading dye. Aliquots containing approximately 30,000cpm were loaded onto an 8 % 
denaturing polyacrylamide gel and resolved at 30mA until the bromophenol blue reached the 
bottom of the gel plate.
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4.1.2 Hydroxyl Radical Footprinting Using Fe(II)/EDTA Complex
Mapping the CRD-BP binding sites on the c-myc CRD-1705-1886 was mediated 
through the use of the Fe(II)/EDTA cleavage complex (Tullius et al. 1986). Initially, binding 
between c-myc CRD (approximately 45nM; 100,000cpm/reaction) and CRD-BP (1500nM) 
was facilitated using the standard EMSA buffer and reaction conditions. Immediately 
following the binding reaction, 6 pL of Fe(II)EDTA cleavage reagent was added to the 20pL 
binding reaction. The cleavage reaction was incubated at room temperature for 10 minutes 
and was terminated by the addition of 5pL 0.1M Thiourea (Sigma). The RNA was extracted 
by ammonium acetate/isopropanol precipitation and the pellet was resuspended in 15pL 
formamide loading dye. Approximately 5pL of the reaction was loaded onto an 8 % 
denaturing polyacrylamide sequencing gel and was resolved at 30mA until the bromophenol 
blue reached the bottom of the gel plate.
Table 8: Reagents used in the RNA footprinting analysis 
Reagent Reagent composition
Fe(II)EDTA 0.4mM iron(II)ammonium sulfate Fe(II)(NH4)2(S0 4 ) 2  (Sigma), 0.8mM
cleavage reagent EDTA/pH 8 , 20mM L-Ascorbic acid sodium salt CftHvOsNa (Sigma)
and 0.35% hydrogen peroxide 
lxAlkaline 50 mM Sodium Carbonate [NaHCO?/Na2CO.d pH 9.2, 1 rnM EDT
hulroksis buffer i Ambion). 3pg of yeast il<Y \ ( M)mg/iul.i i Ambion) Ai
4.1.3 Preparation of c-myc CRD RNA Hydroxyl Ladder and T l Digest
Alkaline ladders were generated by combining 100,000cpm [32P] c-myc CRD-1705- 
1886 RNA and IX Alkaline hydrolysis buffer in a total reaction volume not exceeding 15pL. 
The alkaline preparation was incubated at 95 °C for 10 minutes, transferred to ice and 
combined with 20pL of formamide loading dye and stored at -20°C until required.
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Tl digests were generated by incubating 100,000cpm [32P] c-myc CRD-1705-1886 
RNA in EMSA binding buffer with 1U of RNase T l (Ambion). The RNA/EMSA binding 
buffer mixture was heated to 55°C for 5 minutes and was then allowed to cool to room 
temperature prior to the addition of RNase T l. The T l cleavage reaction was incubated at 
room temperature for 10 minutes and was terminated by phenol/chloroform extraction. The 
RNA was extracted using ammonium acetate/isopropanol precipitation and was resuspended 
in 15pL of formamide loading dye.
4.2 Results and Discussion
4.2.1 CRD-BP Shields the c-myc CRD from Endonucleolytic Attack by a Native 
Mammalian Endoribonuclease
The data presented in Figure 19A-B demonstrates that CRD-BP is capable of 
reducing c-myc CRD cleavage significantly in the presence of the native mammalian 
endoribonuclease. The cleavage profile characteristic of the native mammalian 
endoribonuclease in the presence of c-myc CRD-1705-1886 is presented in Figure 19A, lane 
3 and Figure 20B lane 4. The cleavage fragments generated by the native mammalian 
endoribonuclease were mapped according to previously reported data (Bergstrom et al. 2006) 
and using an RNase T l digest of c-myc CRD (Figure 20A, lane 3).
The “regions” delineating various c-myc CRD cleavage fragments (as indicated in 
Figure 19-21) were arbitrarily assigned. Region I corresponds to nucleotides 1846-1852, 
Region II, 1768-1775 and Region III, 1742-1757. The regions indicated in Figure 22A-B 
were also arbitrarily assigned however their nucleotide positions have not been mapped.
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The rationale behind the utilization of CRD-BP concentrations in the ranges tested 
was based on the results from the saturation binding experiments presented in section 2.3.3. 
It was anticipated that c-myc cleavage would be reduced using CRD-BP concentrations equal 
to the measured dissociation constant because 50% of c-myc CRD would be bound at 
500nM. This prediction was confirmed by the reduction in cleavage fragments observed in 
all three regions indicated in Figure 19A (compare lane 3 with 4 and 5). At 500nM, CRD-BP 
was responsible for a 43% reduction in Region I, a 72% reduction in Region II and a 77% 
reduction in Region III. A comprehensive summary of cleavage reductions from the 
endonuclease shielding experiments is presented in Table 9.
Nuclease B
+  +  + +  +  + Nuclease + + +
CRD-BP + + CRD-BP
+ +
Region I I
Region III 
Region III
1 2 3 4 5 7 8 9 10
>myc CRD-1705-1886 i= >
1 2 3 4 5
Figure 19: CRD-BP shields the c-myc CRD from endonucleolytic attack by a native 
mammalian endoribonuclease (A) Lanes 4-5; native mammalian endoribonuclease 
cleavage reduction in the presence 500nM CRD-BP and lanes 9-10; mammalian 
endoribonuclease cleavage reduction in the presence of 750nM CRD-BP. (B) Complete 
blockage of native mammalian endoribonuclease cleavage in the presence of 1500nM CRD- 
BP. Region I corresponds to nucleotides 1846-1852, Region II corresponds to nucleotides 
1768-1775 and Region III corresponds to nucleotides 1742-1757. (A); Lanes 3-5 and (B); 
lanes 3-5 contained approximately 1-3 units of the native mammalian endoribonuclease.
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Figure 20: Mapping the cleavage sites within the c-myc CRD-1705-1886 that are 
blocked by CRD-BP. (A) Audioradiograph of an 8 % denaturing polyacrylamide gel 
demonstrating cleavage reductions in the c-myc CRD. Lanes 5-7; native mammalian 
endoribonuclease cleavage reduction in the presence 750nM CRD-BP and lanes 4 and 9 
contain native mammalian endoribonuclease in the absence of CRD-BP. (B) 
Audioradiograph of a 12% denaturing polyacrylamide gel containing samples from the 
reactions in Figure 19A. (A) Lanes 3-7 and lanes 3-5 and 8-9 utilized approximately 1-3 
units of native mammalian endoribonuclease.
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Table 9: The presence of purified recombinant 6 xHis-tagged proteins and their effects on 
endoribonucleolytic cleavage in several [32P]RNA targets. Reduction values were 
determined by densitometry of the audioradiographs presented in Figures 19, 21-22.
Protein
CRD-BP
Rpp 2 0
Rpp 2 1 
Rpp 40
Rpp 25
CRD-BP
KNA Target
c-myc CRD 1705-1886
c-zi/vc CRD 1705-1886
I
MDR- 1
I
CRD-BP P-globin
Percent reduction in cleavage
c-myc CRD 1705-1886
Region I: 43% 
Region II: 72% 
Region III: 77%
\  I i5 . I 'M  ■ ... ■ 
|< K O -I I I 'f  =  ?iH lnM
Region I: 0% 
Region II: 0% 
Region 111: 0%
(.Image f .  F ig . 21 tnui '  ■ 
[R p p  201 ^  I500» \ l
Region 1:15% 
Region 11:15% 
Region 111:50%
(Image D, Fig. 21B, lane 4) 
[Rpp 25] = 1500nM
Region I: ~(i% 
Region 11: 73% 
Region III: 6 8 %
(Image A*-Fig. 22Jane .4)
.< Nh-IlP  ..... ...
Region I: 58% 
Region II: 61 % 
Region III: 25%
(Image B, Fig. 22B, lane 4) 
[CRD-BP1 == 500nM
I
Region I: 45% 
Region II: 75% 
Region III: 80%
(Image A, Fig. 19B, lanes 9,10) 
[CRD-BP] ss 500nM
Region I: 0% 
Region II: ()% 
Region lll:D%
( l i n a s e  \ . r i B. 21 i
[K|>|. 2L| = 1SIHI..M
Region I: 95% 
Region II: 95% 
Region III: 95%
(Image B, Fig. 20. lanes 4. 5) 
[CRD-BP) * ISOOnM
Region 1: 0% 
Region II: 0% 
Region III: 0 %
' ImiiKP \ .  I is. 21. /'ini' 7' 
. k ' n - J i l  I ' i h u i M
Region I: 83% 
Region II: 84%: 
Region III: 75%
(Image A. Fig. 22. lane 5} 
<aRh-i;p '
Region I: 52% 
Region II: 95% 
Region III: 95%
(Image B, Fig. 22B, lane 5) 
[CRD-BP1 = 750nM
I
Region I: 95%. 
cgion II: 95%' 
egion III: 95%-
nuu'c I ig 22. lane 
'RD-UPI -  I 5 0 0 i i M
Region I: 58% 
Region II: 64% 
Region III: 40%
(Image B, Fig. 22B, lane 6) 
[CRD-BP] = ISOOnM
I
It was predicted that cleavage reductions would increase at concentrations above the 
measured dissociation constant because at 750nM and 1500nM approximately 75% and 90% 
of c-myc CRD would be bound by CRD-BP respectively. At 750nM, (refer to Figure 19A, 
lanes 9-10) CRD-BP was responsible for a 45% reduction in Region I, a 75% reduction in 
Region II and a 80% reduction in Region III. As presented in Figure 19B (refer to lanes 3-5) 
1500nM CRD-BP was responsible for the 95% cleavage reductions observed in all three 
regions.
Consistent cleavage reductions were observed in Regions II and III at all 
concentrations of CRD-BP tested (See Figure 19A; lanes 4-5, 9-10 and 20B; lanes 4-5).
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However, Region I cleavage reductions were approximately 30% less than the cleavage 
reductions observed in Regions II and III (Figure 19A; compare Region I in lanes 4-5 and 9- 
10 with Regions II and III in the same lanes). This observation suggests that the 1846-1852 
nucleotide portion of c-myc CRD had reduced interactions with CRD-BP and was therefore 
more susceptible to endonuclease attack. Previous studies confirm that CRD-BP has weak 
interactions with c-myc CRD in the region spanning nucleotides 1823-1886 (Doyle et al. 
1998).
Cleavage reductions in Regions I, II and III (Figure 19B; lanes 4-5) were consistent 
when 1500nM CRD-BP was utilized (i.e. 95% reductions). It was predicted at 500nM that a 
significant number of mRNA molecules would be bound by only one molecule of CRD-BP. 
If the c-myc CRD was bound by two proteins (i.e. as observed in Complex II, refer to section
3.3.2 and Figure 13), it is possible that the entire CRD may be protected from the 
endoribonuclease. In contrast, when only one CRD-BP molecule is bound to c-myc portions 
of the CRD (i.e. nts 1852-1846) may remain susceptible to endonucleolytic attack.
The results presented in Figure 20A support the cleavage reductions observed in 
Figure 19. However, in Figure 20A significant cleavage reductions (>90%) were also 
observed at nucleotide position 1727 and 1730 (compare lanes 3 and 9 with lane 4). Based 
on the observations of these experiments the following nucleotides within c-myc CRD are 
shielded from endonucleolytic attack via specific interactions with CRD-BP: 1726, 1729, 
1742, 1747, 1751, 1757, 1768, 1771, 1773, 1775, 1846 and 1852. It should be noted that 
cleavage reductions are not consistent at positions 1757 and 1747 (compare Figure 20A and 
B). This cleavage reduction inconsistency may be due to the use of different CRD-BP 
fractions in these experiments.
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Figure 21: Rpp20, Rpp21 and Rpp40 are unable to shield the c-myc CRD-1705-1886 
from a native mammalian endoribonuclease. Rpp25 is also capable of reducing the 
cleavage activity of the native mammalian endoribonuclease. (A) Lane 2 represents the 
positive control involving c-myc CRD and 1-3U of native mammalian endoribonuclease in 
the absence of recombinant protein. The remaining lanes 4, 6  and 8  contain 1-3U of native 
mammalian endoribonuclease in the presence of 1500nM of the indicated recombinant 
protein. (B) Illustrates the shielding effect elicited by 1500nM Rpp25 in the presence of 1- 
3U of native mammalian endoribonuclease. Region IV illustrates the presence of unique 
cleavage sites not present in lanes 1-2. Region I, II and III corresponds to the nucleotide 
ranges described in Figure 19.
Additional endoribonuclease blocking experiments were conducted to determine if 
other recombinant proteins: Rpp20, Rpp21, Rpp25 and Rpp 40 were capable of shielding the 
CRD from endonucleolytic cleavage. It was predicted that proteins incapable of binding to
the CRD (i.e. Rpp20, Rpp21, Rpp40) would likely be incapable of blocking the activity of 
the native mammalian endoribonuclease. Figure 21 demonstrates at 1500nM, Rpp20, Rpp21 
and Rpp40 were unable to block the activity of the native mammalian endoribonuclease
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(compare lane 2 with lanes 4, 6  and 8 ). It is also apparent that the cleavage intensities in 
lanes 4, 6  and 8  are significantly more intense when compared to the positive control in lane 
2. It is clear from the EMSA data that Rpp20, Rpp21 and Rpp 40 are incapable of binding to 
the CRD. Therefore, it is unlikely that these proteins are contributing to the apparent 
enhanced activity of the native mammalian endoribonuclease via RNA-protein interactions. 
The most likely explanation regarding the difference in cleavage intensities is pipetting error 
or a slight increase in exposure time to the endoribonuclease. In addition, it was shown that 
Rpp25 was capable of shielding the CRD from the native mammalian endoribonuclease 
(refer to regions I, II and III; Figure 21B; lanes 2-4). The most prominent cleavage 
reductions were observed in Region III (i.e. 50%) and to a lesser extent cleavage reductions 
were also observed in Regions I and II (i.e. 15% decrease).
The presence of unique cleavage fragments was also observed in the two reactions 
containing Rpp25 and the native mammalian endoribonuclease (Figure 2 IB, compare lanes 
1-2 with lanes 3-4). The unique cleavage fragment profile, denoted as Region IV, was not 
observed in the positive control (lane 2) or in the reaction containing untreated RNA (lane 1). 
The unique cleavage fragments in Region IV may indicate that Rpp25 has ribonuclease 
activity. In contrast, Rpp25 binding may have induced conformational changes in the CRD 
thereby promoting increased accessibility and susceptibility to endonucleolytic attack in 
unique regions of the transcript. An additional possibility explaining the fragments in Region 
IV could be the presence of a contaminating RNase.
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Figure 22: CRD-BP is capable of shielding MDR-1 and p-globin RNA from a native 
mammalian endoribonuclease. (A) Lane 2 represents the positive control involving MDR- 
1 and 1-3U of native mammalian endoribonuclease in the absence of recombinant protein. 
Lanes 4-6 contain CRD-BP at 1500nM, 750nM and 500nM respectively. (B) Lane 2 
represents the positive control involving P-globin and 1-3U of native mammalian 
endoribonuclease in the absence of CRD-BP. Lanes 4-6 contain CRD-BP at 500nM, 750nM 
and 1500nM respectively.
In previous experiments CRD-BP was shown to bind with considerable affinity and 
specificity to MDR-1. It was predicted that if CRD-BP binds with MDR-1 it should also be 
capable of blocking MDR-1 cleavage by a native mammalian endoribonuclease. CRD-BP 
was observed to shield MDR-1 from endonucleolytic attack in a concentration dependant 
manner and achieved the most significant cleavage reductions at 1500nM. The ability of 
CRD-BP to block MDR- 1 cleavage was consistent with the observations that CRD-BP binds 
with MDR-l RNA (i.e. Kd = 500nM) using EMSA. In addition, the percent cleavage 
reductions observed in Figure 22A are consistent in each individual reaction (compare
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cleavage reductions in Region I, II and III in lane 3). The consistent reductions suggest that 
the entirety of the MDR-1 construct is protected via CRD-BP interactions and therefore is 
inaccessible to endonucleolytic attack.
The results in Figure 22B suggest that CRD-BP is also capable of shielding p-globin 
from cleavage. The cleavage reductions observed in Figure 22B lanes 4-6, do not follow the 
typical concentration dependant response exhibited by the CRD-BP-c-myc CRD and CRD- 
BF-MDR-1 interactions. The presence of significant cleavage reductions observed in Figure 
22B was unexpected because EMSA and EMSA-competition experiments demonstrated that 
CRD-BP does not associate with P-globin. It is possible that these results were caused by 
CRD-BP blocking access to P-globin cleavage sites via steric hindrance rather than through 
specific binding interactions.
The results suggest that CRD-BP is capable of shielding both c-myc CRD and MDR-1 
RNA in a dose-dependant manner from the cleavage activities of a native mammalian 
endoribonuclease via specific RNA-protein interactions. In addition, the results suggest that 
CRD-BP binds to a considerable portion of both MDR-1 and c-myc and at 1500nM, both 
RNA constructs appear to be entirely protected. The results from the endonuclease shielding 
experiments are the first direct in vitro evidence supporting the CRD-BP shielding 
hypothesis.
4.2.2 Mapping the CRD-BP Binding Site of c-myc CRD Using Hydroxyl
Ladder RNA Footprinting Techniques
The endonuclease shielding experiments confirmed that CRD-BP is capable of 
shielding the c-myc CRD from endonucleolytic attack in vitro. The shielding experiments 
also helped elucidate the CRD-BP binding sites within the c-myc CRD. In order to confirm
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the location of CRD-BP binding sites an additional protein mapping technique known as 
RNA footprinting was employed. RNA footprinting is generally carried out using enzymes 
(RNases) or chemicals that cut the RNA backbone (Tillius et al. 1986). A protein will 
generally inhibit the cutting of the RNA backbone at specific sites to which it is bound, 
leaving a gap in the cleavage pattern (i.e. footprint) (Tillius et al. 1986).
The chemical cleavage reagent chosen for this experiment was the EDTA complex of 
iron(II), also known as the Fe(II)/EDTA complex. The Fe(II)/EDTA complex is a negatively 
charged species and does not interact electrostatically with the RNA molecule thereby 
limiting its interference with RNA-protein interactions (Tillius et al. 1986). The 
Fe(II)/EDTA complex generates hydroxyl radicals from the reduction of hydrogen peroxide 
in a reaction known as the Haber-Weiss reaction (Tillius et al. 1986). The hydroxyl radical is 
thought to cleave the RNA backbone by attacking ribose moieties (Tillius et al. 1986). 
Regions of the RNA backbone that are occluded by protein are cleaved with decreased 
efficiency by the radical and the result is a series of cleavage fragments exhibiting reduced 
intensity (Tillius et al. 1986).
Initially, a wide range of cleavage reagent concentrations were utilized in order to 
generate a clear and highly resolved cleavage pattern. Experiments investigating the effects 
of altering the concentration and volume of cleavage reagents and incubation times are 
illustrated in Figure 23A. There was no significant difference in cleavage efficiency at the 
Fe(II)/EDTA concentrations tested (Figure 23A, compare lanes 3-7 and see figure legend for 
concentrations employed).
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Figure 23: Fe(II)/EDTA RNA footprinting optimization experiments. (A) Lanes 3-7 
illustrates the effect of increasing [Fe(II)/EDTA] from 0.4mM/0.8mM, 1.4mM/2.8mM, 
4.8mM/12.6mM, 14.4mM/28.8mM and 50mM/100mM, for this experiment, unless 
otherwise stated, [Vitamin C] = 20mM and [H2O2] = 0.35% and cleavage reagent volume 
was equal to 6 pL. (A) lanes 10-14 illustrate the effect of increasing the volume of the 
Fe(II)EDTA cleavage reagent, lane 10 utilized 3pL, lane 11, 4.5pL, lane 12, 9pL and 
lane 13 15pL, lane 14, 20 pL (A) lanes 17-21 illustrate the effect of increasing the 
concentration of H2O2, lane 17 utilized 0.1%, lane 18, 0.2%, lane 19, 0.35%, lane 20, 
1%, and lane 21, 2% the [Fe(II)/EDTA] utilized was 0.4mM/0.8mM. (B) lanes 1-5 
illustrate the effect of increasing the concentration of glycerol in the EMSA binding 
buffer and its effect on Fe(II)/EDTA cleavage. (B) lane 1 RNA alone, lane 2, 0.5%, lane 
3, 5%, lane 4, 15% and lane 5, 20%, (lanes 6-9 are identical conditions as outlined in 
lanes 2-5). All cleavage reactions contained 100,000cpm [32P]c-myc CRD 1705-1886 
and cleavage all reactions were incubated for 1 0  minutes at room temperature.
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In addition, no significant difference in Fe(II)/EDTA-induced cleavage was 
observed when different cleavage reagent volumes were tested, except when an equal 
volume of cleavage reagent was employed (Figure 23A, compare lanes 10-14). 
However, increasing the strength of hydrogen peroxide did have a positive effect on the 
cleavage efficiency (compare lanes 17-21). An additional factor affecting the cleavage 
efficiency was the strength of glycerol used in the binding buffer. When glycerol 
strengths were in excess of 5% an inhibitory effect on the cleavage efficiency was 
observed (Figure 23B, compare lanes 4-5 to lanes 2-3).
The Fe(II)/EDTA cleavage treatment failed to generate a distinct footprint 
however, subtle reductions in cleavage were observed in Figure 24. Lane 4 depicts the 
Fe(II)/EDTA cleavage profile characteristic of [32P] c-myc CRD-1705-1886 in the 
absence of CRD-BP (i.e. negative control). The alkaline hydrolysis ladder (lane 3) 
exhibited a uniform cleavage profile with the exception of two enriched fragments 
located between nucleotides 1794-1842; which were also observed in lanes 4-9. The 
cleavage pattern observed in the negative control was hallmarked by several enriched 
fragments which have been mapped and are indicated in Figure 24. The appearance of 
the enriched cleavage fragments in the negative control and their absence in the alkaline 
hydrolysis sample may be due to the fact that the Fe(II)/EDTA cleavage reaction takes 
place under non-denaturing conditions. Under non-denaturing conditions the RNA 
maintains its native conformation and as a result certain structural elements may be more 
accessible and/or susceptible to the hydroxyl radical. In contrast, the denaturing 
condition employed in the alkaline hydrolysis reaction ensures that the RNA is fully 
denatured, leaving all portions of the molecule equally susceptible to cleavage.
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Figure 24: Mapping CRD-BP binding sites within the c-myc CRD using a hydroxyl 
radical mediated cleavage reaction. Audioradiograph of an 8 % denaturing 
polyacrylamide gel illustrating the Fe(II)/EDTA cleavage reaction involving the 
incubation of 45nM [32P] c-myc CRD-1705-1886 in EMSA binding buffer with and 
without CRD-BP. Lanes 5-8 include 1500nM CRD-BP from different purified fractions. 
Lane 9 represents untreated [32P]c-myc CRD. All reactions were carried out as described 
in section 4.1.2 and 4.1.3. Regions indicated by rectangles represent significant (i.e. <
50%) cleavage reductions. T  1 "“ J ° -----------* nM—  ^ 1  r32r
CRD 1705-1886.
Lanes  and 2 represent RNase T  digests of [ P] c-myc
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When comparing cleavage reactions containing 1500nM CRD-BP (Figure 24, 
lanes 5-8) to the negative control it is apparent that several regions of cleavage are 
significantly reduced. The cleavage fragments corresponding to nucleotides 1741 and 
1748 (lane 4) are reduced by 75% in lanes 5-8. An equivalent reduction was also 
observed at discrete fragments in the nucleotide region spanning 1767-1775 (Figure 24, 
compare lane 4 with lanes 5-8). At positions 1787 and 1791, a 50% reduction in cleavage 
intensity was observed and a 75% reduction was also observed at positions 1843, 1855 
and 1864 (Figure 24, compare lane 4 with lanes 5-8).
A partial map of potential CRD-BP binding sites within the c-myc CRD was 
generated when the results in Figure 24 were combined with the observations from 
Figure 20A-B. The observations in Figure 20A suggest that nucleotide positions 1727 
and 1730 are bound by CRD-BP at 750nM because these sites are 90-95% protected from 
the native mammalian endoribonuclease. Position 1741 and 1742 in Figure 20A 
(compare lanes 4 and 5) and 20B (compare lanes 3 and 4) were also protected (100% and 
80% respectively) from endonuclease activity and in Figure 24 position 1741 was 
protected from the hydroxyl radical. The data regarding positions 1727, 1730, 1741 and 
1742 strongly suggests their location as a potential CRD-BP binding site. According to 
Figure 20B, the nucleotides in the range of 1747-1757 (compare lanes 2 and 3) 
demonstrate a 75% reduction in cleavage with the greatest reduction being observed at 
position 1751. Similar reductions at position 1750 were also observed in Figure 24, 
compare lanes 4 to 5-8. Due to the presence of significant cleavage reductions in the 
region spanning 1747-1757, in particular at position 1751, it is suggested that this region 
represents a potential CRD-BP binding site. In addition, due to the proximity and the
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presence of a cytosine rich region between 1742 and 1747; the region spanning 1742- 
1757 should be considered a potential CRD-BP binding site.
1705 1727 1730 1742 1747 1751 1757
ACCAG AUCCC GGAGU UGGAA AACAA UGAAA AGGCC CCCAA GGUAG UUAUC CUUAA
1768 1775 l7®  1791
AAAAG CCACA GCAUA CAUCU GUCCG UCCAA GCAGA GGAGC AAAAG CUCAU UUCUG
1843 1864
AAGAG GACUU GUUGC GGAAA CGACG AGAAC AGUUG AAACA CAAAC UUGAA CAGCU
1886
ACGAA ACUCU UGUGC GU
Figure 25: Potential CRD-BP binding sites on the c-myc CRD 1705-1886 primary 
sequence. Binding sites were mapped according to the data presented in Figures 20A-B 
and Figure 24. Arrows indicate nucleotide positions exhibiting strong cleavage 
reductions as determined through RNA footprinting techniques (arrows denoting 
nucleotide 1705 and 1886 indicate the start and end of the CRD sequence). Nucleotides 
in bold indicate ranges in which CRD-BP binding is predicted to occur.
In Figure 20A (compare lanes 4 and 5) and Figure 20B (compare lanes 3 and 4) a 
75% cleavage reduction was observed at and between nucleotide positions 1768-1775. In 
addition, Figure 24 shows similar cleavage fragment reductions in the regions spanning 
1768-1775 and 1787-1791 (compare lanes 4 with lanes 5-8). Together these results 
suggest that CRD-BP may interact with nucleotides ranging from 1768 to 1775 and 1787 
to 1791. An additional possibility is that CRD-BP binds to the entire region spanning 
1768-1790. The presence of several cytosine and uracil residues (i.e. pyrimidine-rich 
tracts) and the proximity of these two sites support the possibility of the 1768-1791
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binding site. Significant cleavage reductions (75%) were also observed between
positions 1843 and 1864 (Figure 24, compare lanes 4 to 5-8) and between positions 1846
and 1852 in Figure 20B (compare lanes 3 and 4). Together these results suggest the
presence of a CRD-BP binding site spanning nucleotide positions 1843-1864. Based on
the positions and spacing of potential binding sites it seems likely that CRD-BP binds to
larger stretches of nucleotides rather than to specific positions. This belief is supported
by evidence that members of the VICKZ family bind to larger elements rather than to
individual nucleotides (refer to summary in 1.4.3 in Table 1). A summary of the
endonuclease shielding and Fe(II)/EDTA footprinting data is presented in Table 10.
Table 10: Mapping potential CRD-BP binding sites on c-myc CRD-1705-1886 using 
endonuclease shielding experiments and Fe(II)/EDTA mediated RNA footprinting. 
Potential CRD-BP sites as determined through RNA footprinting were compared to the 
ODN mapping evidence reported in Coulis et al. 2000; N/A indicates nucleotide regions 
not mapped in the Coulis investigation.
Cleavage
Siles
Percent
Reduction
1 1
T\ pe of Experiment Ajjrt 
with 
al. 2(
1727 90% Fig. 20A Shielding Yes
1730 90% Fig. 20A Shielding N/A
1742 70-80% Fig. 20A, Fig. 
24
Shielding/Fe(II)/EDT A Yes
174" 75% Fig. 20A-B Shielding Yes
1751 95% Fig. 20A-B Shielding Yes
1757 60% Fig. 20A-B Shielding N/A
1768 75% Fig. 20A-B Shielding Yes
P 7 I 75% Fig. 20A-B Shielding Yes
1773 75% Fig. 20A-B Shielding Yes
1775 75% Fig. 20A-B Shielding Yes
1787 50% Fig. 24 Fe(II)/EDTA Yes
1791 50%. 1 ig. 34 led li/I .D IA No
1843 40% Fig. 24 Fe(Il)/EDTA N/A
1S64 75% Fig. 20A-B Shielding Yes
1852 75% Fig. 24 Ke(lI)/FDTA Yes
1855 75% Fig. 24 Fe(II)/EDTA Yes
I
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 4 -  TESTING THE SHIELDING HYPOTHESIS AND MAPPING 101
Predicted CRD-BP binding site regions
■  1727-1730
■  1742-1757UlaMUII
■  1768-1775
■  1787-1791
■  1843-1864
1768
1791
J- . A'S.HT AV^y'"A"cJ
/-•T V-1» « K a.
1 V
1742
1705
dG = -37*73 [ i n i t i a l l y  -43,21 unknoun
1/ 1-
■sc* r r
Figure 26: Predicted CRD-BP binding sites and minimal free energy proposed 
secondary structure of c-myc CRD 1705-1886 as predicted by mfold  analysis based 
on the computer algorithm described by Zuker 1999.
Additional experimental evidence supports the belief that CRD-BP-c-myc CRD 
interactions require several specific binding associations at several nucleotides regions. 
In one study, complementary oligonucleotides (ODNs) were used to map the CRD-BP 
binding sites within the c-myc CRD (Coulis et al. 2000). A total of eight different ODNs, 
each 15 nucleotides in length, were designed to bind to complementary regions within the 
CRD (Coulis et al. 2000). A crude cell lysate from K562 cells containing CRD-BP and
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one of the eight ODNs were added simultaneously to radiolabelled c-myc CRD-1705- 
1886 using the standard EMSA conditions employed in the current investigation. It was 
predicted that the ODNs would bind to complementary regions on the CRD thereby 
occluding potential CRD-BP binding sites. Reductions in binding as a result of ODN 
interference were reported (Coulis et al. 2000). Four regions within the CRD were 
shown to play a key role in CRD-BP-c-myc associations and these include: 1741-1755, 
1763-1777, 1772-1788 and 1861-1875.
There are several instances of region overlap between the results of the previous 
(Coulis et al. 2000) and current investigations. The nucleotide region spanning 1741- 
1755 was essentially identical to the current, predicted binding site mapped to region 
1741-1757. The similarities between these predicted sites suggest this region is a bona 
fide CRD-BP target in vitro. In addition, the predicted secondary structure for the 1741- 
1757 region (refer to Figure 26) contains several single stranded pyrimidines, stem and 
hair pin loops; all three of which are well established KH domain and VICKZ recognition 
targets (Ross et al. 1999; Jian et al. 2003). The CRD-BP binding site at 1763-1777 
shown by Coulis et al. 2000, was also observed in the current study which reports a 
similar binding site within the stem loop region spanning nucleotides 1768-1775 (refer to 
Figure 26). In addition, the CRD-BP binding site spanning 1843-1864 overlaps slightly 
with the observed region at 1861-1875 as reported by Coulis et al. 2000. Additional 
similarities between these two studies are reflected in the apparent absence of CRD-BP 
binding sites within the regions spanning 1705-1725 and 1790-1841.
The predicted secondary structure of the CRD and the superimposed CRD-BP 
binding sites are illustrated in Figure 26. Figure 26 clearly demonstrates the prevalence
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of c-myc-CRD-BP interactions at various hairpin, stem and branch loop structures. The 
presence of cis-acting elements such as hair-pin loops and other distortions in the c-myc 
CRD may contribute to its instability and susceptibility to endoribonucleases. Previous 
experiments have shown that the c-myc CRD-1705-1792 is susceptible to cleavage by the 
native mammalian endoribonuclease within four of its five stem and hair-pin loop 
structures (Bergstrom et al. 2006). The identical native mammalian endoribonuclease 
used in this investigation cleaves the 1705-1886 CRD at several locations where CRD-BP 
is known to bind and in many cases these locations are found within loop structures (e.g. 
nts 1750, 1756, 1727, 1730, 1770, 1771 and 1852). The presence of CRD-BP binding 
sites within regions targeted by the native mammalian endoribonuclease supports the 
hypothesis that CRD-BP could serve as a stabilizing factor for c-myc in vitro. The 
evidence reported in this chapter confirms that CRD-BP is capable of blocking a native 
mammalian endoribonuclease from cleaving c-myc CRD via specific interactions with 
RNA structural elements.
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Chapter 5 
General Discussion
5.1 General Overview
The VICKZ family of RNA-binding proteins are implicated in mRNA localization, 
nuclear export, turnover and translational control (Vikessa et al. 2006). The coding region 
determinant binding protein (CRD-BP) is a member of the VICKZ family and has been 
shown to interact with a variety of mRNA targets that influence cell growth, differentiation 
and proliferation (Vikessa et al. 2006). In vitro evidence has shown that CRD-BP is capable 
of binding to an instability sequence in the coding region of c-myc mRNA (Prokipcak et al. 
1994). It has also been demonstrated that the c-myc CRD is cleaved by a native mammalian 
endoribonuclease in vitro (Bergstrom et al. 2006). Furthermore, c-myc mRNA in vivo 
degradation intermediates corresponding to the CRD region have been identified using 
ligation mediated-PCR (Hanson et al. 2001). These observations provided the motivation to 
test the CRD-BP shielding hypothesis. The shielding hypothesis proposes that RNA-protein 
interactions between the CRD and CRD-BP protect the c-myc transcript from 
endonucleolytic attack (Prokipcak et al. 1994). To date the shielding hypothesis has not been 
directly tested in vitro.
The goal of this investigation was to directly test the CRD-BP shielding hypothesis. 
Testing the proposed shielding hypothesis in vitro would be the first step towards 
determining if the CRD-BP-c-myc shielding interaction occurs in vivo. Investigating this 
relationship in cells is of great importance because both CRD-BP and c-myc are implicated in 
carcinogenesis (Ioannidis et al. 2004). The results of this investigation confirm that RNA-
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protein interactions between CRD-BP, c-myc CRD and MDR-1 RNA protect these transcripts 
from endonuclease attack.
5.2 Assessing the Ability o f CRD-BP and Other Recom binant 
Proteins to Bind to c-myc CRD, ft-Globin and M D R -1 RNA  
Using the Electrophoretic M obility Shift Assay
The primary objective of this phase of the investigation was to detect RNA-protein 
interactions using EMSA. It was determined that CRD-BP and Rpp25 were capable of 
binding to c-myc CRD RNA. In contrast, Rpp20, Rpp21 and Rpp40 were unable to form 
RNA-protein interactions with c-myc CRD RNA. The presence and absence of RNA-protein 
interactions between the c-myc CRD RNA, Rpp25, Rpp21, Rpp20 and Rpp40 were discussed 
in detail in section 3.2.2. Finally, a novel RNA target recognized by CRD-BP has been 
identified. It was shown that CRD-BP binds avidly to MDR-1 RNA.
5.2.1 Binding Mechanisms Facilitating CRD-BP-RNA Interactions
It was essential to determine if purified CRD-BP could bind to the c-myc CRD RNA 
as previously shown (Prokipcak et al. 1994; Doyle et al. 1998). In these previous studies 
native and various recombinant forms of CRD-BP were shown to interact with the c-myc 
CRD using in vitro methods such as UV-crosslinking, EMSA and EMSA-antibody supershift 
experiments (Prokipcak et al. 1994; Doyle et al. 1998). In the current investigation, EMSA 
was chosen due to its sensitivity in detecting binding interactions between RNA and protein 
at nM concentrations (Haynes 1999).
The results confirm that CRD-BP was capable of forming RNA-protein interactions 
with the c-myc CRD-1705-1886 and with MDR-1 RNA in vitro. The binding reported in this
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investigation was predicted due to the fact that CRD-BP is endowed with multiple RNA- 
binding domains including four KH domains and two RNA recognition motifs (Doyle et al. 
1998).
Previously reported EMSA results (refer to section 3.2.2) revealed that CRD-BP 
binds to both c-myc CRD RNA constructs (nts 1705-1792 and 1705-1886). The competition 
assay results suggest that CRD-BP binds more avidly to the 1705-1886 region. The binding 
profiles exhibited by the CRD-BP, 1705-1886 and 1705-1792 interactions were hallmarked 
by the presence two binding complexes (i.e. Complex I and II). However, the Kd for the 
CRD-BP, 1705-1886 interaction was significantly lower than the recorded Kd for the CRD- 
BP, 1705-1792 interaction (data not shown). Upon comparison of the predicted mfold 
secondary structures for both CRD regions it is apparent that one of the proposed CRD-BP 
binding sites (nts 1843-1864) is absent from the 1705-1792 CRD region. The ability of 
CRD-BP to form similar binding complexes when challenged with both CRD regions 
suggests that the 1705-1792 region contains the necessary binding sites. However, its higher 
IQ value (approximately lOOOnM) suggests that the absence of the 1843-1864 region impacts 
the specificity and stability of this RNA-protein interaction.
The RNA-protein interactions observed between CRD-BP, c-myc and MDR- 1 RNA 
are believed to occur via a sequential, cooperative binding mechanism. The sequential 
mechanism was hallmarked by the presence of two distinct binding complexes (Figure 13, 
15A-C, E). The formation of Complex I at low concentrations of CRD-BP, the emergence of 
Complex II at intermediate concentrations of CRD-BP and the predominance of Complex II 
at concentrations > the calculated Kd is suggestive of a sequential binding mechanism.
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It is possible that the formation of Complex I may represent an intermediate state in 
which one molecule of CRD-BP is bound to one RNA molecule. The emergence of 
Complex II suggests that a second molecule of CRD-BP engages in interactions with a 
Complex I species in a concentration dependant manner. The formation of Complex II may 
serve to increase the stability and specificity of the RNA-protein interaction.
The recognition, binding and stabilization of RNPs may involve RNA-protein 
interactions, protein-protein interactions (i.e. self-associations) or a combination of the two. 
The association between VglRBP and VLE mRNA has been shown to utilize both RNA- 
protein and protein-protein interactions (Git et al. 2002). It was determined that an RNA- 
protein complex (i.e. similar to Complex I) was the result of one molecule of VglRBP 
binding to the 3 '-UTR of VLE RNA (Git et al. 2002). The interaction between VglRBP and 
the VLE 3-U TR  was determined to be the initial step necessary for the formation of higher 
order binding complexes (Git et al. 2002). The self-association of a second VglRBP protein 
with the VglRBP already bound to the VLE 3'-UTR resulted in the formation of higher 
order binding complexes (i.e. similar to Complex II) (Git et al. 2002). Currently, it is 
believed that VICKZ protein-protein interactions may be mediated through their RRMs 
(Maris et al. 2005).
The data from the current investigation suggests that CRD-BP interacts with c-myc 
and MDR-1 RNA via a sequential mechanism involving RNA-protein interactions. The first 
step in this proposed mechanism likely involves the binding of one protein to a binding site 
on the RNA molecule. The subsequent step involves a second protein binding to a different 
site on the RNA. Interactions that require protein-protein interactions as a first step can be 
differentiated from mechanisms that require RNA-protein binding as a first step.
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Mechanisms requiring protein-protein interactions as a first step are generally favored by 
dilution of the protein into an RNA-containing solution (Nielsen et al. 2004). If the first step 
in CRD-BP-RNA interactions was due protein-protein interactions only one complex would 
be observed on an audioradiograph. The data in Figure 15A-C, E demonstrate that the 
dilution of concentrated CRD-BP into an RNA-containing solution does not facilitate the 
exclusive formation of Complex II. The results in Figure 15A-C, E suggests that Complex I 
represents the formation of an intermediate complex necessary for the concentration 
dependant formation of Complex II. An additional experiment could have added support to 
the claim that Complex I represents the first step required for the formation of Complex II. If 
Complex I was the rate determining first step then reducing the incubation time in the EMSA 
reaction to 1 or 2 minutes would favor the formation of Complex I.
The induced fit  model may help explain the proposed sequential, cooperative 
binding mechanism between CRD-BP and the c-myc CRD. Current evidence suggests that 
RNA secondary structures are fairly rigid whereas other regions are associated with greater 
flexibility (Maris et al. 2005). However, when proteins bind to secondary structure elements 
other regions in the RNA may undergo conformational (Maris et al. 2005). These initial 
interactions may induce conformational changes in the RNA that expose or create a suitable 
binding site for a second RNA-binding protein. It has been proposed that during the 
formation of Complex I, abundant free (i.e. un-bound) RNA molecules become bound by 
CRD-BP. When CRD-BP binds (presumably via the interactions of its 4 KH-domains) 
conformational changes are induced in the RNA. These conformational changes in the RNA 
may provide the basis for complex transitions (i.e. the disappearance of Complex I and the 
formation of Complex II) as concentrations of CRD-BP increase.
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It is also possible that RNA-binding proteins are subject to conformational changes 
upon binding to RNA. For example, when CRD-BP binds to its target region (i.e. stem loop 
or hair-pin structure) conformational changes may be induced in the protein and within the 
RNA. Conformational changes in the RNA may facilitate the exposure/creation of a new 
RNA binding site and conformational changes in the protein may provide the basis for the 
formation of protein-protein interactions. In the current model, Complex I formation occurs 
when CRD-BP binds to a target sequence/structure on the RNA. As a result of the initial 
RNA-protein interaction both the RNA and protein undergo conformational changes. The 
induced changes in the RNA expose a second RNA binding site that is recognized by a 
second protein. The second protein then engages in RNA-protein interactions as well as 
protein-protein interactions with the initial protein molecule (i.e. Complex II formation). The 
combined RNA-protein and protein-protein interactions may contribute to the stability of the 
complex.
5.3 Testing the CRD-BP Shielding Hypothesis and M apping the 
CRD-BP Binding Sites on c-myc CRD RNA
It has been hypothesized that CRD-BP increases c-myc mRNA stability by binding 
and shielding the CRD from endonucleolytic degradation (Prokipcak et al. 1994). A native 
mammalian endoribonuclease purified in our laboratory has the ability to cleave the CRD 
region of c-myc RNA (Bergstrom et al. 2006). Previous EMSA observations outlined in 
section 3.2.2 indicate that CRD-BP is capable of binding to the in vitro transcribed c-myc 
CRD and MDR-1 RNA. The ability to bind to the CRD and MDR- 1 RNA with considerable 
stability and specificity suggests that CRD-BP may shield the body of these transcripts from 
the activity of the native mammalian endoribonuclease. The data presented in Chapter 4
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provides the first direct in vitro evidence supporting the CRD-BP shielding hypothesis. In 
addition, the proposed CRD-BP binding sites within the c-myc CRD were determined using 
two RNA footprinting techniques.
5.3.1 CRD-BP Shields c-myc CRD and M D R -1 RNA from Endonucleolytic 
Attack by a Native Mammalian Endoribonuclease
It was determined that CRD-BP is capable of shielding c-myc CRD RNA at the 
locations cleaved by the native mammalian endoribonuclease. At lower concentrations of 
CRD-BP (i.e. 500nM and 750nM), shielding is observed but the CRD region is not uniformly 
protected. However, complete and uniform protection from the endoribonuclease is observed 
at higher concentrations of CRD-BP (i.e. 1500nM). The differences observed in the 
shielding pattern are likely related to the binding kinetics of CRD-BP with the CRD. A 
considerable amount of unbound RNA is available for cleavage at CRD-BP concentrations of 
500nM and 750nM. In addition, a considerable amount of RNA is present in Complex I 
configuration. RNA found in Complex I may only be bound by a single molecule of CRD- 
BP and specific regions of the CRD may remain unprotected and therefore susceptible to 
cleavage. The lack of uniform shielding observed in Figure 19A, specifically in the 1846- 
1852 region, could be accounted for by the presence of CRD in Complex I configuration. At 
1500nM it can be assumed that the majority of the RNA was bound by CRD-BP in Complex 
II configuration. In this configuration the endonuclease is unable to gain access to cleavage 
sites and the result is complete and uniform protection (Figure 19B).
It was also determined that CRD-BP is capable of shielding MDR-1 RNA at the 
locations cleaved by the native mammalian endoribonuclease. At lower concentrations of 
CRD-BP (500nM and 750nM) a uniform reduction in cleavage was observed. In addition, at
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1500nM of CRD-BP, uniform and complete shielding of MDR- 1 RNA was observed (Figure 
22A). At 500nM and 750nM concentrations a significant amount of MDR-1 RNA exists in 
its un-bound state which accounts for the presence of cleavage fragments (Figure 22A lanes 
4-6). The uniform cleavage reductions suggest that MDR-1 is entirely protected in the 
presence of 500nM of CRD-BP. Based on the results from the saturation binding 
experiments (Figure 15E), Complex I and Complex II configurations exist at 500nM and 
750nM of CRD-BP. According to the proposed cooperative, sequential binding mechanism; 
one molecule of CRD-BP is bound to MDR-1 in Complex I and in Complex II, two CRD-BP 
molecules are bound to MDR-1. The shielding evidence suggests that Complex I 
configuration is sufficient to block the endonuclease from gaining access to MDR-1 RNA 
cleavage sites (i.e. requiring only one RNA-protein interaction). In contrast, Complex II is 
required for complete and uniform shielding of c-myc CRD. If one CRD-BP molecule is 
sufficient to occlude the MDR- 1 RNA structure from endonucleolytic attack, how and why 
does Complex II form? Complex II may form as a result of RNA-dependant protein-protein 
interactions between two CRD-BP molecules. The combined RNA-protein and protein- 
protein interactions may function to enhance the stability of Complex II.
5.3.2 Mapping the CRD-BP Binding Sites on the c-myc CRD
The CRD-BP binding sites were determined using a combination of two RNA 
footprinting techniques. The data from both footprinting experiments was consistent and 
considerable overlap in cleavage reductions was observed. According to the data, five 
proposed CRD-BP binding sites are present within the c-myc CRD. The regions: 1727-1730, 
1741-1757, 1768-1775, 1787-1791 and 1843-1864 are presented in Figure 26. In several
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cases, the binding sites reported in the present study were supported by the findings by 
Coulis et al. 2000 (refer to Table 10 for detailed summary). The presence of five binding 
sites does not imply that five individual proteins bind to the c-myc CRD. A more likely 
scenario is that one CRD-BP molecule binds to one or more sites simultaneously via the 
interactions of its multiple KH domains.
When the proposed binding sites were superimposed onto the CRD mfold predicted 
structure (Figure 26), several structural elements important for binding emerged. In most 
cases the presence of single stranded stem, and hair-pin loops were the predominant features 
found within the proposed binding regions. Secondary structure elements such as single 
stranded loops are commonly recognized by RNA-binding domains (Siomi et al. 1997). 
Specifically, KH domains are known to initiate RNA-protein interactions by inserting their 
alpha helicies into various stem, bulge and hair-pin loop structures (Siomi et al. 1997).
It should be noted that the proposed map depicting the CRD-BP binding sites is not 
complete. An effort should be made to challenge the CRD-BP-c-myc interaction with a panel 
of RNases (i.e., V I, SI and T l). By employing a panel of RNases, more regions of potential 
interaction could be elucidated and previously mapped regions could be confirmed.
Many similarities in the CRD-BP-MDR-1 RNA and CRD-BP-c-myc RNA 
interactions are apparent. For example, their IQ values were identical (500nM), and both 
exhibited cooperative, sequential binding mechanisms. In addition, both interactions were 
capable of blocking the activity of an endoribonuclease. The unifying element in both 
interactions was CRD-BP and the only variable was the RNA. Therefore, it was anticipated 
that both RNAs would share similar sequence and structural features that support interactions
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with CRD-BP. MDR- 1 RNA cleavage sites were not mapped and this prevented the precise 
determination of CRD-BP binding sites on the MDR-1 RNA construct.
Rejpon A'
Region B
dG = -3 7 .3  [ i n i t i a l l y  -4 0 .5 ] unknown
B
A—C—
*  X
V  /  \
\  /  1 Hair-pin ktopB p
\  I
gA />•« / V s .  /
1 .  - V  *~c—K
y  X  X *  y c
\ -
I f
\  // *
I'M
G  ^ > Ws g. «. c» /
y ~ J  ,,/ e
' \ ?,7
Bulge l o o p Y ^ J
° ?*? ?»? 
H ? * | 
y*f nS*5
C*ff*yrpf*p&e
f \a Hair-pin loop A
\
dG = -36.73 [initially -41.4]
Figure 27: The mfold predicted minimal free energy folding for (A) fi-globin RNA 
(nts 1-145) and (B) MDR-1 RNA
The m/oM predicted secondary structure for (3-globin RNA (nts 1-145) and MDR-1 
RNA (nts 735-915) are depicted in Figure 27. MDR-1 and CRD RNA share several 
structural features such as multiple hair-pin, branch loop and stem-loop structures. CRD-BP
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has been shown to bind to hair-pin and stem loop structures within the CRD. Therefore, it is 
likely that the hair-pin and stem-loop structural features found in MDR-1 RNA are also 
recognized and bound by CRD-BP. The P-globin predicted secondary structure is largely 
double stranded interspersed with multiple, small stem loop structures. The inability of CRD- 
BP to bind with P-globin RNA is likely due to its absence of hair-pin and stem loop 
structures.
Table 11: Sequence alignment between CRD-BP binding sites and MDR-1 RNA sequence
Proposed (UI)-BI’ binding 
site on c-myc  CRD
Sequence Alignment 
inaleli in 
M D R -\
<r Sequence 
identity
Corresponding 
secondary structure
(nts 1726-1729) 
ACAA
(nts 105-108)
ACAA 
mis 1 15 1 K<>
: : -  m S S B m m S S ^M m
100% Hair-pin loop B
(nts 1741-17.%)
CCAAG GU AGUU AU CCU
(nts 15-21) 
CCAGGUA
86% Bulge-loop and double 
stranded region
(ills 3-12) 
AGGAAGACUA
Man pm loop \
(nts 1767-1774) 
ACAGCAUA
(nts 150-157) 
ACAGGAGA
75% Double stranded region A
(nts 126-129) 100% ll.iir pin loop |{
(nts 1787-1790) 
CCAAG
(nts 15-19) 
CCAGG
100% Hair-pin loop B
(nts 1843-1804) (nts 125-131) 
AACAGUliG AA AC ACAAACTJUG A AACAGHU
100% ll.iii-pm loop B
(ills 109-120) 
Al'ACACAAAAl'U
8-t'( ■Hi
The c-myc CRD RNA sequences bound by CRD-BP were compared to MDR-1 and P- 
globin RNA sequence using the LALIGN sequence alignment program as described by 
Huang et al. 1991. The rationale behind the sequence alignments was to determine if the 
CRD-BP binding sites found in c-myc CRD RNA were also shared in the MDR-1 and P-
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globin RNA sequences. The CRD sequences used in the alignment and the corresponding 
MDR-1 and $-globin RNA sequence matches are summarized in Table 11 and 12.
Table 12: Sequence alignment between CRD-BP binding sites and (3-globin RNA sequence
Proposed ('KI)-ltP binding 
site on c-mu' CRI)
(nts 1726-1729)
ACAA
I n t s  1 7 4 1 - 1 7 5 6 ) 
C C A A G G l ' A C i l I U A l I C C U
mis 1767-1774) 
A C A G C A L ' A
(nts 1787-1790) 
CCAAG
Sequence Alignment U Sequence Corresponding 
msitcli in identity secondary
|i -globin
(nts 48-51)
ACAA
( n l s  5 0 -5 5 )
C C A G G . U
( n t s  100-1 1 0 ) 
C A A G I T ' G A A G C U  
( n t s  4 6 - 5 2 ) 
A C A C C A I J
(nts 100-104)
CAAG
( n l s  110 - 1 1 6 )(nts 1843-1864)
.\\c\c.n'G\\\< ac \ wet i g \ v .i i g w
(nts 35-44) 
AACCUCAAAC
mi
secondary structure
100%
8 6'4 
7 5 ' ;  
86%
100% 
100% 
SO' (
Region A, branch-loop 
and ds-region
R e g i o n  A .  b r a n c h - l o o p  
a n d  d s - r e g i o n
Region C, ds-region and
2 stem loops
Region a, branch loop
Region C, ds-region 
Region C
R e g i o n  I t .  d s - r e c i o n .  o e m
The c-myc sequences used in the alignment shared significant sequence homology 
with several MDR-1 and P-globin RNA sequences. In addition, the MDR-1 RNA sequences 
sharing significant sequence identity to c-myc RNA contained secondary structure elements 
such as hair-pin loops (compare to figure 26-27). In contrast, (3-globin RNA sequences 
sharing significant sequence identity to c-myc RNA were predominantly found in double 
stranded regions (compare to figure 26-27). The presence of double stranded regions may be 
one of the underlying reasons why CRD-BP exhibited low affinity for P-globin RNA. The 
combined sequence alignment data and secondary structures analysis suggest that CRD-BP 
likely recognized and bound to MDR- 1 at hair-pin loop B.
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5.4 Concluding Remarks
Several studies have attempted to define the function of VICKZ proteins by 
examining their interactions with mRNA targets and other proteins involved in post- 
transcriptional processes (Ross et al. 1997; Neilsen et al. 2003). It is generally accepted that 
VICKZ proteins play a significant role in mRNA localization (Neilsen et al. 2004; Rackham 
et al. 2004). Structural studies have confirmed that VICKZ proteins possess nuclear import 
and nuclear export signals which may account for their presence and functionality in the 
cytoplasm and nucleoplasm (Doyle et al. 2000). VICKZ proteins are reported to bind to 
specific secondary structural elements on target mRNA molecules during pre-mRNA 
processing events in the nucleus (Vikessa et al. 2006). The association of VICKZ proteins 
and numerous other factors with mRNA contributes to nuclear export, RNP granule 
formation and localization within the cytoplasm (Vikessa et al. 2006).
There is a clear relationship between VICKZ proteins and their mRNA targets. When 
VICKZ protein expression is altered, changes in the expression of their mRNA targets are 
also observed (Yisraeli 2005). For example, when CRD-BP expression was knocked down 
MCF-7 cells, a decrease in c-myc mRNA levels was observed (Ioannidis et al 2005). 
However in tumor cells, over-expression of CRD-BP has no apparent effect on c-myc mRNA 
levels (Ross et al. 2001). The seemingly contradictory evidence requires a closer 
examination of the mechanisms by which CRD-BP affects c-myc mRNA levels.
The data presented in this thesis provides the first direct in vitro evidence supporting 
the CRD-BP-c-rayc CRD shielding hypothesis initially proposed by Prokipcak (1994). The 
data also indicates that CRD-BP can bind with considerable specificity to MDR-1 RNA. It 
was also demonstrated that the shielding hypothesis applies to RNA-protein interactions
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between CRD-BP and MDR-1 RNA in vitro. The ability to shield transcripts from 
degradation may increase mRNA levels by enhancing transcript stability in the cytoplasm.
The ribosomal pausing model proposed by Lemm and Ross (2002), demonstrates a 
potential implication of the in vitro shielding hypothesis. During translation the c-myc 
transcript interacts with multiple trans-acting factors including CRD-BP. Translational 
elongation may be interrupted (i.e. pause) when the translational machinery reaches a region 
upstream of the CRD which contains an abundance of rare codons (Lemm and Ross 2002). 
During these pauses, the transcript is susceptible to degradation by endoribonucleases. 
However, due to the presence of CRD-BP, cleavage sites within the CRD are occluded and 
the integrity of the transcript is ensured. It should be noted that the proposed protective 
function of CRD-BP may also preserve transcript integrity during RNP granule assembly and 
transport within the cytoplasm.
Studies examining CRD-BP over-expression in tumor cells have not reported 
increases in c-myc mRNA levels. However, the levels of IGF-ll and H19 mRNA did 
increase in response to CRD-BP over-expression. The increase in RNA levels was not 
unexpected because both IGF-ll and H19 are known RNA targets of CRD-BP (Ioannidis et 
al. 2004). The absence of increased c-myc mRNA levels suggests that other factors such as 
endoribonucleases may contribute to the maintenance of this transcript.
The mfold predicted secondary structure of the full length c-myc transcript contains 
numerous CRD-like structures. It was predicted that many of these structures may also be 
targeted by endoribonucleases. In addition, these CRD-like regions may also interact with a 
variety of RNA-binding proteins including the AU-rich binding proteins, HuC, HuD and 
HuR (King 2000). It is also possible that the expression of other RNA-binding proteins that
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bind c-myc may be reduced or absent in tumor cells. Their reduced or absent expression may 
leave transcripts like c-myc exposed and susceptible to degradation at regions other than the 
CRD. In addition, CRD-BP may contribute to the stabilization and increased expression of 
mRNA encoding endoribonucleases in tumor cells. The decreased/absent expression of other 
RNA-binding proteins and/or the stabilization of endoribonucleases could account for the 
maintenance of c-myc mRNA levels in tumor cells over-expressing CRD-BP.
The altered expression of c-myc mRNA and MDR-1 mRNA contributes to the highly 
proliferative and chemotherapeutic resistant phenotypes associated with various cancers. If 
the shielding hypothesis is true in vivo then CRD-BP may exacerbate cancerous phenotypes 
through increased mRNA stabilization. However, in several cancer cell models, CRD-BP 
over-expression does not always correlate with increased c-myc mRNA expression (Ross et 
al. 2001). In other cases where CRD-BP has been knocked down to undetectable levels in 
cells, c-myc mRNA expression is significantly reduced (Ioannidis et al. 2005). To date, no 
known studies have attempted to correlate CRD-BP expression with MDR-1 mRNA levels in 
vitro or in vivo.
If the shielding hypothesis is to be confirmed in vivo future studies need to focus on the 
inter-relationships between CRD-BP, c-myc mRNA or MDR-1 mRNA and the native 
mammalian endoribonuclease. Several examples demonstrate that that RNA-binding 
proteins and endoribonucleases play vital roles in the regulation of mRNA stability. For 
example, the presence and activity of endoribonucleases could account for the normal levels 
of c-myc expression observed in tumor cells over-expressing CRD-BP. Future studies should 
attempt to address if in fact CRD-BP is capable of exerting its protective effect in cells. 
Studies involving tumor cells provide an abundant source of CRD-BP and therefore would be
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a suitable cell model. Initially c-myc, CRD-BP and native mammalian endoribonuclease 
mRNA and protein levels would need to be established in the wild-type tumor. CRD-BP and 
native mammalian endoribonuclease knock down experiments could then be used to establish 
how each protein individually affects c-myc mRNA levels. If c-myc mRNA levels decreased 
as a result of CRD-BP knockdown and if c-myc mRNA levels increased as a consequence of 
endonuclease knockdown, this evidence would lend support to the shielding hypothesis in 
vivo.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
References
(2003). The QIAexpressionist: A handbook for high-level expression and purification of 
6xHis-tagged proteins. QIAGEN: 1-128.
Alberts, B., Bray, D, Lewis, J, Raff, M, Roberts, K, Watson, JD (1994). Molecular 
biology of the cell. New York NY, Garland.
Ambion. (2004). mMessage mMachine: Instruction Manual. Retrieved March 9, 2006.
Aravind, L., Iyer, LM, Anartharaman, Y (2003). The two faces of Alba: The evolutionary 
connection between proteins participating in chromatin structure and RNA metabolism. 
Genome Biol. 4(10): Article R64.
Audic, Y., Hartley, RS (2004). Post-transcriptional regulation in cancer. Mol. Cell. 
Biol.(96): 479-498.
Baber, J., Libutti, D,Levens, D,Tjandra, N (1999). High Precision solution structure of 
the C-termianl KH domain of heterogeneous nuclear ribonucleoprotein K, a c-myc 
transcription factor. J. Mol. Biol. 289: 949-962.
Barreau, C., Paillard, L, Osborne, B (2006). AU-rich elements and associated factors: are 
there unifying principles? Nucleic acids res. 33(22): 7138-7150.
Beelman, C., Parker, R (1995). Degradation of mRNA in eukaryotes. Cell (81): 179-183.
Bergstrom, K., J. Urquhart, et al. (2005). Purification and characterization of a novel 
mammalian endoribonuclease. J. Cell Biochem In Press 1-19.
Bremer, K., Stevens, A, Schoenberg, DR (2003). An endonuclease activity similar to 
Xenopus PMR1 catalyzes the degradation of normal and nonsense-containing human beta 
globin mRNA in erythroid cells. RNA(9): 1157-1167.
Brewer, G. (2000). Regulation of c-myc mRNA decay in vitro by a phorbol ester- 
inducible, ribosome-associated component in differentiating megakaryoblasts. J. Biol. 
C W  275(43): 33336-33345.
Brewer, G. (2003). Messenger RNA decay during ageing and development. Aeging Res. 
Rev  ^1(2002): 607-625.
Brewer, G., Ross, J (1989). Regulation of c-myc mRNA stability in vitro by a labile 
destabilizer with enhanced nucleic acid component. Mol. Cell Biol. 9(5): 1996-2006.
Buratti, E., Baralle, FE (2004). Influence of RNA secondary structure on the Pre-mRNA 
splicing process. Mol. Cell B iol 24(24): 10505-10514.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
REFERENCES xii
Cairo, G., Pietrangelo, A (1994). Transferrin receptor gene expression during rat liver 
regeneration. J. Biol. Chem1269(9): 6405-6409.
Chang, K.-Y., Ramos, A (2005). The double stranded RNA-binding motif, a versatile 
macromolecular docking platform. FEBS 272: 2109-2117.
Chao, L., Jamil, AK, Kim, SJ, Huang, L, Marrtinson, HG (1999). Assembly of the 
cleavage and polyadenylation apparatus requires about 10 seconds in vivo and is faster 
for strong than for weak poly(A) sites. Mol. Cell BioL(19): 5588-5600.
Chen, Y., Varani, G (2005). Protein families and RNA recognition. FEBS 272: 2088- 
2097.
Chkeidze, A., Lyakhov, DL, Makeyev, AV, Morales, J, Kong, J, Liebhaber, SA (1999). 
Assembly of the alpha-globin mRNA stability complex reflects binary interaction 
between the pyrimidine rich 3'-untranslated region determinant and poly(C)binding 
protein (alphaCP). Mol. Cell. BioL 19(7): 4572-4581.
Coulis, C., Lee, C, Nardone, V, Prokipcak, RD (2000). Inhibition of c-myc expression in 
cells by targeting an mRNA-protein interaction using antisence oligonucleotides. Mol. 
PharmL 57: 485-494.
Cunningham, K., Dodson, RE, Nagel, MA, Shapiro, DJ, Schoenberg, DR (2000). Vigilin 
binding selectively inhibits cleavage of the vitellogenin mRNA 3'-untranslated region by 
the mRNA endonuclease polysomal ribonuclease 1. Proc. Natl. Acad. Sci. U.S.A. 97(23): 
12498-12502.
Dang, C. (1999). c-Myc target genes involved in cell growth, apoptosis and metabolism. 
Mol. Cell. Biol. 19(1): 1-11.
Derrigo, M., Cestelli, A, Savettieri, G, Diliegro, I (2000). RNA-protein interactions in the 
control of stability and localization of mRNA. Int. J. Mol. Med.(5): 111-123.
Deschenes-Furry, J., Angus, LM, Belanger, G, Mwanjewe, J, Jasminm BJ (2005). Role of 
ELAV-like RNA-binding proteins HuD and HuR in the post transcriptional regulation of 
acetylcholinesterase in neurons and skeletal muscles. Chem-Biol. Interactions 157(158): 
43-49.
Doyle, G., Betz, N, Leeds, PF, Fleisig, AJ, Prokipcak, RD, Ross, J (1998). The c-myc 
coding region determinant binding protein: a member of a family of KH domain RNA- 
binding proteins. Nucleic acids resL 26(22): 5036-5044.
Doyle, G., Bourdeau-Heller, JM, Coulthard, S, Meisner, LF, Ross, J (2000). 
Amplification in human breast cancer of a gene encoding a c-myc mRNA binding 
protein. Cancer res. 60: 2756-2759.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
REFERENCES xiii
Facchini, L., Chen, S, Marhin, WW, Lear, JN, Penn, LZ (1998). The role of Myc in 
growth and transformations, recent discoveries lead to new insights. FASEB 7,(12): 633- 
651.
Figueroa, A., Cuadradro, A, Fan, J, Atasoy, U, Muscat, GF, Munoz-Canoves, P, Gorospe, 
M, Munoz, A (2003). Role of HuR in skeletal myogenesis through coordinate regulation 
of muscle differentiation genes. Mol. Cell. BioL 23(14): 4991-5004.
Ghisolfi, L., Joseph, G, Amalric, F, Erard, M (1992). The glycine rich domain of 
nucleolin has an unusual supersecondary structure responsible for its RNA-helix 
destabilizing properties. J. Biol. Chem. 267(5): 2955-2959.
Git, A., Standart, N (2002). The KH domains of Xenopus VG1RBP mediate RNA 
binding and self association. RNA 8: 1319-1333.
Goto, M., Masuda, S, Saito, H, Inui, K (2003). Decreased expression of P-glycoprotein 
during differentiation in the human intestinal cell line Caco-2. Biochem. Pharmacol 
66(1): 1162-1170.
Grishin, N. (2001). KH domain: one motif, two folds. Nucleic acids resL 29(3): 638-643.
Guerrier-Takada, C., Eder, PS, Gopalan, V, Altman, S (2002). Purification and 
characterization of Rpp25, an RNA-binding protein subunit of human ribonuclease P. 
RNA 8: 290-295.
Guhaniyogi, J., Brewer, G (2001). Regulation of mRNA stability in mammalian cells. 
Gene 265: 11-23.
Hann, S., Eisenma, RN (1984). Proteins encoded by the human c-myc oncogene: 
differential expression in neoplastic cells. Mol. Cell BioL{A)\ 2486-2479.
Hanson, M., Schoenberg, DR (2001). Identification of in vivo mRNA decay 
intermediates corresponding to sites of in vitro cleavage by polysomal ribonuclease 1. J. 
Biol. Chem. 276(15): 12331-12337.
Haynes, S. (1999). RNA-Protein interactions. Totowa, New Jersey, Humana Press.
Hermecking, H. (2003). The MYC oncogene as a cancer drug target. Curr. Cancer Drug 
Targets 3: 163-175.
Huang, X and Miller, M (1991). PCMA: fast and accurate multiple sequence alignment 
based on profile consistency Adv. Appl. Math. (1991) 12:337-357,
Ioannidis, P., Kottaridi, C, Dimitriadis, E, Courtis, N, Mahaira, LG, Talieri, M, 
Giannopoulos, A, Iliadis, K, Papaioannou, D, Nasioulas, G, Trangas, T (2004).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
REFERENCES xiv
Expression of the RNA-binding protein CRD-BP in brain and non-small cell lung tumors. 
Cancer lettL 209: 245-250.
Ioannidis, P., Mahaira, LG, Papaioannou, D, Teixeira, MR, Heim, S, Andersen, JA, 
Evangelou, E, Dafni, U, Pandis, N, Trangas, T (2003). CRD-BP: a c-Myc mRNA 
stabilizing protein with an oncofetal pattern of expression. Anticancer Res. 23(3A): 2179- 
2183.
Ioannidis, P., Mahaira, LG, Perez, SA, Gritzapis, AD, Sotiropoulou, PA, Kavalakis, GJ, 
Antsaklis, Al, Baxevanis, CN, Papamichail, M (2004). CRD-BP/IMP1 expression 
characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in 
MCF-7 cancer cells. J. Biol. Chem,, 280(20): 20086-20093.
Jarrous, N., Reiner, R, Wesolowsi, D, Mann, H, Guerrier-Takada, C, Altman, S (2001). 
Function and subnuclear distribution of Rpp21, a protein subunit of the human 
ribonucleoprotein ribonuclease P. RNA 7: 1153-1164.
Jiang, T., Guerrier-Takada, C, Altman, S (2001). Protein-RNA interactions in the 
subunits of human nuclear RNase P. RNA 7: 937-941.
Jones, T., Cole, MD (1987). Rapid cytoplasmic turnover of c-myc mRNA: requirement 
of the 3' untranslated sequences. Mol. Cell BioL 7(12): 4513-4521.
Kiledjian, M., Day, N, Trifillis, P (1999). Purification and RNA binding properties of the 
polycytidylate-binding proteins alpha-CPl-2. Methods enzymol 17: 84-91.
Kong, J., Ji, X, Liebhaber, SA (2003). "The KH domain protein alpha-CP has a direct 
role in mRNA stabilization independent of its cognate binding site." Mol. Cell. Biol. 
23(4): 1125-1134.
Lafon, I., Carballes, F, Brewer, G, Poiret, M, Morello, D (1994). Developmental 
expression of AUF1 and HuR, two c-myc mRNA binding proteins. Oncogene 16: 3413- 
3421.
Lee, C., Bradley, G, Ling, V (1998). Increased P-glycoprotein messenger RNA stability 
in rat tumor cells in vivo. J. cell. ph ysioL {\ll): 1-12.
Lee, C., Leeds, P, Ross, J (1998). Purification and characterization of a polysome- 
associated endoribonuclease that degrades c-myc mRNA in vitro. J. Biol. Chem. 273(39): 
25216-25222.
Lee, L., Dolde, C, Barrett, J, Wu, CS, Dang, CV (1996). A link between c-Myc-mediated 
transcriptional repression and neoplastic transformation. J. Clin. Investigation 97(7): 
1687-1695.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
REFERENCES xv
Leeds, P., Kren, BT, Boylan, JM, Betz, N, Steer, JC, Gruppuso, PA, Ross, J (1997). 
Developmental regulation of CRD-BP, an mRNA-binding protein that stabilizes c-myc 
mRNA in vitro. Oncogene 14: 1279-1286.
Lemm, I., Ross, J (2002). Regulation of c-myc mRNA decay by translational pausing in a 
coding region instability determinant. Mol. Cell. Biol. 22(12): 3959-3969.
Levens, D. (2003). Reconstructing MYC. Genes Dev^ 17: 1071-1077.
Li, Y., Altman, S (2001). A subunit of human nuclear RNase P has ATPase activity. 
Proc. Natl. Acad. Sci. U.S.A. 98(2): 441-444.
Liao, B., Patel, M, Hu, Y, Charles, S, Herrick, DJ, Brewer, G (2004). Targeted 
knockdown of the RNA-binding protein CRD-BP promotes cell proliferation via an IGF- 
II-dependant pathway in human K562 leukemia cells. J. Biol. Chem. 279(47): 487lb- 
48724.
Mao, C., Goolsby, K, Wang, S, Dodson, RE, Ross, J, Shapiro, DJ (2006). Analysis of 
RNA-protein interactions by a microplate-based fluoresence anisorophy assay. Analy. 
BiochemL Article in press.
Maris, C., Dominguez, C, Allain, FH-T (2005). The RNA recognition motif, a plastic 
RNA-binding platform to regulate post-transcriptional gene expression. FEBS J 272: 
2118-2131.
Mueller-Pillasch, F., Lacher, U, Wallrapp, C, Micha, A, Zimmerhack, F, Hameister, H, 
Varga, G, Friess, H, Buchler, M, Gunther-Beger, H, Via, MR, Adler, G, Gress, T (1997). 
Cloning a gene highly overexpressed in cancer coding for a novel KH-domain containing 
protein. Oncogene 14: 2729-2733.
Neugerbauer, K. (2002). On the importance of being co-transcriptional. J. Cell. 5ci.(115): 
3865-3871.
Nielsen, J., Adolph, SK, Rajpert-De Meyts, Lykke-Andersen, J, Koch, G, Christiansen, J, 
Nielsen, FC (2003). Nuclear transit of human zipcode-binding protein IMP1. Biochem. J. 
376(2): 383-391.
Nielsen, J., Christiansen, J, Lykke-Andersen, J, Johnsen, AH, Wewer, UM, Nielsen, FC 
(1999). A family of insulin-like growth factor II mRNA-binding proteins represses 
translation in late development. Mol. Cell. BioL 19(2): 1262-1270.
Nielsen, J., Kristensen, MA, Willemoes, M, Nielsen, FC, Christiansen, J (2004). 
Sequential dimerization of a human zipcode-binding protein IMP1 on RNA: a 
cooperative mechanism providing RNP stability. Nucleic acids res. 32(14): 4368-4376.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
REFERENCES xvi
Ostareck-Lederer, A., Ostareck, DH, Standart, N, Thiele, BJ (1994). Translation of 15- 
lipoxygenase mRNA is inhibited by a protein that binds to a repeated sequence in the 3'- 
untranslated region. EMBO 13(6): 1476-1481.
Park-Lee, S., Kim, S, Laird-Offringa, LA (2003). Characterization of the interaction 
between neuronal RNA-binding protein HuD and AU-rich RNA. J. Biol Chem. 278(41): 
39801-39808.
Parker, R., Song, H (2004). The enzymes and control of eukaryotic mRNA turnover. 
Nature 11(12): 121-127.
Prokipcak, R., Herrick, DJ, Ross, J (1994). Purification and properties of a protein that 
binds to the C-terminal coding region of human c-myc mRNA. J. Biol. Chem. 269(12): 
9261-9269.
Promega. (2005). Restriction enzyme resourse. Retrieved March 9, 2006.
Rackham, O., Brown, CM (2004). Visualization of RNA-protein interactions in living 
cells: FMRP and IMP1 interact on mRNAs. EMBO 23(16): 3346-3355.
Ross, A., Oleynikov, Y, Kislauskis, EH, Taneja, KL, Singer, RH (1997). Characterization 
of a beta-actin mRNA Zipcode-Binding Protein. Mol. Cell. Biol. 17(4): 2158-2165.
Ross, J., Lemm, I (2001). Overexpression of an mRNA-binding protein in human 
colorectal cancer. Oncogene 20: 6544-6550.
Russell, J., Liebhaber, SA (1996). The stability of human beta-globin mRNA is 
dependent on structural determinants positioned within its 3' untranslated region. Blood 
87(12): 5314-5323.
Sargent, L., Zhou, X, Keck, CL, Sanderson, ND, Zimonjic, DB, Popescu, NC, 
Thorgeirsson, SS (1999). Nonrandom cytogenic alteration in hepatocellular carcinoma 
from transgenic mice overexpressing c-Myc and transforming growth factor alpha in 
liver. Amer. J. Path. 154(4): 1047-1055.
Schoenberg, D., Cunningham, KS (1999). Characterization of mRNA endonucleases. 
Methods: A companion guide to methods in enzymology(\iy. 60-73.
Schultz, J., Copley, RR, Doerks, T, Ponting, CP, Bork, P (2000). SMART: A web-based 
tool for the study of genetically mobile domains. Nucleic acids res. 28: 231-234.
Siomi, H., Dreyfus, G (1997). RNA-binding proteins as regulators of gene expression. 
Current opinion gen. dev  ^7: 343-353.
Tessier, C., Doyle, GA, Clark, BA, Pitot, HC, Ross, J (2004). Mammary tumor induction 
in transgenic mice expressing an RNA-binding protein. Cancer res± 64: 209-214.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
REFERENCES xvii
Tullius, T., Dombroski, BA (1986). Hydroxyl radical footprinting: high resolution 
information about DNA-protein contacts and applications to lambda repressor and Cro 
protein. Proc. Natl. Acad. Sci. U.S.A. 83: 5469-5473.
Varmus, H. (1984). The molecular genetics of cellular oncogenes. Annu Rev Genet( 18): 
553-612.
Vennstrom, B., Sheiness, D, Zabielski, J, Bishop, JM (1982). Isolation and 
characterization of c-myc, a cellular homolog of the oncogene v-myc of avian 
myelocytomatosis virus strain. J Virol{42): 773-779.
Wang, Z., Kiledjian, M (2000). The poly(A)binding protein and an mRNA stability 
protein jointly regulate an endoribonuclease activity. Mol. Cell. BioL 20(17): 6334-6341.
Weiss, J. (1997). The Hill equation revisited:use and misuses. FASEB J. 11(11): 835-841.
Yang, F., Schoenberg, DR (2004). Endonuclease-mediated mRNA decay involves the 
selective targeting of PMR-1 to polyribosome-bound substrate mRNA. Mol. cell(14): 
435-445.
Yeilding, N., Rehman, MT, Lee, WM-F (1996). Identification of sequences in c-myc 
mRNA that regulate its steady state levels. Mol. Cell. BioL 16(7): 3511-3522.
Yeilding, N., Rehman, MT, Lee, WM (1996). Isolation and characterization of c-myc, a 
cellular homolog of the oncogene (v-myc) of avian myelcytomatosis virus strain. J. Virol 
29(42): 773-779.
Yisraeli, J. (2005). VICKZ proteins: a multi-talented family of regulatory RNA-binding 
proteins. Mol. Cell. BioL 97: 87-96.
Zhao, Z., Chang, F-C, Fumeaux, HM (2000). The identification of an endonuclease that 
cleaves within an HuR binding site in mRNA. Nucleic acids res. 28(14): 2695-2701.
Zuker, M. (1999). Mfold web server for nucleic acid folding and hybridization prediction. 
Nucleic acids res. 31(13): 3406-3415.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
